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The action potential (AP) waveform controls the opening of voltage-gated calcium 
channels (VGCCs) at presynaptic nerve terminals. The calcium ion flux through these VGCCs acts 
as a second messenger, triggering the release of neurotransmitter. The frog and mouse 
neuromuscular junctions (NMJs) have long been model synapses for the study of 
neurotransmission, but the presynaptic AP waveforms from these NMJs have never been recorded 
because the nerve terminals are too small impale with an electrode for electrophysiological 
recordings. Neurotransmission from nerve terminals occurs at highly organized structures called 
active zones (AZs), and the relationships between the AP, VGCCs, and neurotransmission at AZs 
are poorly understood. Understanding these relationships is important for the study of Lambert-
Eaton myasthenic syndrome (LEMS), an autoimmune disorder in which neurotransmitter release 
from the NMJ is decreased, leading to severe muscle weakness. This reduced neurotransmission 
is thought to be caused by an antibody-mediated removal of presynaptic VGCCs and disruption of 
AZ structure. Furthermore, 3,4-diaminopyridine (3,4-DAP; the FDA-approved treatment for 
LEMS) was thought to indirectly increase calcium flux into the AZs by broadening the presynaptic 
AP, but this mechanism has come under scrutiny. Here, we use voltage imaging to optically record 
AP waveforms from frog and mouse motoneuron terminals. We find that the AP waveforms from 
these terminals are very brief in duration. We hypothesize the brief duration of these APs helps 
prevent a depletion of docked synaptic vesicles in AZs by limiting calcium flux during APs, and 
 v 
is thus an important mechanism by which healthy NMJs maintain reliable neurotransmission 
during repeated stimulation. We also show that clinically relevant concentrations of 3,4-DAP 
increase calcium flux by broadening the AP. Next, we use our recorded AP waveforms to constrain 
computational models of mammalian AZs, and utilize these models to investigate the effects of 
LEMS on the AZ. We demonstrate that the disruption of AZ structure plays an essential role in 
LEMS pathology. Finally, we show that disrupting the calcium-sensing proteins in the AZ could 
result in LEMS pathology and hypothesize that anti-VGCC antibodies may not be solely 
responsible for LEMS in many LEMS patients. 
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1.0 Introduction 
Neurons are the primary cell type of the nervous system. They communicate with other 
cells via an electrochemical signal, where a wave of electrical energy, referred to as the action 
potential (AP), is sent from the cell body to the presynaptic terminal of the axon. Upon reaching 
the axon terminal, the AP causes voltage-gated calcium channels (VGCCs) to open, and a 
subsequent influx in calcium ions. These calcium ions act as a second-messenger, binding to 
calcium-sensing proteins. The activation of these proteins then causes neurotransmitter-containing 
docked synaptic vesicles to release their contents into the synaptic cleft, which causes a chemical 
signal to be transmitted to the cell on the postsynaptic side of the synaptic cleft.  
Neurons in the central nervous systems can contain thousands of connections to other 
neurons, which can result in complex modulation of the mechanisms responsible for 
neurotransmission. In contrast, the motoneurons of the spinal cord, which allow the nervous 
system to control muscle contraction, have a one-to-one connection between presynaptic nerve 
terminals and postsynaptic muscle cells. For this reason, in addition to their large size, motoneuron 
synapses onto muscle fibers, called neuromuscular junctions (NMJs), have been a model for the 
study of synaptic transmission.  
Release of neurotransmitter from the presynaptic terminals of neurons occurs at specialized 
regions of the presynaptic membrane called active zones (AZs), which contain docked synaptic 
vesicles, VGCCs, and a variety of structural, membrane fusion facilitating, and calcium-sensing 
proteins. The function of the AZ is essential to the ability of the neuron to release neurotransmitter, 
and several diseases and toxins impact the ability of the AZ to function properly. One such disease 
that targets the NMJ is Lambert-Eaton Myasthenic syndrome (LEMS).  
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LEMS is a rare autoimmune-mediated neuromuscular disease in which the immune system 
attacks the VGCCs in the AZ (as well as other AZ proteins). The decrease in the number of VGCCs 
leads to a reduced calcium influx during an AP, and a subsequent reduction in the amount of 
neurotransmitter that is released.  This reduction in transmitter release results in severe muscle 
weakness. Recently, the FDA has approved 3,4-diaminopyridine (3,4-DAP) for the treatment of 
LEMS, which indirectly augments calcium ion flux into the terminal, thereby increasing 
transmitter release. However, treatment with 3,4-DAP only results in a modest improvement in 
symptoms for LEMS patients.  
In this chapter, many topics will give a brief overview in terms of the nervous system as a 
whole and then will focus on the neuromuscular junction. The mouse and frog neuromuscular 
junctions will be a particular focus, as these are the model organisms used for research in this 
dissertation. Chapter 2 has been published in the Journal of Neuroscience (Ginebaugh et al., 2020), 
chapter 3 has been published in the Journal of Biological Chemistry (Ojala et al., 2021), and 
chapter 4 is expected to be submitted for publication in the near future. 
1.1 Action potential propagation in neurons 
All cells are surrounded by a lipid membrane. The difference in ion concentrations inside 
and outside of this membrane causes it to act as a capacitor, resulting in a voltage across the 
membrane. Multiple cell types, including muscle cells, neurons, and some endocrine cells, utilize 
this transmembrane voltage as a means to communicate information throughout the cell. In 
general, the voltage is communicated along the length of the cell membrane primarily through 
voltage-gated sodium channels and voltage-gated potassium channels (and, to a lesser extent, 
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VGCCs), which control the flux of charged ions into and out of the cell. The electrical signal 
mediated via the voltage-gated sodium and potassium channels is a wave of depolarizing 
membrane voltage that triggers an all-or-none voltage spike, known as the action potential (AP). 
The AP is often considered as a binary signal broadcasting throughout the nerve, causing 
a release of neurotransmitter into the synapse upon reaching the axon terminal (Burkitt, 2006; 
Lapicque, 2007; Rowan et al., 2016). However, since the analysis of the squid giant axon action 
potential by Hodgkin and Huxley (Hodgkin & Huxley, 1939, 1945, 1952a, 1952b, 1952c, 1952d, 
1952e; Hodgkin, Huxley, & Katz, 1952), it has become clear that the AP waveform itself is an 
important part of the computation of the neuron. The size, shape, and conduction velocity of the 
AP play an important role in determining the function of the neuron. The AP is not a binary pulse, 
but in fact its properties (amplitude, shape, and conduction velocity) can vary greatly between 
different types of neurons and between different parts of a neuron as it propagates. Neurons 
regulate the propagation and shape of the AP with a heterogeneous distribution of ion channels 
and a variety of feedback mechanisms.  
Despite the importance of the AP waveform shape and propagation to the function of 
nerves and synapses, the shape of the AP waveform and how changes in this waveform impact the 
behavior of neurons are relatively understudied. This is primarily due to the fact that the axons and 
dendrites of most neurons are too small to probe with an electrode (with a few notable exceptions 
such as the squid giant axon). Therefore, standard electrophysiology techniques can generally only 
be used in the soma of neurons, and cannot be used to record propagation of the AP throughout 
the cell.  
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1.2 The active zone 
Active zones (AZs) are specialized structures on the presynaptic plasma membrane of 
synapses where neurotransmitter release occurs (Couteaux & Pecot-Dechavassine, 1970; Sudhof, 
2012). Early imaging studies showed that AZs contain docked synaptic vesicles and numerous 
intramembranous particles (Heuser, Reese, & Landis, 1974; Peper et al., 1974; Pfenninger et al., 
1972). These intramembranous proteins are comprised of the structural and functional proteins 
necessary for synaptic vesicle exocytosis, as well as ion channels such as VGCCs.  
When an AP invades the presynaptic terminal, the VGCCs convert the electrical signal to 
a calcium-ion second messenger signal. These calcium ions then bind to calcium-sensing proteins, 
which trigger transmitter-containing vesicle fusion with the plasma membrane. Although many of 
the core components of the AZ are evolutionarily conserved, the specific types of particular 
proteins (e.g. voltage-gated calcium channels, calcium-sensing protein subtypes), as well as the 
structure of the AZ can vary significantly between (and even within) different species and neuronal 
subtypes (Sudhof, 2012). These differences in AZ structure can greatly affect the function of the 
neuron, including the latency and amount of neurotransmitter released during an AP as well as the 
plasticity of the synapse during repeated stimulation (Baydyuk, Xu, & Wu, 2016; Laghaei et al., 
2018; Slater, 2015). Thus, these differences in AZ structure result in differences in the information-
transmitting properties of the neurons.  
1.2.1 Voltage-gated calcium channels 
Among the intramembranous proteins in the AZ, one of the most important types for the 
synchronous (AP-triggered) release of neurotransmitter are the VGCCs. These channels play an 
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important role in converting the electrical AP waveform to a chemical signal of calcium ions which 
act as a messenger to trigger vesicle fusion. Although VGCCs exist both within and outside the 
AZ, the presence of VGCCs inside the AZ is essential for a rapid release of neurotransmitter 
following an AP (Eggermann et al., 2011; Kaeser & Regehr, 2014). 
VGCCs are comprised of a pore-forming α1 subunit, as well as α2, β, γ, and δ auxiliary 
subunits (differentially present depending on the sub-type of calcium channel). Although variation 
in the auxiliary subunits can cause physiological changes in the channel, the variation in the α1 
subunit is the primary determinant of the channel behavior. The α1 subunit is a 190 kDa protein 
comprised of ~2000 amino acid residues, which form four repeated domains (I-IV) each containing 
six transmembrane segments (S1-S6) (Takahashi et al., 1987; Tanabe et al., 1987). During a 
depolarization of the membrane, the S4 segment acts as the voltage sensor responsible for voltage-
mediated activation of the channel (Bezanilla, 2000; Catterall, 2010, 2011).    
There are 10 different α1 subunits, which are classified into three families (Cav1, Cav2, 
Cav3) based on structural and functional characteristics (Ertel et al., 2000; Snutch & Reiner, 1992). 
The α1 subunits in each family are subdivided into different calcium current types according to 
the electrophysiological and pharmacological properties of the currents and the channels that cause 
them. These calcium current subtypes are referred to as L-type (Cav1.1, 1.2, 1.3, and 1.4), P/Q-
type (Cav2.1), N-type (Cav2.2), R-type (Cav2.3), and T-type (Cav3.1, 3.2, and 3.3) (Catterall, 
2011). L-type currents were the first to be discovered, and are characterized in part by large 
conductance, slow voltage-dependent inactivation, high voltage of activation, and sensitivity to 
dihydropyridines (Reuter, 1979; Tsien, 1983). They also display calcium-dependent inactivation 
(Hofer et al., 1997; Imredy & Yue, 1994). T-type channels have small channel conductance, rapid 
activation, and low voltage of activation, and are particularly utilized by neurons for repetitive 
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firing and peacemaking purposes (Catterall, 2011). P/Q-, N-, and R-type channels are more rapid 
than L- and T-type and are often used in neurons for coupling of excitation to rapid 
neurotransmitter release. P/Q-type channels are sensitive to the spider toxin ω-agatoxin IVA 
(Mintz et al., 1992). Furthermore, some subtypes of P/Q-type channels demonstrate calcium-
dependent modulation of channel properties (Forsythe et al., 1998; Lee et al., 1999). N-type are 
selectively blocked by the cone snail toxin ω-conotoxin GVIA (Olivera et al., 1994; Tsien et al., 
1988). R-type channels are sensitive to the peptide SNX-482 (Newcomb et al., 1998). 
A majority of synapses utilize P/Q-type or N-type channels to trigger release of 
neurotransmitter. Among these are the mouse NMJ, which utilizes mainly P/Q-type VGCCs (Katz 
et al., 1997) for fast exostosis, and the frog NMJ which utilizes mainly N-type VGCCs (Katz et 
al., 1995). However, when the AP waveform is altered in the mouse NMJ with drug treatments, 
other types of VGCCs such as N-type (Giovannini et al., 2002) or L-type (Flink & Atchison, 2003) 
may also contribute to transmitter release. Furthermore, experiments on knockout mice without 
the ability to produce P/Q-type VGCCs have shown that compensatory mechanisms exist to 
replace missing VGCC types with other VGCC types (Urbano et al., 2003). This is also evident of 
these compensatory mechanisms in some diseases that result in removal of a VGCC subtype (see 
section 1.3).  
1.2.2 Calcium-activated potassium channels 
Another type of ion channel that is found in some active zones is the calcium-activated 
potassium channel. Calcium-activated potassium channels are generally separated into three 
different subtypes: “big-conductance” (BK), “small-conductance” (SK), and “intermediate-
conductance” (IK). These channels are found throughout the nervous system and have a variety of 
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functions. SK and IK channels differ from BK channels because SK and IK channels are activated 
by intracellular calcium independently of membrane voltage, whereas BK channels are activated 
by a combination of membrane voltage and intracellular calcium (Kshatri, Gonzalez-Hernandez, 
& Giraldez, 2018; Yang, Zhang, & Cui, 2015). Here, we will focus primarily on BK channels 
because they localize within AZs at NMJs (Robitaille et al., 1993b).  
BK channels activate rapidly enough to have an effect on the repolarization phase of APs 
(Pattillo et al., 2001; Sun, Yazejian, & Grinnell, 2004). This, along with evidence from calcium 
buffer experiments, shows that BK channels are located within nanometers of VGCCs (Fakler & 
Adelman, 2008). Recent research has proposed a mechanism for this colocalization: RIM-binding 
proteins (evolutionarily conserved AZ proteins) bind to both VGCCs and BK channels and localize 
them to the AZ (Sclip et al., 2018). The ability of BK channels to affect the AP waveform and to 
colocalize with VGCCs in the AZ suggests that BK channels are part of an important feedback 
mechanisms by which VGCCs, which open in response to an AP, can modify the AP waveform 
(Fakler & Adelman, 2008; Lee & Cui, 2010). 
Blocking BK channels has been shown to increase transmitter release at both mature frog 
(Anderson et al., 1988; Flink & Atchison, 2003; Robitaille & Charlton, 1992; Robitaille et al., 
1993b) and mouse NMJs (Anderson et al., 1988; Vatanpour & Harvey, 1995). However, BK 
channels are present, but decrease transmitter release when blocked, at Xenopus nerve-muscle co-
cultures (Pattillo et al., 2001) and do not affect transmitter release during single APs at Drosophila 
NMJs (Ford & Davis, 2014), suggesting that BK channels can have a variable and complex 
relationship with VGCCs, APs, and transmitter release that is not fully understood. Because there 
is a large amount of variability in BK channel effects between synapses, this suggests that BK 
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organization in the AZ may be variable between synapses (Ford & Davis, 2014; Pattillo et al., 
2001; Robitaille et al., 1993b; Vatanpour & Harvey, 1995). 
1.2.3 Active zone proteins contributing to calcium sensing and vesicle release 
The minimal machinery necessary for vesicle exocytosis is the SNARE (soluble N-
ethylmaleimide-sensitive factor attachment proteins receptor) complex. This complex contains 
target-membrane associated SNARE proteins and a vesicle associated SNARE protein. The target-
membrane associated SNARE proteins are synatxin-1 and synaptosomal-associated protein of 25 
kDa (SNAP-25), and the vesicle associated SNARE protein is vesicle-associated protein 
synaptobrevin (VAMP) (Sollner et al., 1993; Sudhof, 2012).  However, the SNARE complex by 
itself cannot create the rapid and tightly regulated vesicle release seen at the AZ. For this to occur, 
several other proteins must interact with the SNARE complex (Hayashi et al., 1994; Sudhof, 2012, 
2013). Among these other proteins, the calcium sensing proteins necessary to help accelerate the 
vesicle fusion process are the most relevant to this work.  
There are multiple types of calcium sensing proteins that can contribute to vesicular 
release, the most important group of which are the proteins of the synaptotagmin family. Mammals 
express 17 isoforms of synaptotagmin (Dean et al., 2012; MacDougall et al., 2018), 8 of which 
bind calcium (Gustavsson & Han, 2009). Of these, synaptotagmin-1 is known to be the main 
calcium sensor for fast calcium-dependent vesicle release at a variety of synapses, and is the most 
well-studied of the synaptotagmin family (Martens, Kozlov, & McMahon, 2007). In brief, upon 
being activated by bound calcium, the synaptotagmin-1 interacts with the SNARE complex to 
significantly accelerate the vesicle fusion process. This allows for the rapid release of transmitter 
following and AP-mediated influx of calcium. Synaptotagmin-2 is less well studied than 
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synaptotagmin-1, but is thought to act similarly (Pang et al., 2006b). There is evidence that both 
synaptotagmin-1 and synaptotagmin-2 are present in the AZs of mouse NMJs (Pang et al., 2006a). 
For some time, it has been hypothesized that the existence of a second calcium sensor could 
be responsible for facilitation seen at a variety of synapses (Yamada & Zucker, 1992). Recently, a 
series of knock-out experiments showed that eliminating  synaptotagmin-7 resulted in a loss in 
synaptic facilitation, and thus this second sensor was identified to be synaptotagmin-7 (Jackman 
et al., 2016). Compared to synaptotagmin-1, synaptotagmin-7 is vastly understudied, but it has 
gained a considerable amount of attention since its discovery as the second calcium sensor. It is 
now understood that synaptotagmin-7 is responsible for short-term facilitation at a variety of 
synapses. Synaptic facilitation (an increase in the probability of transmitter release after prior 
activity) is hypothesized to be controlled by a calcium sensor with very slow kinetics for binding 
and unbinding calcium (Yamada & Zucker, 1992). Synaptotagmin-7 is an attractive candidate 
because it appears to have a calcium binding off rate of approximately 6 times slower than 
synaptotagmin-1 (Hui et al., 2005; Jackman & Regehr, 2017). As a result, synaptotagmin-7 can 
remain activated and contribute to vesicle release over the course of several APs. However, the 
mechanism by which synaptotagmin-7 contributes to vesicular release is not yet fully understood, 
and synaptotagmin-7 also appears to have a variety of other functions (Chen et al., 2017; Luo & 
Sudhof, 2017). To contribute to synaptic facilitation, it is possible that synaptotagmin-7 interacts 
with the SNARE complex in a manner similar to that proposed for synaptotagmin-1, but it has also 
been hypothesized to act through different mechanisms such as altering the interaction between 
synaptotagmin-1 and the SNARE complex (Jackman et al., 2016). 
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1.2.4 Coupling of active zone components 
For synaptic vesicle fusion to occur following the invasion of the AP into the presynaptic 
terminal, the VGCCs must open, calcium must flow in and diffuse from the VGCC to the calcium 
sensor, and the calcium sensor must then trigger the fusion of the vesicle with the plasma 
membrane. At fast synapses such as the NMJ, this process occurs in less than a millisecond 
(Eggermann et al., 2011; Katz & Miledi, 1965a; Llinas, Steinberg, & Walton, 1981; Sabatini & 
Regehr, 1996).  
It is a known physical law that diffusion time is proportional to the square of the distance. 
Based on the low latency between influx of calcium and the subsequent release of transmitter at 
fast synapses, the VGCCs must be within 100 nm of the calcium sensing proteins  (Stanley, 2016). 
The intraterminal cytoplasmic volume immediately surrounding the opening of a single VGCC is 
often referred to as the calcium nanodomain. Following an AP, a high density of calcium ions will 
rapidly fill the nanodomain region. This density can be high enough such that a single VGCC can 
cause calcium-mediated fusion of synaptic vesicles in its nanodomain (although this is a low 
probability event (Luo et al., 2015)). In contrast, multiple VGCCs located near each other (but not 
necessarily within nanodomain distance) can create a high-density cloud of calcium in the volume 
around the VGCC cluster. This region is known as the microdomain, and can extend from 100 nm 
to 1 μm (Eggermann et al., 2011; Neher & Sakaba, 2008). For transmitter release to be triggered 
by a calcium microdomain, multiple VGCCs must open to create a sufficiently high concentration 
of calcium. 
In the nanodomain, the fast calcium buffer BAPTA is able to bind calcium ions before they 
trigger vesicle release by activating calcium sensing proteins, whereas the slow calcium buffer 
EGTA is not. In the microdomain however, both EGTA and BAPTA can prevent calcium from 
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causing vesicle release. Thus, buffer experiments using BAPTA and EGTA can reveal if vesicular 
fusion is triggered by nanodomain or microdomain coupling with VGCCs (Adler et al., 1991; 
Stanley, 2016). 
Both nanodomains and microdomain coupling can be effective for inducing transmitter 
release, and the primary coupling type differs between different types of neurons (Stanley, 2016). 
Interestingly, at the rodent Calyx of Held the preference appears to shift from microdomain 
coupling in neonates towards tighter nanodomain coupling in adults (Fedchyshyn & Wang, 2005). 
However, at the healthy frog NMJ, where speed is a priority, experimental results have consistently 
shown nanodomain coupling of VGCCs located close to vesicles as the cause of transmitter release 
(Heuser & Reese, 1981; Luo et al., 2015; Wachman et al., 2004) 
1.3 Properties of the neuromuscular junction 
Neuromuscular junctions (NMJs) are essential for movement, and thus are essential for 
most animal life. Because of the this, NMJs have evolved a variety of properties allowing them to 
function under a wide range of conditions. Two important such properties are the strength and 
reliability of NMJs. Here, strength refers to the fact that a typical presynaptic AP will cause a 
release of transmitter in excess of what is necessary to lead to the contraction of the postsynaptic 
muscle fibers, ensuring muscle activation. Reliability refers to the fact that the NMJ can repeatedly 
stimulate, or cause sustained contraction of, the postsynaptic muscle fibers (Meriney & Dittrich, 
2013; Wood & Slater, 2001).  
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1.3.1 The frog neuromuscular junction 
The frog NMJ has been used for decades as a model synapse for NMJs as well as for the 
study of neurotransmission as a whole. Notably, the Nobel Prize winning work elucidating the 
nature of neurotransmission by Katz and colleagues was performed in the frog NMJ (Del Castillo 
& Katz, 1957a, 1957b, 1957c; Del Castillo & Katz, 1957d; Katz & Thesleff, 1957a, 1957b). The 
frog NMJ is used as a model synapse for several reasons: its size and accessible location (often on 
top of the muscle fibers) make it easy to study, and its one-to-one presynaptic terminal to 
postsynaptic muscle fiber ratio make it so deconvolution of multiple inputs is not necessary to 
interpret experimental results from muscle fibers.  
A single frog NMJ contains approximately 600 AZs (Figure 1A) (Laghaei et al., 2018). 
Each AZ is a highly organized structure comprised of two rows with a total of 20-40 docked 
synaptic vesicles. The gap between the vesicles contains two double rows of intramembranous 
particles, with each double row placed close to a row of vesicles, containing a total of 
approximately 200-250 intramembranous particles per AZ (Figure 1B) (Heuser et al., 1979; 
Heuser et al., 1974; Pawson, Grinnell, & Wolowske, 1998a). Despite the presence of 12,000-
24,000 docked vesicles in the approximately 600 AZs, an average AP causes a release of 
neurotransmitter from only 415 vesicles (Laghaei et al., 2018). This means that during an AP, each 
AZ has a 0.67 probability of releasing transmitter from a synaptic vesicle. Assuming an average 
of 30 docked synaptic vesicles per AZ, then the probability of any given vesicle released its 
neurotransmitter during an AP is only 0.022. However, this low number of vesicles released during 
an AP, as compared with how many vesicles are ready to be released, is still significantly more 
than what is required to elicit a muscle contraction (Wood & Slater, 2001). 
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More recent research using single pixel optical fluctuation analysis on calcium imaging 
suggests that of the 200-250 intramembranous particles in the frog AZ, only 30-40 of them are 
VGCCs. This suggests a one-to-one relationship between docked synaptic vesicles and VGCCs. 
Furthermore, calcium imaging found that calcium channels in the frog AZ have only a 0.2 
probability of opening during an AP (Luo et al., 2015; Luo et al., 2011). Thus, only approximately 
7 VGCCs would be expected to open in each AZ of the frog NMJ during an AP. This paucity of 
VGCCs combined with the low probability of VGCCs opening during an AP provides a 
mechanism which can explain the low probability of release for synaptic vesicles. The resulting 
unreliable vesicle release per AZ is thought to contribute to the reliability of the synapse as a whole 
by ensuring that, even during repeated stimulation, the synapse will not become depleted of docked 
synaptic vesicles. 
1.3.2 The murine neuromuscular junction 
The mouse (and sometimes rat) NMJ is also often use as a model synapse, particularly 
because mice are much closer in physiology to the human NMJ than the frog or other model 
organisms like crayfish or Drosophila. Whereas the frog NMJ has a long, linear shape with long, 
linear AZs, the mouse NMJ has a “pretzel” shape with much smaller AZs (Figure 1C). Each AZ 
generally contains a row of 2 docked synaptic vesicles surrounded on both sides by double rows 
of intramembranous particles, containing approximately 20 particles total (Figure 1D) (Fukuoka 
et al., 1987; Nagwaney et al., 2009). The average mouse NMJ contains approximately 700 of these 
smaller AZs (Laghaei et al., 2018), each placed approximately 500 nm apart (Ruiz et al., 2011). 
During a single AP, the mouse NMJ releases approximately 160 vesicles of neurotransmitter. This 
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corresponds to a 0.22 probability of release from any given AZ during an AP, and a 0.11 





Figure 1 The stucture of the frog and mouse NMJs and their AZs. 
A, A frog NMJ stained with Alexa-594 α-bungarotoxin (BTX; red) to show the approximate location of 
AZs by staining postsynaptic acetylcholine receptors and Alexa-488 peanut lectin (PNA; green) to outline the 
synapse. Image from (Laghaei et al., 2018). B, A freeze-fracture replica of an AZ from a frog NMJ. The 
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hypothesized locations of synaptic vesicles are superimposed as white circles, and the hypothesized location of 
VGCCs are superimposed as black circles. The filled black circles represent the number of VGCCs predicted to 
open after a single AP. Original freeze-fracture image from (Heuser & Reese, 1981), and the adapted image from 
(Luo et al., 2011). C, A mouse NMJ stained with Alexa-594 α-bungarotoxin (BTX; red) to show the shape of the 
NMJ and an Alexa-488 conjugated antibody to identify the bassoon protein the AZs (BSN; green). Image from 
(Laghaei et al., 2018). D, A freeze-fracture replica of an AZ from a mouse NMJ. The hypothesized locations of 
synaptic vesicles are superimposed as white circles. Scale bar = 50 nm. Adapted from (Nagwaney et al., 2009) and 
(Fukuoka et al., 1987). E, Diagrams of a single AZ from a frog NMJ (left) and mouse NMJ (right). Diagram shows 
docked synaptic vesicles (blue spheres), N-type VGCCs in the frog AZ (red disks), P/Q-type VGCCs in the mouse 
AZ (purple disks), and other intramembranous AZ particles (yellow disks). Adapted from (Laghaei et al., 2018) and 
originally from (Urbano et al., 2003), copyright (2003) National Academy of Sciences. 
1.4 Lambert-Eaton Myasthenic Syndrome 
1.4.1 Clinical properties 
Lambert-Eaton myasthenic syndrome (LEMS) is an autoimmune-mediated neuromuscular 
disease which results from the immune system targeting AZs proteins at the NMJ, mainly by 
producing antibodies targeting P/Q-type VGCCs. LEMS is a rare disease with a prevalence of 3.4 
cases per million people (Titulaer, Lang, & Verschuuren, 2011a). LEMS is often considered a 
paraneoplastic syndrome because 50-60% of cases are associated with small-cell lung carcinoma 
(Titulaer et al., 2011b), and in rare cases has been associated with other malignancies such as non-
small cell lung carcinoma (Wirtz et al., 2002) and prostate carcinoma (Titulaer & Verschuuren, 
2008). Paraneoplastic instances of LEMS tend to be associated with older, male patients with a 
long-term history of smoking, whereas idiopathic LEMS patients tend to be younger and are more 
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likely to be female. In almost all paraneoplastic LEMS cases, LEMS symptoms precede the 
diagnosis of small-cell lung carcinoma, and LEMS patients are routinely screened for lung cancer 
after their LEMS diagnosis (Titulaer et al., 2011a). The paraneoplastic relationship of LEMS with 
small-cell lung carcinoma is due to the fact that small-cell lung carcinomas are neuroendocrine in 
origin (Kalemkerian et al., 2013) and tend to overexpress VGCCs as well as other AZ proteins 
(David et al., 1993). Thus, paraneoplastic LEMS is a result of the immune system response to the 
tumor (Roberts et al., 1985). 
LEMS is diagnosed based on clinical symptoms, electrophysiological measurements, and 
tests for the presence of antibodies (Kesner et al., 2018; Titulaer et al., 2011a). The primary 
symptom of LEMS is severe muscle weakness. It tends to start in the proximal legs and then 
spreads to the proximal arms, followed by the distal limbs and cranial muscles (Schoser et al., 
2017). LEMS is often associated with decreased tendon reflexes, and is frequently associated with 
autonomic dysfunction including dry mouth, constipation, and erectile dysfunction. Symptoms 
tend to progress faster in paraneoplastic LEMS than in idiopathic LEMS (Titulaer et al., 2011a). 
Repeated nerve stimulation tests using electromyography are often utilized for the 
diagnosis of LEMS. EMG tests of LEMS patients often display three primary findings: a reduced 
compound muscle AP amplitude at rest, a decrease in response over time during low-frequency 
repetitive nerve stimulation, and an increase in response over time during high-frequency repetitive 
nerve stimulation (Eaton & Lambert, 1957). However, these typical electrophysiological 
properties are not seen in all LEMS patients, and other tests such as examining post-exercise 
facilitation are also used (Oh, 2016; Oh et al., 2007). 
The presence of antibodies targeting P/Q-type VGCCs is thought to support a LEMS 
diagnosis (Vincent, Lang, & Newsom-Davis, 1989), but is not a complete explanation of the 
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immune nature of LEMS. Although anti-P/Q-type VGCCs are the most common antibody type, 
they are only present in 80-95% of LEMS patients (Kesner et al., 2018; Lennon et al., 1995; 
Motomura et al., 1997; Takamori et al., 1995). However, injection of serum from LEMS patients 
without P/Q-type antibodies into mice was able to passively transfer LEMS symptoms to mice, 
indicating that seronegative LEMS is still antibody mediated (Nakao et al., 2002). Furthermore, 
some small-cell lung carcinoma patients without LEMS have been found to produce P/Q-type 
antibodies (Titulaer et al., 2009), and anti-VGCC antibody titers were not found to be predictive 
of long term disease outcome (Maddison et al., 2001). This suggests that the immune nature of 
LEMS is more complicated than simply the presence or absence of P/Q-type VGCC antibodies. 
There are multiple types of antibodies that target different parts of the P/Q-type VGCC protein 
(Parsons & Kwok, 2002). Furthermore, LEMS patients have been found to produce many types of 
antibodies other than anti-P/Q-type, and the titer and types of antibodies can vary greatly between 
patients. 25-40% of LEMS patients produce N- and/or L-type VGCC antibodies, but most of these 
patients also produced P/Q-type antibodies (Johnston et al., 1994; Martin-Moutot, De Haro, & 
Seagar, 2008; Motomura et al., 1997). Antibodies have also been found for both synaptotagmin-1 
(Takamori et al., 1995) and M1-type presynaptic muscarinic acetylcholine receptors (Takamori, 
2008) in LEMS patient serum. 
1.4.2 LEMS neuromuscular physiology 
Because LEMS is an antibody-mediated disease, and because many of the proteins targeted 
by LEMS are well-conserved between species, LEMS can be passively transferred to mice by 
repeatedly injecting them with serum from human LEMS patients (Fukunaga et al., 1983; Lang et 
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al., 1984). The creation of these LEMS mice has allowed for a wide variety of investigations into 
the neuromuscular physiology of LEMS.  
Early freeze fracture electron microscopy studies of biopsied muscle tissue from human 
LEMS patients showed a decrease in the number of presynaptic AZs and a disorganization of 
particles in remaining AZs (Fukunaga et al., 1982). Similar results were found by freeze fracture 
electron microscopy in presynaptic terminals of LEMS-model mouse NMJs (Fukunaga et al., 
1983; Fukuoka et al., 1987). This disruption of the AZ structure is generally thought to be due to 
the antibody-mediated loss of P/Q-type VGCCs, and explains the muscle weakness seen in LEMS 
patients: the reduction in P/Q-type VGCCs leads to a reduced influx of calcium ions during an AP, 
which results in a reduction of neurotransmitter release and a subsequent reduction in muscle 
activation. This hypothesis is further supported by evidence that P/Q-type calcium current in 
LEMS mice is 30-40% less than in controls (Smith et al., 1995; Xu, Hewett, & Atchison, 1998). 
Furthermore, the lateral displacement of remaining P/Q-type calcium channels may cause a further 
reduction in transmitter release, as movement of the VGCCs away from the calcium-sensing 
protein will reduce their effectiveness. 
Blocking the P/Q-type VGCCs in a healthy mouse NMJ will normally completely block 
neurotransmitter release, suggesting that under healthy conditions P/Q-type VGCCs are the only 
type of AZ close enough to the vesicles in the AZ to induce transmitter release. However, in LEMS 
mice, other VGCC types (primarily L-type) have been found to contribute to transmitter release 
(Flink & Atchison, 2002; Smith et al., 1995; Xu et al., 1998). This is generally thought to be a 
compensatory attempt by the NMJ to increase transmitter release by overexpressing VGCC types. 
Despite this compensation, LEMS mouse NMJs release 60-75% less neurotransmitter than healthy 
controls (Flink & Atchison, 2002; Fukunaga et al., 1983; Lang et al., 1983; Tarr et al., 2014; Tarr 
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et al., 2013b). Since L-type VCGGs do not contain the synaptic protein interaction (synprint) site 
that is necessary to associate with AZs, they are likely place outside of the AZ (Catterall, 1999; 
Mochida et al., 2003; Sheng, Westenbroek, & Catterall, 1998). Indeed, preliminary experiments 
on LEMS passive-transfer mice found that L-type channel contribution to transmitter release is 
blocked by the addition of low concentrations of DM-BAPTA buffer, suggesting that the L-type 
channels are not within close proximity to the calcium sensing proteins in the AZs (Flink, 2003). 
1.5 Treatment of Lambert-Eaton Myasthenic Syndrome 
In patients with paraneoplastic LEMS, the treatment of cancer is the main priority, and 
successful treatment of the cancer often also results in the treatment of LEMS. For idiopathic 
LEMS patients, there is no cure. However, the FDA has recently approved 3,4-Diaminopyridine 
for the treatment of LEMS under the brand name Firdapse. There are also several 
immunomodulatory therapies available. 
1.5.1 Symptomatic treatment with 3,4-Diaminopyridine 
3,4-Diaminopyridine (3,4-DAP) is currently the only FDA approved treatment option for 
LEMS. Although it was only recently approved, it has been used off-label under a compassionate 
care provision as a LEMS treatment for several decades. 3,4-DAP is a voltage-gated potassium 
channel blocker. By blocking potassium channels, it broadens the AP, which increases the 
probability that the remaining VGCCs in the AZ will open during a given AP. This then results in 
an increase in calcium ion flux during an AP, and a subsequent increase in transmitter release. 
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However, 3,4-DAP dosing is limited by side effects. It is well tolerated in general, usually only 
causing mild side effects such as a paresthesia and gastrointestinal symptoms (Keogh, 
Sedehizadeh, & Maddison, 2011; Titulaer et al., 2011a). However, at high doses (> 100 mg per 
day) it can cause seizures (Lindquist & Stangel, 2011; Sanders et al., 2018; Sanders et al., 2000). 
Thus, 3,4-DAP dosing is typically limited to 80 mg/day (Kesner et al., 2018). A standard dose of 
3,4-DAP has been found to result in a serum concentration of approximately 1-1.5 μM (Haroldsen 
et al., 2015a; Haroldsen et al., 2015b; Ishida et al., 2015; Thakkar et al., 2017; Wirtz et al., 2009). 
Ex vivo experiments with these concentrations have been shown to approximately double 
neurotransmission from presynaptic NMJ terminals in LEMS mice. However, in mice with a 75% 
reduction in transmitter release compared to healthy controls, this only improves the transmitter 
release to 50% of healthy controls (Tarr et al., 2014). As a result, 3,4-DAP only provides a mild 
symptomatic improvement in LEMS patients, and normal physical activity is often not possible 
for LEMS patients even with 3,4-DAP treatment.  
1.5.2 Immunotherapies and cholinesterase inhibitors 
Although 3,4-DAP is the only FDA approved treatment for LEMS, it often only provides 
a moderate improvement in symptoms. Several other therapies are also used for the treatment of 
LEMS including cholinesterase inhibitors, immunosuppressants, intravenous immunoglobulin, 
and plasma exchange therapy. 
Cholinesterase inhibitors are compounds which prevent the degradation of acetylcholine 
in the synaptic cleft. Pyridostigmine is a cholinesterase inhibitor that is commonly used for the 
treatment of myasthenia gravis, and is occasionally used for the treatment of LEMS. Clinical 
studies on pyridostigmine in LEMS have found that pyridostigmine by itself is not effective, but 
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in combination with 3,4-DAP it may have an improvement in symptoms over 3,4-DAP alone (Tim, 
Massey, & Sanders, 2000; Wirtz et al., 2009). 
Other than drugs which target the behavior of the NMJ, such as 3,4-DAP and 
pyridostigmine, there are also several treatments for LEMS which target the immune system. Since 
3,4-DAP alone is often not able to completely alleviate symptoms, immunotherapy is often used 
(often in addition to 3,4-DAP) in a large portion (up to 70%) of patients (Maddison et al., 2001; 
Titulaer et al., 2011a).  If treatment with 3,4-DAP is not sufficient to alleviate chronic weakness, 
an immunosuppressive combination of prednisolone and azathioprine is often used as next line of 
treatment in addition to 3,4-DAP (Maddison et al., 2001; Newsom-Davis, 1998). However, 
treatment with prednisolone and azathioprine was found to only result in a mild improvement in 
symptoms, and high doses of prednisolone were still required 3 years after beginning treatment 
(Maddison, 2012; Maddison et al., 2001). There has been some evidence that Rituximab, which 
destroys B lymphocytes, may cause a moderate improvement in symptoms of LEMS patients 
(Boutin et al., 2013; Maddison et al., 2011; Pellkofer, Voltz, & Kuempfel, 2009). However, long 
term use of immunosuppressants carries an increased risk of infection, and can also result in severe 
side effects. Side effects for prednisolone include weight gain, diabetes, depression, psychosis, 
glaucoma, and gastrointestinal hemorrhaging. Side effects for azathioprine include flu-like 
symptoms, pancreatitis, and hepatitis (Skeie et al., 2010). Furthermore, there is a theoretical 
concern in patients with paraneoplastic LEMS that immunosuppression drugs may reduce the 
ability of the immune system to suppresses the growth of the tumor (Kesner et al., 2018; Maddison 
et al., 1999; Titulaer & Verschuuren, 2008). 
For the treatment of LEMS with a rapid onset of symptoms, intravenous immunoglobulin 
or plasmapheresis are sometimes used in combination with other treatments. Plasmapheresis 
 23 
removes the plasma, which contains the antibodies, from the blood. Plasmapheresis has been 
shown to create a rapid improvement in LEMS symptoms, but this improvement only lasts for 2 
to 4 weeks (Newsom-Davis, 2003; Newsom-Davis & Murray, 1984). Because of this relatively 
short period of benefit, plasmapheresis is not commonly prescribed, especially in the United States. 
1.5.3 Potential for treatment with calcium channel agonists 
3,4-DAP indirectly increases calcium ion flux into the presynaptic terminal by broadening 
the AP. Recently, drugs have been developed which act directly on VGCCs to increase calcium 
flux during and AP. The drug (R)-roscovitine was an early example of a drug with such an effect, 
and was found to prolong the mean open time of N- and P/Q-type VGCCs (DeStefino et al., 2010). 
However, (R)-roscovitine also inhibits cyclin-dependent kinases, making it unattractive for clinical 
use due to the lack of drug target specificity. More recently, several analogs have been made based 
on the chemical structure of (R)-roscovitine which retain the effect on VGCCs but no longer inhibit 
cyclin-dependent kinases at physiological concentrations of ATP (Wu et al., 2018a).   
One such drug is GV-58. GV-58 is a direct VGCC positive allosteric gating modifier which 
prolongs the mean opening time of N- and P/Q-type VGCCs, and does not have any measurable 
effects on cyclin-dependent kinases. Ex vivo experiments with the maximally effective dose of 
GV-58 have shown that it has a similar effect on transmitter release to clinically relevant 
concentrations of 3,4-DAP, approximately doubling the transmitter release in LEMS mice (Tarr et 
al., 2013b). However, when combined with 3,4-DAP it has been shown to have a super-additive 
effect, where the combination of the two drugs has a greater effect than the sum of the effects of 
each drug. This super-additive effect occurs because 3,4-DAP increases the likelihood that VGCCs 
open during a given AP, and the GV-58 holds those open channels open for longer. The 
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combination of these two drugs has been shown in ex vivo experiments in LEMS model mice to 
completely restore transmitter release to the levels of healthy control mice (Tarr et al., 2014). As 
a result, GV-58 and other calcium channel agonists are a promising potential treatment for LEMS, 
especially in combination with 3,4-DAP.  
1.6 Voltage imaging 
The action potential in neurons is typically recorded through the use of microelectrodes or 
patch-clamp electrophysiology. Although this technology is very sensitive and has high temporal 
resolution, it is limited by the ability to use these electrodes on small cellular compartments. With 
a few notable exceptions (such as the squid giant axon), most axons and dendrites are too small to 
probe with an electrode (Peterka, Takahashi, & Yuste, 2011). As a result, most recordings of the 
AP are from the soma of neurons. However, due to the geometry as well as the number, type, and 
distribution of ion channels throughout the cell, the AP can vary greatly between different parts of 
the neuron (Rowan et al., 2016). Voltage imaging is a developing technology that provides a means 
to potentially overcome the pitfalls of traditional electrophysiology. In voltage imaging, a voltage 
sensitive indicator is placed into the membrane of the cell. The fluorescence response of these 
indicators changes as the voltage across the membrane changes. This allows the recording of the 
voltage with a camera that can detect these changes in fluorescence.  
Voltage indicators generally fall into two different categories: genetically encoded 
indicators or voltage sensitive dyes (Kulkarni & Miller, 2017). Voltage sensitive dyes were first 
developed in the 1970s, but early dyes were limited by many issues such as slow response to 
voltage changes and low sensitivity. Since then, many advances have been made. Recent work has 
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employed photoinduced electron transfer as the voltage sensitive mechanism. These recent 
photoinduced electron transfer-based dyes are both fast and sensitive enough to monitor subtle 
changes in membrane potential dynamics (Huang, Walker, & Miller, 2015; Miller, 2016). 
Genetically encoded voltage indicators were first developed in 1997. They allow for a more 
targeted approach of specific neuronal subtypes, but have several limitations such as the targeting 
of the genetic expression (Kulkarni & Miller, 2017).  
Voltage imaging essentially has two different uses: 1) simultaneously measuring voltage 
from multiple neurons, and 2) measuring voltage from small regions of single neurons. Briefly, 
the first use of simultaneously recording voltages from multiple neurons would allow researchers 
to understand the communication between neurons in neural circuits with as many neurons as can 
be imaged. This has been performed in vitro for several years now, but technological advances in 
both the voltage indicators as well as camera technology has made in vivo recordings available 
only recently. When combined with optogenetics, voltage imaging allows for “all optical 
electrophysiology”, which will certainly make many important discoveries in neuroscience in the 
coming years (Hochbaum et al., 2014).  
The second use of voltage imaging is to record the action potential in smaller regions of 
the neuron, such as the axons or dendrites (Ford & Davis, 2014; Ginebaugh et al., 2020; Hoppa et 
al., 2014; Popovic et al., 2011; Rowan et al., 2016). Using voltage imaging to record the action 
potential in smaller regions of the neuron allows us to understand the computation performed by 
the axons and dendrites and the contributions these regions play to the behavior of the neuron as a 
whole. When measuring the voltage in multiple neurons simultaneously, it is possible to measure 
the voltage in the smaller parts of the neurons. However, the large recording window and the 
camera speed required to record from many neurons at once often makes these smaller sections of 
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the neurons only a few pixels wide, limiting the accuracy of such recordings. Currently, most of 
the multi-neuron voltage imaging experiments focus mainly on the AP waveforms in the somas. 
In the future, as camera and voltage indicator technology improve, it may be possible to accurately 
resolve all sections of each neuron simultaneously.   
1.7 Computational modeling of the active zone 
1.7.1 The advantages of computational modeling 
The small scale of the AZ makes it very difficult to investigate experimentally. This is 
largely due to the fact that intermembranous particles are spaced as little as 14 nm apart (Fukuoka 
et al., 1987), well below the Abbe diffraction limit of ~200 nm (Abbe, 1873). Electron microscopy 
techniques such as freeze-fracture electron microscopy (Fukunaga et al., 1983; Fukuoka et al., 
1987; Heuser et al., 1974; Pawson et al., 1998a; Pawson, Grinnell, & Wolowske, 1998b; Peper et 
al., 1974; Pfenninger et al., 1972) and electron tomography (Nagwaney et al., 2009) can investigate 
the structure of the AZ, but are limited by their inability to investigate live cells and difficulty in 
determining the identity of particles found by this form of imaging. Electrophysiology experiments 
using BAPTA and EGTA buffers can also provide some information about the distance between 
particles within the AZ, but can only give a general estimate of how close different particle types 
are spaced and cannot estimate the number of particles. Super-resolution microscopy techniques 
have also provided information about the active zone structure (Nishimune et al., 2016). However, 
super-resolution techniques that could resolve the location of particles in the AZ currently have 
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several limitations such as the development of appropriate probes for the particles in the AZ 
structure (Collot et al., 2019).  
Computational modeling provides a means to investigate the AZ on a scale below the limits 
of microscopy. Computational modeling can also be used to understand complex molecular 
interactions and predict their effects on cellular physiology, and to ask questions that may never 
be possible experimentally (e.g., what electrophysiological changes occur by rearranging a frog 
AZ to the structure of a mouse AZ without altering any biophysical parameters? (Laghaei et al., 
2018)).  
1.7.2 Selecting a method for computational modeling 
A variety of methods and software exist for the computational simulations of biological 
systems. One important factor in selecting the proper tool is the scale of the system in question. 
For simulations of multiple neurons, programs such as NEURON (Carnevale & Hines, 2005; Hines 
& Carnevale, 1997, 2001) or algorithms such as an integrate-and-fire network can be used. 
NEURON is also useful for modeling of neurons as a whole. However, NERUON is limited in its 
scale, and cannot model important sub-cellular physiology such as complex sub-cellular 
geometries or the behavior of ions on a small scale.  
For the modeling of sub-cellular physiology, a variety of programs exist as well. Many of 
these programs, such as STEPS (Hepburn et al., 2012), use a voxel-based approach. In this 
approach, a sub-cellular region is divided into voxels, and the concentration of particles is 
estimated in each voxel at each time step. 
One of the most important factors determining the rate of transmitter release is the behavior 
and dynamics of calcium ions as they enter into and diffuse throughout the AZ. At the small scale 
 28 
of the AZ, the 3D structure of the cell often becomes an important factor in determining the 
behavior of the system, and is essential to include for accurate modeling. The complex and 
irregular geometry of the AZ, in addition to the fact that the number of particles in a small section 
of the AZ may be very low, makes models which use voxel-based approaches inaccurate (Stefan 
et al., 2014). Thus, programs such as STEPS are able to model a region smaller than programs 
such as NERUON, but are still not able to model at the scale of the AZ. A way to avoid these 
issues is to use a particle-based spatial stochastic approach. In a particle-based model, each 
molecule is simulated and stochastically diffused through the cell. As a result, arbitrarily complex 
3D cellular ultrastructures and low concentrations of particles can be accurately modeled in the 
simulation. 
The software used in this research to model the AZ is called MCell. MCell uses Monte 
Carlo methods to create particle-based, stochastic, realistic reaction-diffusion simulations of 
subcellular systems with arbitrarily complex 3D geometry (Kerr et al., 2008; Stiles et al., 1996). 
Because it is particle based, the location of each ion diffusing throughout the AZ is simulated at 
each timestep, allowing for an accurate model of the calcium dynamics at the scale of the AZ. 
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2.0 The frog motor nerve terminal has very brief action potentials and three electrical 
regions predicted to differentially control transmitter release 
The action potential (AP) waveform controls the opening of voltage-gated calcium 
channels and contributes to the driving force for calcium ion flux that triggers neurotransmission 
at presynaptic nerve terminals. Although the frog neuromuscular junction (NMJ) has long been a 
model synapse for the study of neurotransmission, its presynaptic AP waveform has never been 
directly studied, and thus the AP waveform shape and propagation through this long presynaptic 
nerve terminal are unknown. Using a fast voltage-sensitive dye, we have imaged the AP waveform 
from the presynaptic terminal of male and female frog NMJs and shown that the AP is very brief 
in duration and actively propagated along the entire length of the terminal. Furthermore, based on 
measured AP waveforms at different regions along the length of the nerve terminal, we show that 
the terminal is divided into three distinct electrical regions: A beginning region immediately after 
the last node of Ranvier where the AP is broadest, a middle region with a relatively consistent AP 
duration, and an end region near the tip of nerve terminal branches where the AP is briefer. We 
hypothesize that these measured changes in the AP waveform along the length of the motor nerve 




Action potential (AP) invasion of the presynaptic nerve terminal activates voltage-gated 
calcium channels (VGCCs) positioned within active zones (AZs; highly organized site of synaptic 
transmission that contain an ordered array of synaptic vesicles and VGCCs) of the motor nerve 
terminal (Cohen, Jones, & Angelides, 1991; Heuser & Reese, 1981; Pumplin, Reese, & Llinas, 
1981; Robitaille, Adler, & Charlton, 1990), resulting in an influx of calcium that triggers the 
exocytosis of neurotransmitter (Dodge & Rahamimoff, 1967; Luo et al., 2015; Meriney & Dittrich, 
2013). Although the frog neuromuscular junction (NMJ) has been a model synapse for the study 
of synaptic transmission, its AP has never been directly studied due to the small diameter of the 
nerve terminal making traditional electrophysiological recording difficult. 
The size and shape of the AP waveform greatly impacts transmitter release by controlling 
both the activation of VGCCs and the driving force for calcium entry through VGCCs while they 
are open (Borst & Sakmann, 1999; Pattillo et al., 1999; Sabatini & Regehr, 1997). The AP has 
been recorded from isolated adult frog spinal neurons (Dambach & Erulkar, 1973; Erulkar & 
Soller, 1980; Ovsepian & Vesselkin, 2006). However, the shape of the AP waveform at the adult 
motor nerve terminal is likely different because recordings in other neurons have found large 
discrepancies between AP waveforms at the soma and axon (Hoppa et al., 2014; Popovic et al., 
2011; Rowan et al., 2016). Furthermore, the AP waveform has been shown to vary along the axons 
of other types of neurons due to several factors including the geometry of the axon and distributions 
of different types of voltage-gated ion channels (Hoppa et al., 2014; Rowan et al., 2016).  
It was originally hypothesized that the AP is actively propagated along the length of the 
frog motor nerve terminals by voltage-gated sodium channels distributed along the entire length 
of the terminal (Braun & Schmidt, 1966; Katz & Miledi, 1965b, 1968). However, the possibility 
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that the AP may be passively propagated through these nerve terminal branches has also been 
proposed (Mallart, 1984; Robitaille & Tremblay, 1987). Furthermore, active propagation of the 
AP has been called into question by reports of proximal-distal gradients in neurotransmitter release 
magnitude along the length of frog motor nerve terminals (Bennett, Jones, & Lavidis, 1986a; 
Bennett, Jones, & Lavidis, 1986b; Bennett, Lavidis, & Lavidis-Armson, 1989; D'Alonzo & 
Grinnell, 1985; Mallart, 1984; Tremblay, Robitaille, & Grenon, 1984; Zefirov & Khalilov, 1985), 
and because these changes are not caused by differences in proximal-distal distribution of AZ 
structure (Pawson et al., 1998b).  
Here, we use a fast voltage-sensitive dye (Huang et al., 2015) to record the presynaptic AP 
waveform at the frog NMJ and investigate the changes to this waveform as it propagates down the 
motor nerve terminal. We show (1) that the AP waveform is very brief in duration, (2) the 
presynaptic terminal of the frog NMJ has three distinct electrical regions, and (3) that the changes 
in the AP waveform as it propagates along the length of the terminal are not caused by changes in 
nerve terminal geometry. Using imaged AP waveforms and previously validated computer 
simulations, we predicted effects of our recorded AP waveforms on presynaptic calcium entry and 
transmitter release, and hypothesize that changes in the shape of the AP may be responsible for 
proximal-distal differences in neurotransmitter release that were previously reported. 
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2.2 Materials and Methods 
2.2.1 Cutaneous pectoris nerve-muscle preparations 
Experiments were performed on cutaneous pectoris nerve-muscle preparations from both 
male and female adult frogs (Rana pipiens). Frogs were anesthetized in a 0.1% tricaine solution, 
then decapitated and double-pithed in adherence to the procedure approved by the University of 
Pittsburgh Institutional Animal Care and Use Committee. Preparations were dissected bilaterally 
and bathed in normal frog Ringer’s solution (NFR; 116 mM NaCl, 2 mM KCl, 5mM dextrose, 1 
mM MgCl2, 1.8 mM CaCl2, pH 7.3-7.4, and 10 mM BES).  
2.2.2 Voltage imaging 
The BeRST 1 dye (Huang et al., 2015) was stored in 5 mM aliquots in DMSO at -80°C. 
On the day of use, 0.5 μL of BeRST 1 dye stock solution was diluted into 4.5 μl of DMSO initially, 
and then this mixture was diluted into 0.5 ml of NFR (for a final BeRST 1 concentration of 5 μM). 
This final loading solution also contained 10 μg/ml of Alexa Fluor 488-conjugated α-bungarotoxin 
(BTX) to counter stain postsynaptic receptors at the NMJ. To load nerve terminals with dye for 
the voltage-imaging procedure, the neuromuscular preparation was mounted over an elevated 
Sylgard platform in a 35 mm dish and incubated with the dye mixture described above for 90 
minutes. The dye-loaded and BTX-stained preparation was then rinsed with NFR, mounted on the 
microscope stage, and the nerve was drawn into a suction electrode for supra-threshold stimulation. 
If the BTX conjugated to Alexa Fluor 488 did not completely block muscle contractions, 10 μM 
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curare was added to the imaging saline to completely block postsynaptic acetylcholine receptors 
and prevent nerve-evoked muscle contractions. 
For voltage imaging, tissue was mounted on an Olympus BX61 microscope equipped with 
a 60x water immersion objective. Nerve terminals were identified using the BTX staining, and this 
label was also used to bring the terminals into focus for voltage imaging. Superficial nerve 
terminals tended to load a higher concentration of BeRST 1 dye and produce noticeable less-noisy 
data than nerve terminals embedded deeper in the muscle. Thus, all terminals imaged were on the 
surface of the muscle. After locating a well-stained nerve terminal, we selected an imaging region 
of interest (ROI) of approximately 80x30 μm that contained a large portion of the nerve terminal 
branch (Figure 2A, B). All voltage imaging was performed in NFR at room temperature (20-25 
°C). 
Presynaptic nerve terminals in the frog cutaneous pectoris nerve-muscle preparations were 
stimulated at 0.2 Hz, and BeRST 1 dye fluorescence was recorded by an EMCCD camera (Pro-
EM 512, Princeton Instruments). Image capture was coupled to illumination by a 640 nm laser (89 
North laser diode illuminator) that only illuminated the tissue during the brief 100 μs image 
collection window. The entire AP waveform was sampled through a moving-bin acquisition 
scheme, where 100 bins were collected sequentially over the time course of an AP waveform that 
was elicited repeatedly at 0.2 Hz. A custom routine on a Teensy 3.5 USB development board 
(PJRC) created a delay between the stimulation of the nerve and the triggering of the camera and 
laser. This delay was increased by 20 μs after each stimulation in the collection time course. After 
100 bins were collected, the delay was reset to 0. This process was repeated 5-20 times for each 





Figure 2 Imaging of the nerve terminal. 
A, An image of a presynaptic motor nerve terminal stained with BeRST 1 dye. B, The same nerve terminal 
as in A stained with Alexa Fluor 488 α-BTX. C, An Otsu local thresholding algorithm applied to the terminal in A to 
create an image mask. D, An outline of the Otsu threshold image applied as an ROI for BeRST 1 dye imaging. E, The 
Otsu local thresholding image with the end of the terminal removed for analysis. F, The outline of the Otsu 
thresholding image with the end removed and applied as an ROI for the BeRST 1 dye imaging. All scale bars are 10 
µm. 
2.2.3 Image and data analysis 
Images were analyzed in ImageJ and MATLAB (Mathworks) using custom written scripts. 
In ImageJ, the image stacks were stabilized for x-y drift using an “align slices in stack” ImageJ 
plugin (https://sites-google-com.pitt.idm.oclc.org/site/qingzongtseng/template-matching-ij-
plugin; see Tseng et al., 2012; Tseng et al., 2011). Then, an Otsu local image threshold (Otsu, 
1979) was applied to the average fluorescence z-projection of the stabilized BeRST 1 image stack 
 35 
to create an unbiased ROI selection containing the nerve terminal (Figure 2C, D). The average 
signal inside a subsection of this ROI (depending on the experiment) was used as the nerve signal. 
For control experiments, a region at least 20µm from the end and last node of Ranvier (Figure 2E, 
F) was used as the nerve signal (Figure 3A). The region outside of the Otsu selected ROI (Figure 
2C, D) was averaged and used as the background signal (Figure 3C). Both the background and 
nerve signals were then low-pass filtered offline (fpass = 4kHz, Figure 3B, D). We processed our 
signals both with and without filtering. We divided the unfiltered and filtered background 
fluorescence (Figure 3C, D) from the unfiltered and filtered nerve fluorescence (Figure 3A, B), 
respectively, to give us the unfiltered and filtered fluorescence signal (Figure 3E, F). To correct 
for z-axis drift (during which the live image could drift slightly in a non-linear fashion; see Figure 
3E, F), we fit a cubic B-spline to the points in the fluorescence time course during which there was 
no AP stimulation (the first and last 15 points of the 100 total points in each series). We then 
divided this spline from each point in the fluorescence signal to give us a ∆F/F fluorescence signal 
that did not fluctuate as a result of drift of the nerve muscle preparation (Figure 3G, H).  
The APs from the ∆F/F fluorescence signal were then averaged to create a single AP 
waveform (Figure 3I). To prevent discrepancies caused by including excessively noisy data, this 
analysis was performed both with (Figure 3B, D, F, H) and without (Figure 3A, C, E, G) the 
lowpass filter. We then calculated the R2 value between the averaged unfiltered and filtered AP 
waveforms (Figure 3I). Since we are not using a linear model, R2 is not an exact measure of fit 
between the filtered and unfiltered data, and is greatly affected by the ratio of the signal strength 
to the baseline noise. This provides a benefit in that not only will the R2 value detect a poor fit 
between the filtered and unfiltered data, but will also provide a low value if the AP signal is not 
sufficiently detected in comparison to the noise (see Figure 3S). This is essential because 
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normalizing any small signal on an otherwise flat waveform could appear as an AP. Thus, in this 
instance the R2 is analogous to the range-normalized root-mean-square deviation (NRMSD). 
However, R2 is less sensitive to outliers than the range-normalized (NRMSD) and provides easier-
to-interpret results. Thus, we used the R2 value only as a heuristic method to determine the quality 
of our recordings, and not for any statistical purposes. 
For some recordings, image artifacts in the background (for example, a free-floating piece 
of connective tissue stained with BeRST 1 dye) resulted in noisy data due to the improper 
background use for calculating the nerve signal. If the R-squared was less than 0.95 for the full 
image (Figure 7) and 20 μm ROI data (Figure 8) or 0.85 for the 10-pixel diameter small-circle ROI 
data (Figure 9), a subsection of the background near the nerve terminal of approximately 15x30 
μm was used rather the complete region outside the Otsu-selected ROI. If neither the full 
background selection or the smaller background sub-section resulted in an R-squared value higher 
than the values listed above, the recording was considered too noisy and was not included in the 
data analysis. If the recording was of high enough quality for analysis, the average AP was 
normalized to the baseline of the trace (the average value of the first 15 points), then cubic spline 
interpolation at an oversampled time resolution of 2 μs was fit to the filtered data, and the full 
width at half maximum (FWHM) of the AP waveform was calculated (Figure 3J).  
We performed this procedure on the same nerve terminal both in the presence and absence 
of 1μM tetrodotoxin, and showed that these optically recorded AP signals were Na+ channel 






Figure 3 Analysis of the AP waveform and the impact of TTX. 
Analysis of the AP waveform and the impact of TTX. A, C, The unfiltered fluorescence signals from the 
nerve and background selection of 800 sequential images collected from a motor nerve terminal ROI. B, D, The nerve 
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and background signals from A and C low-pass filtered at 4 kHz, including the ringing artifact on the edges of the 
recording (truncated in the vertical axis). E, F, The unfiltered and filtered fluorescence signals, created by dividing 
the fluorescence values in C from A, or D from B, respectively, showing eight AP waveforms (red) with a cubic spline 
fit (black) thorough the unstimulated (baseline) points. G, H, The unfiltered and filtered fluorescence signal after 
correcting for the baseline by dividing the cubic spline from the fluorescence signal in E and F. I, The average of the 
8 unfiltered AP waveforms from G (black dots) compared with the average of the eight filtered AP waveforms from 
H (magenta line). Comparing the two provides an R2 value, which represents a measure of the fit weighted by the 
signal strength compared with the baseline noise. J, The average filtered AP waveform from I, fit with an interpolating 
cubic spline and then normalized to the baseline of the trace (based on the average value of the first 15 points of the 
average filtered AP waveform). K–N, The unfiltered and filtered fluorescence signals from the nerve and background 
selection of 1000 images of the same nerve terminal as in A–D but in the presence of 1 μM TTX. O, P, The unfiltered 
and filtered fluorescence signals, created by dividing the fluorescence values in M from K or N from L, respectively, 
showing the signal (red) with a cubic spline fit (black) thorough the unstimulated (baseline) points. Q, R, The 
unfiltered and filtered fluorescence signal after correcting for the baseline by dividing the cubic spline from the 
fluorescence signal in O and P. S, The average of the 10 stimulation cycles of the unfiltered signal from Q (black 
dots) compared with the average of the 10 stimulation cycles of the filtered signal filtered from R (green line). The 
low R2 value shows that the TTX eliminates the presence of the sodium-dependent AP waveform. T, A comparison 
of the average filtered fluorescent signal before (magenta) and after (green) the application of TTX. 
 
Because the BeRST 1 dye stains all lipid membranes and connective tissues after bath 
application, the background was proportional to the total fluorescence, rather than being limited to 
standard camera shot noise. Thus, the background was divided, rather than subtracted, from the 
nerve signal to give us the fluorescence value used for analysis. Dividing the background also 
provided an additional advantage of eliminating the ringing artifacts caused by the lowpass filter 
overshooting the time domain. Furthermore, even when the ringing artifacts were removed, 
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dividing the background still resulted in a less noisy signal (determined by higher R-squared 
values) than subtraction (Figure 4).   
Based on previous research, we expected only a minor distortion caused by our use of 100 
µs collection windows (Popovic et al., 2011). To confirm this prediction, we first created a 
theoretical AP waveform in MATLAB using a normalized gaussian with a standard deviation of 
100 μs that consisted of 20000 points over 2000 time units, creating a waveform with a FWHM of 
235 μs (10 points per μs across a 2000 μs window created a smooth curve). We sampled this 
waveform every 20 µs with a 100 µs recording window (averaging all points within the window), 
mimicking our imaging procedure, or every 20 µs with a 50 µs recording windows, and compared 
the results to the true waveform we created. We found that using a moving-bin sampling approach 
with a 50 μs or 100 µs recording window created only a small increase in the FWHM of the 
theoretical AP waveform (1.5% or 4.2%, respectively; Figure 5A). We then confirmed that our 
sampling scheme had little effect on our experimental data by recording from a single motor nerve 
terminal with our 20 µs moving-bin acquisition scheme using 20, 50, and 100 µs recording 
windows, and found little difference in the predicted waveforms (Figure 5B). However, the data 
collected with the 100 µs recording window was much less noisy (and had much better R-squared 
values) than the data recorded with the 50 µs and 20 µs recording windows for the same number 
of images (Figure 5B). Thus, we chose to use 100 µs recording windows and we chose not to 
correct for the small distortion in the AP waveform. 
We made several attempts to calibrate the voltage by zeroing membrane potential using 
gramicidin (Hoppa et al., 2014; Maric et al., 1998; Meunier, 1984; Podleski & Changeux, 1969). 
However, we found that we were unable to block tissue movement caused by gramicidin even in 
the presence of a myosin chain blocker (BHC; Heredia et al., 2016). Thus, we chose to only report 
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changes in the width of the voltage-imaging-measured AP waveforms, as is common in other 
papers with voltage imaging (Ford & Davis, 2014; Popovic et al., 2011; Rowan et al., 2016; 
Rowan, Tranquil, & Christie, 2014; Rowan & Christie, 2017). As such, the focus of this report is 





Figure 4 Dividing the background signal from the nerve signal produces a better signal-to-noise waveform 
than subtracting the background signal. 
A–D, The unfiltered and filtered data from the same 800 images of a nerve terminal shown in Figure 3A–D. 
Here, the y-axis is expanded to show the full ringing artifact in the filtered data. E, F, The unfiltered and filtered 
fluorescence signals created by dividing the background fluorescence from the nerve fluorescence. G, H, The 
unfiltered and filtered fluorescence signals created by subtracting the background fluorescence from the nerve 
fluorescence. Notice how subtraction does not remove the ringing artifact in the filtered data. I–L, The fluorescence 
signals (red lines) with the outer 100 data points on each side (E–H, gray bars) removed to exclude the ringing artifact 
remaining in the filtered fluorescence data created by subtraction (H), fit with a cubic spline through the unstimulated 
points (black line). M–P, The unfiltered and filtered fluorescence signal after correcting for the baseline by dividing 
the cubic spline from the fluorescence signals. Q, R, The average of 6 unfiltered AP waveforms (black dots) compared 
with the average of six filtered AP waveforms (red line). Notice how subtracting the background created a noisier 
signal and weaker signal-to-noise ratio, and therefore a lower R2 value, even with the removal of the ringing artifact. 
S, T, The average filtered AP waveforms, fit with interpolating cubic splines and then normalized to the baseline of 








Figure 5 A 100μs recording window only causes a small distortion of the AP waveform, but improves the 
recording quality (as judged by the R2 values). 
A, A theoretical waveform created from a normalized Gaussian curve (black dots), compared with a 
waveform created by sampling the Gaussian with a 50 μs recording windows every 20 μs (magenta) and a waveform 
created by sampling the Gaussian with a 100 μs recording windows every 20 μs, mimicking our imaging procedure 
(green). This creates a theoretical 1.5 and 4.2% increase in the AP FWHM for the 50 and 100 μs recording windows, 
respectively. B, Normalized AP waveforms created from 1000 images each, with 20 μs (black), 50 μs (magenta), or 
100 μs (green) moving bin recording windows. The AP FWHM from the 100 μs recording window is slightly larger 
than from the 20 μs recording window, but has a better R2 value for the same number of images. 
2.2.4 MCell simulations 
MCell (www.mcell.org) was used to computationally study the impact of the 
experimentally recorded AP waveforms on AP-triggered calcium entry, and the impact of these 
waveforms on vesicle release from a modeled presynaptic nerve terminal AZ based on the frog 
NMJ. In brief, MCell is a particle-based, stochastic diffusion-reaction simulator that tracks the 
diffusion of particles through arbitrarily complex 3D structures (Kerr et al., 2008).  
Here, we utilized two different models. First, to measure the impact of the AP waveforms 
on VGCCs, a model which consisted of a box containing 10000 VGCCs was created. This box 
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model simply allowed for faster simulations and easier analysis of these VGCC characteristics 
because these simulations did not need to keep track of numerous other parameters. During a 
MCell run, an AP waveform triggered VGCCs to open stochastically according to an AP driven 
Markov-model ion channel gating scheme (Figure 6). When open, calcium ions entered the 
simulation environment from VGCCs at a rate determined by the instantaneous driving force. The 
total calcium inside the box and the probability of VGCCs opening were recorded during the AP 
waveform input. 
Second, we used a previously-described frog computational model of a frog motor nerve 
terminal active zone to measure the impact of the experimental AP waveforms on transmitter 
release, as has been described previously (Dittrich et al., 2013; Homan et al., 2018; Laghaei et al., 
2018; Ma et al., 2014). This single AZ model contained 26 synaptic vesicles and 26 VGCCs 
(driven by the same voltage-dependent gating scheme (see below and Figure 6) as in the box 
model) arranged in a double row at a 1:1 VGCC to synaptic vesicle stoichiometry (Luo et al., 
2011). The bottom of each vesicle contained synaptotagmin-1 and second sensor binding sites 
(similar to synaptotagmin-7) responsible for triggering vesicle release (Ma et al., 2014). During an 
AP waveform, calcium diffused into the AZ model and bound to either calcium buffer (which was 
distributed evenly throughout the terminal) or to the calcium sensor sites (synaptotagmin-1 or 
second sensor sites) on the synaptic vesicles. When a sufficient amount of calcium was bound to 
the sensor sites (see Dittrich et al., 2013; Ma et al., 2014), the vesicle was considered to be 
“released”. Since these simulations are stochastic, 4800 simulations were run for each waveform 
input. 
The only differences between the previous reported frog AZ model and the AZ model used 
in this work were different AP waveform inputs to the model (see Figure 8F and Figure 13A), and 
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new rate constants for the AP driven Markov chain ion channel gating scheme which drives the 
behavior of VGCCs in our model (Figure 6) (Dittrich et al., 2013). This gating scheme, like the 
scheme used in previous models, is a linear four-state model with three closed states and one open 
state. When in the open state, calcium ions enter the simulations environment from VGCCs with 
Poisson probability based on the parameter k = (−γG/2e) ∗ (Vm − E𝐶𝑎), where Vm is the 
membrane voltage (determined by the AP waveform input), G = 2.4 is the channel conductance, 
ECa = +50mV is the equilibrium potential, e is the elementary charge, and γ = 0.9 is a scaling 
constant to account for the fact that the channel conductance was originally determined in 2 mM 
extracellular calcium. The rates for forward transitions between the states were determined by rate 
constants multiplied by the voltage-dependent parameter α, and reversal rates were determined by 
rate constants multiplied by the voltage-dependent parameter β, where 𝛼 = 0.06 exp((Vm + 24) /
14.5) and 𝛽 = 1.7/(exp ((𝑉𝑚 + 34)/16.9) +  1). These rate constants were parametrized based 
on an experimentally measured whole-cell calcium current (see Dittrich et al., 2013; Pattillo et al., 
2001). α and β were the same as used in previous models, but the forward and reversal rate 
constants were reparametrized to fit the predicted calcium current activated by our newly recorded 
AP waveform. 
To modify our experimentally imaged APs for input into MCell (importantly, to set the AP 
waveform to a membrane voltage, and to put the waveform in a MCell-friendly format), we 
normalized the waveforms to a resting potential of -60 mV and a peak voltage of 30 mV. To 
remove fluctuations near the onset of the rising phase of the APs caused by noise in the 
experimental data, we standardized the beginning of the rising edge of each AP by replacing the 
first 10% of the rising edge with a line that had the same slope as the next 10% of the rising edge. 
To reduce fluctuations caused by noise after repolarization of the APs, we smoothed the 
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Figure 6 The four-state Markov chain VGCC gating scheme. 
The gating scheme that determines the opening behavior of VGCCs in both the frog AZ MCell model and 
the 10,000 VGCC MCell box simulation. 
2.2.5 NEURON simulations 
A passive model of a frog motoneuron nerve terminal was simulated in NEURON, version 
7.7 (https://www.neuron.yale.edu/neuron/; Hines & Carnevale, 1997, 2001). This model was a 
single tube with a length of 200 μm (approximately the average length of our recorded nerve 
terminals) and a diameter of 3.14 μm (the average diameter of our recorded nerve terminals). The 
axial resistance was set to 110 Ω cm (Miralles & Solsona, 1996), the leak conductance was set to 
1e-5 S/cm2 (Lindgren & Moore, 1989), the membrane capacitance was set to 1 μF/cm2, and the 
temperature was set to 20°C. A recorded AP waveform was input into one end of the passive tube 
with a single electrode voltage clamp, and the shape and FWHM of the AP waveform as it 
passively propagated were recorded. 
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2.3 Results 
2.3.1 Action potentials at the adult frog neuromuscular junction are brief in duration 
To date, there have been several studies of the action potential waveforms at small nerve 
terminal boutons using voltage-sensitive dyes (Popovic et al., 2011; Rowan et al., 2016; Rowan et 
al., 2014). However, there have been no AP waveform measurements at the long, linear, adult 
motor nerve terminals present at the frog NMJ. Using a live-cell imaging approach, we measured 
the response of a fast voltage-sensitive dye (BeRST 1) to AP waveforms propagating along the 
frog motor nerve terminal (although the temporal resolution of BeRST 1 has not been recorded, 
dyes with a similar chemical structure respond to changes in membrane potential in approximately 
25 ns; Beier et al., 2019). For all experiments, we measured the full width at half maximum 
amplitude (FWHM) to characterize effects on the duration of the AP. 
We found the AP in the adult frog motor nerve terminal to be very brief (the average 
FWHM of all control recordings (n = 32) was 273.9 ± 10.7 μs; Figure 7). This is much briefer than 
might have been expected based on AP waveforms previously recorded from isolated adult frog 
spinal neurons (Dambach & Erulkar, 1973; Erulkar & Soller, 1980; Ovsepian & Vesselkin, 2006) 
and cultured embryonic frog motoneuron varicosities (Pattillo et al., 2001; Yazejian et al., 1997), 
where AP FWHM values range between 800-1200 μs. Interestingly, we also found a relatively 
large variability in the measured AP FWHM values across different NMJs (ranging from ~200 μs 
to ~400 μs FWHM). This is consistent with the large range in quantal content observed across 
individual NMJs (Laghaei et al., 2018), even when corrected for nerve terminal length (Grinnell 






Figure 7 AP durations from all control images. 
A scatter plot showing the range of AP durations (FWHM) from all control images (line = mean 6 SEM), 
where the nerve ROI selection was at least 20mm from both the end of the terminal and the last node of Ranvier. The 
AP waveform in the frog motor nerve terminal is very brief and can vary between terminals. 
2.3.2 Differences in action potential duration along the length of motor nerve terminal 
branches reveal three distinct electrical regions.   
Previous studies have shown that transmitter release varies along the length of the frog 
NMJ (Bennett et al., 1986a; Bennett et al., 1986b; Bennett et al., 1989; D'Alonzo & Grinnell, 1985; 
Mallart, 1984; Tremblay et al., 1984; Zefirov & Khalilov, 1985). There is some debate as to the 
average magnitude and distribution of these proximal-distal changes: some studies suggest a 
continuous proximal-distal decrease in transmitter release (Bennett et al., 1986a; Bennett et al., 
1986b; Bennett et al., 1989), while others suggest that the transmitter release is greatest near the 
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point at which the axon enters the presynaptic nerve terminal near the last node of Ranvier, reduces 
slightly but maintains a consistent level throughout the middle 60-90% of the nerve terminal, and 
then is reduced near the ends of the nerve terminal (D'Alonzo & Grinnell, 1985). Initially, this 
behavior was hypothesized to have been caused by proximal-distal changes in the structure of the 
AZs. However, freeze-fracture electron microscopy studies subsequently showed that there are no 
proximal-distal changes in AZ structure (Pawson et al., 1998b). Thus, we tested the hypothesis 
that these proximal-distal changes in transmitter release could be caused by changes in the AP 
waveform as it propagates through the nerve terminal. 
To study the AP waveform along the length of frog motor nerve terminal branches, we 
performed our voltage-imaging procedure near the entry of the axon into the presynaptic nerve 
terminal just after the last node of Ranvier and again at the end of a nerve terminal branch (Figure 
8A, B). In addition to the BeRST 1 images, we also documented the full length of NMJ nerve 
terminal branches we were studying using Alexa Fluor 488 α-bungarotoxin (BTX) images, which 
were combined using image stitching (Preibisch, Saalfeld, & Tomancak, 2009) to create images 
of the full length of the nerve terminal branches under study. We then measured the length of the 
recorded nerve terminal branches using a skeletonizing method (Figure 8) (Arganda-Carreras et 
al., 2010). Since the average nerve terminal branch length was approximately 200 μm (194.6 ± 7.8 
μm), we analyzed the voltage-imaging data using multiple equally-distributed ROIs, each 20 μm 
in length, each corresponding to approximately 10% of the nerve terminal branch length. In 
particular, we focused on the first, second, and third 20μm ROIs starting from the last node of 
Ranvier as compared to the first, second, and third 20μm ROIs starting from the end of the nerve 
terminal (Figure 8A, B). This analysis revealed significant differences in the AP waveform 
 50 
duration near the last node of Ranvier and near the end of the nerve terminal, but no significant 
differences along the long middle portion of these long nerve terminal branches (Figure 8D-F).  
These data do not suggest that the AP waveform duration decreases linearly with distance 
along the presynaptic nerve terminal branch, but only changes immediately after the axonal entry 
into the nerve terminal and near the tip of the nerve terminal branch. Based on these data, we 
propose that there are three distinct regions in the presynaptic nerve terminal of the frog NMJ 
where electrical signals are different: A beginning region immediately after the last node of 
Ranvier, a middle region consisting of 60-80% of the nerve terminal with a relatively consistent 
AP duration, and an end region near the tip of nerve terminal branches. 
To further examine this hypothesis and to ensure that our results were not an artifact of our 
method of ROI selection for the data analysis, we reanalyzed the images by placing 5 ROIs, each 
consisting of 10-pixel diameter (2.667 μm) circles spaced 15 μm apart from their center along the 
nerve terminal just after each last node of Ranvier and near the end of the nerve terminal (Figure 
9A, B). Because these data are created with a different method of analysis than the 20μm ROIs, 
multiple comparison corrections were performed separately for the 20 μm ROI and small-circle 
ROI data. Consistent with our analysis of 20 μm ROIs, these small-circle ROIs revealed significant 
differences near the last node of Ranvier where the axon enters the nerve terminal and near the end 
of the nerve terminal, but no significant differences along the long middle portion of the nerve 
terminal (Figure 9C, D). 
To test if these changes in the AP waveform could be caused by passive propagation along 
the terminal, we created a passive model of the frog NMJ nerve terminal in NEURON and 
stimulated it with a recorded AP waveform from near the last node of Ranvier (Figure 8F, Figure 
10A, and Figure 13A). Our model predicted that passive propagation would result in a broadening 
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of the AP waveform as it decays (Figure 10). Furthermore, our model predicted that passive 
propagation would also cause broadening under a wide variety of different values for axon 
diameter, leak conductance, axial resistance, and membrane capacitance (data not shown).  
These data confirm the existence of three distinct electrical regions within the presynaptic 
nerve terminal. Furthermore, the lack of broadening due to decay in the AP waveform as it 
propagates approximately 200 μm from near the last node of Ranvier to near the end of the nerve 
terminal suggests that the AP is actively propagated throughout the presynaptic motor nerve 
terminal in frogs (consistent with predictions from early studies; Braun & Schmidt, 1966; Katz & 





Figure 8 There are three distinct electrical regions along the frog motoneuron terminal. 
A, A BeRST 1 dye image of nerve terminal near the last node of Ranvier. The myelinated axon and the last 
node of Ranvier are labeled in this image, along with the first, second, and third 20-μm-long ROIs identified by red 
outlines (labeled Node 1, Node 2, Node 3) starting from the last node of Ranvier and moving into a long nerve terminal 
branch. B, A BeRST 1 dye image of nerve terminal near the end of a long nerve terminal branch with the first, second, 
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and third 20 μm long ROIs identified by red outlines (labeled End 1, End 2, and End 3), starting from the end of the 
nerve terminal. C, A BTX-labeled image of the full length of the long nerve terminal branch shown in A and B, 
overlaid with the skeletonized version of this nerve terminal branch (red). D, Plot of imaged AP FWHM data derived 
from 14 long motor nerve terminal branches (gray symbols, one set of which was taken from A and B) for each of 6 
ROIs; 3 near the last node of Ranvier and 3 near the end of the nerve terminal branch (as shown in A and B). The 
mean data (±SEM) are shown using black symbols. Statistical significance between ROIs along the terminal is 
determined by Friedman test with Dunn’s multiple post hoc comparisons test. *p < 0.05, **p < 0.01, ****p < 0.0001. 
E, Plot of FWHM data from the four ROIs in the middle region of long nerve terminal branches (gray symbols). 
Summary data are shown in black symbols. Within these middle regions (Node 2–End 2), there is no significant 
difference between any of these ROIs. p = 0.0633, Friedman test. F, AP waveforms from Node 1 (green), End 3 






Figure 9 The use of small-circle ROIs for image analysis confirms the presence of three distinct electrical 
regions within motor nerve terminal branches. 
A, A BeRST 1 dye image of a representative nerve terminal branch near the last node of Ranvier. The region 
of the motor nerve terminal near the last node of Ranvier is sampled with five circle ROIs placed 15μm apart, labeled 
Circle Node 1 (CN1) through CN5. Each circle is 10 pixels (2.667 μm) in diameter. B, A BeRST 1 dye image of a 
representative nerve terminal branch near the end of the nerve terminal with five circle ROIs place 15 μm apart, labeled 
Circle End 1 (CE1) through CE5. C, Plot of imaged AP FWHM data derived from 14 long motor nerve terminal 
branches (gray symbols, one of which was taken from A and B) for each of the 10 ROIs identified in A and B. The 
mean data (±SEM) are shown using black symbols. Statistical significance between ROIs along the terminal is 
determined by Friedman test with Dunn’s multiple post hoc comparisons test. *p < 0.05, **p < 0.01, ***p < 0.001, 
****p < 0.0001. D, Plot of data from six ROIs in the middle region of long nerve terminal branches (gray symbols), 
with summary data (black symbols). Within this middle region (CN3– CE3), there is no significant difference between 
any of these ROIs. p = 0.2161, Friedman test. 
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Figure 10 NEURON simulation predictions for changes to the AP waveform caused by passive propagation 
over a 200 μm long nerve terminal. 
A, Waveform input based on recorded AP waveforms from near the last node of Ranvier (black), and the 
predicted change to the AP waveform caused by passive decay to the end of the long nerve terminal branch (gray 
dotted line). B, The two waveforms from A normalized and aligned to the half-maximum of their rising edge, showing 
a predicted 44% increase in the FWHM between the AP near the last node of Ranvier and near the end of the terminal. 
C, The predicted FWHM (black) and amplitude (gray) of the AP waveform (measured every 20 μm) as it passively 
propagates along a 200 μm long nerve terminal. 
 
2.3.3 The propagation speed of the AP waveform does not change along the length of the 
terminal 
The propagation speed of the AP waveform along the length of the presynaptic motor nerve 
terminal of the frog NMJ has previously been experimentally estimated using extracellular 
recording techniques (Braun & Schmidt, 1966; Katz & Miledi, 1965b; Nikol'kii et al., 2002). 
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Furthermore, it had been suggested that the AP propagates slower near the last node of Ranvier 
and faster near the end of the nerve terminal (Braun & Schmidt, 1966; Nikol'kii et al., 2002). 
However, these prior studies relied on reconstructing the electrical activity within the nerve 
terminal based on recordings from extracellular currents, which are prone to significant variation 
due to variances in the extracellular tissue surrounding the nerve terminal and the placement of the 
electrode with respect to the nerve terminal. To directly examine the propagation speed of the AP 
in the adult frog NMJ nerve terminal, we compared the time between the half maximums of the 
rising edge of the AP waveforms from the small-circle-ROI voltage imaging data from near the 
last node of Ranvier and at the tip of the nerve terminal branch (e.g., CN1 and CE1 from Figure 
9). By combining these data with the distances recorded from the stitched BTX images of the total 
nerve terminal branch length, we were able to measure the propagation speed of APs (0.6586 ± 
0.0700 m/s). We also compared the propagation speed between the first (CN1) and last (CN5) 
ROIs near the last node of Ranvier (0.6006 ± 0.0588 m/s) and the first (CE5) and last (CE1) ROIs 
near the end of the nerve terminal (0.6584 ± 0.0828 m/s) to determine if the AP was propagating 
at different speeds near the last node of Ranvier vs. the end of the nerve terminal branches. There 
was no significant difference in AP propagation speed found between any of these three 
measurements, and the average between the three groups was 0.6392 ± 0.0403 m/s. We repeated 
this analysis using our larger 20μm ROI data by assuming that the AP represents the center of the 
ROI (so the distance between the first and last ROIs from each image was assumed to be only 40 
μm) and found almost identical results (Figure 11). These results are consistent with the average 
speeds determined by extracellular recordings (Braun & Schmidt, 1966; Katz & Miledi, 1965b; 
Nikol'kii et al., 2002), but do not agree with the extracellular data that had suggested that the AP 
propagates slower near the end of the motor nerve terminal (Braun & Schmidt, 1966; Nikol'kii et 
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al., 2002). Furthermore, this propagation speed is similar to the AP propagation speed determined 
in Drosophila NMJs when imaging a genetically encoded voltage sensor (Ford & Davis, 2014), 
although the AP of the Drosophila NMJ is approximately 6 times broader than the AP waveforms 
recorded at the frog NMJ.  
 
 
Figure 11 Comparison of the AP propagation speeds near the last node of Ranvier, near the end of the 
terminal, and along the length of the entire terminal using both 20mm ROI and small-circle ROI data. 
There is no significant difference in AP propagation speed in different regions of the terminal (n = 14; p = 
0.7515 for 20 μm ROIs, p = 0.3189 for small-circle ROIs; Friedman test), and there is no significant difference between 
the 20 μm and small-circle ROI measurements in any region (full length: p = 0.5416, node: p = 0.2166, end: p = 
0.5830; Wilcoxon matched-pairs signed rank test). Data shown as mean + S.D. 
2.3.4 Motor nerve terminal width does not correlate with AP duration or propagation 
speed within the motor nerve terminal 
Although nerve terminal diameter would be predicted to play a role in determining the 
shape and propagation speed of the AP waveform, research in other neurons types has reported 
that the diameter of the presynaptic nerve terminal has a negligible effect on the shape and 
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propagation of AP waveforms, as compared to the effect of ion channel expression (Rowan et al., 
2016). To investigate the impact of nerve terminal geometry on the AP waveform and to test if 
changes in nerve terminal geometry could be responsible for the observed changes in the frog NMJ 
AP waveform, we measured the area of the imaged nerve terminal region contained in all three of 
the 20μm ROIs near the last node of Ranvier, as well as near the end of the nerve terminal. By 
dividing this area by the length between the two first and last ROIs, we calculated the average 
width of the axon near the last node of Ranvier and at the end of the nerve terminal. We then 
calculated the correlation between axon width, the 20μm ROI AP FWHM, and the 20μm ROI 
propagation speeds in a combined dataset of the values near the end of the terminal and near the 
last node of Ranvier (where the AP FWHMs of the three 20μm ROIs near the last node of Ranvier 
are averaged together for each terminal, and the same is done for the three 20 μm ROIs near the 
end of each terminal). We note that our imaging procedure was limited to measuring the width of 
the nerve terminal, so our analysis of the terminal geometry was based on a two-dimensional image 
assuming a symmetrical three-dimensional geometry. Using this approach, we found no 
correlation between terminal width and either AP FWHM or AP propagation speed but did find a 
correlation between AP FWHM and AP propagation speed (Figure 12A, C, E). We then repeated 
this analysis using propagation speed and AP FWHM values from our small-circle ROIs and found 
similar results (Figure 12B, D, F).   
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Figure 12 Measured motor nerve terminal width does not correlate with either AP duration (FWHM) or 
propagation speed, but propagation speed correlates with AP FWHM. 
Combined data from near the end of the terminal and near the last node of Ranvier (n = 28), using both the 
20 μm ROIs (left) and small circle ROIs (right), showing that measured motor nerve terminal width does not correlate 
with either AP duration (FWHM) or propagation speed, but propagation speed correlates with AP FWHM. A, B, Lack 
of correlation between the measured motor nerve terminal widths and AP durations (FWHM). C, D, Lack of 
correlation between the measured motor nerve terminal widths and the propagation speeds of the APs. E, F, Significant 
correlation between the AP duration (FWHM) and the AP propagation speed. All correlations are calculated with 
Kendall’s τ coefficient, and p values were adjusted using Bonferroni’s correction. 
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2.4 Discussion 
The shape of the AP waveform at the motor nerve terminal impacts the behavior of 
presynaptic VGCCs, and thus is an important modulator of neurotransmitter release at the 
presynaptic nerve terminal. Although the adult frog NMJ has long been a model synapse for the 
study of synaptic transmission, its AP waveform has never been directly recorded. The lack of 
information regarding this AP waveform has hindered the ability to investigate the voltage-driven 
control of synaptic transmission, and also impacts computational simulations which depend on AP 
waveform-driven ion channel gating and ion flux  (Dittrich et al., 2013; Homan et al., 2018; 
Laghaei et al., 2018; Ma et al., 2014). Furthermore, there has been debate as to whether APs within 
the long linear presynaptic terminals of the adult frog NMJ are actively or passively propagated. 
Therefore, to examine the duration and propagation of the presynaptic AP at the frog NMJ, we 
used the voltage-sensitive dye (BeRST 1) and showed that the AP waveform is extremely brief 
and is actively propagated throughout the nerve terminal. 
For the data reported here, we selected nerve terminals for our imaging procedure that 
contained long (> 120 μm), linear nerve terminal branches. Thus, it is possible that short nerve 
terminals or terminals with significant branching may display different changes in their AP 
waveform duration along the length of these smaller branched segments.  
2.4.1 Very brief AP waveforms may aid in maintaining strength and reliability at the NMJ 
Voltage imaging of the presynaptic terminal of the frog NMJ revealed that the average AP 
waveform had a FWHM of only 273.9 ± 10.7 μs. This is much briefer than expected based on 
electrophysiological recordings from both adult frog motoneuron cell bodies in the spinal cord 
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(Dambach & Erulkar, 1973; Erulkar & Soller, 1980; Ovsepian & Vesselkin, 2006), and cultured 
frog embryonic motoneuron synaptic varicosities onto muscle cells (Pattillo et al., 2001; Yazejian 
et al., 1997). This leads us to wonder what advantages for adult NMJ function might be provided 
by a very narrow AP at these motor nerve terminals? 
This question has been addressed in detail within the central nervous system at the Calyx 
of Held synapse; a very large synapse in the mammalian auditory brainstem that functions to 
differentiate between temporal activation of cochlear hair cells in each ear to aid in sound 
localization (Tsuchitani, 1997). The AP at the mammalian calyx of Held has been shown to 
become briefer in duration over development (560 μs FWHM before hearing onset and 190 μs 
after hearing onset), but has been shown not to change in amplitude over this same time period 
(Taschenberger & von Gersdorff, 2000). This AP duration change is thought to be caused by 
changes in presynaptic voltage-gated sodium channels (faster inactivation and recovery) and 
potassium channels (higher density and faster activation kinetics) (Elezgarai et al., 2003; Leao et 
al., 2005; Nakamura & Takahashi, 2007). The very short duration of mature APs at the calyx of 
Held reduces the activation of presynaptic VGCCs, decreasing the probability of release from each 
of the roughly 700 AZs (Borst & Sakmann, 1998; Taschenberger et al., 2002; Yang & Wang, 
2006). These and other developmental refinements at the calyx of Held lead to fast and dependable 
communication at this relay synapse. The NMJ is also a strong and reliable relay synapse that is 
expected to release enough transmitter with each AP to trigger postsynaptic muscle contraction 
(Wood & Slater, 2001). The NMJ accomplishes this strength and reliability by assembling 
hundreds of presynaptic AZs that each contain 20-40 single vesicle release sites (docked vesicles 
and their associated VGCCs). In contrast to the calyx of Held synapse, the frog NMJ does not 
show frequency-dependent depression, and in fact typically displays facilitation during pairs or 
 62 
short trains of APs (Laghaei et al., 2018). This is likely due in part to the very low probability for 
release at each of the thousands of single vesicle release sites contained within hundreds of AZs 
(Tarr et al., 2013b). In this way, a very brief presynaptic AP can ensure that very few presynaptic 
VGCCs open (Luo et al., 2015; Luo et al., 2011), sparing most release sites from participating in 
AP-evoked release. This mechanism may aid in preserving transmitter release-ready capability 
during subsequent APs, even at high frequency.  
2.4.2 Changes in the width of the AP waveform can explain proximal-distal changes in 
neurotransmitter release 
To computationally predict how proximal-distal changes in the AP waveform could alter 
calcium triggered transmitter release, we input our experimentally-imaged AP waveforms from 
the three regions of the presynaptic nerve terminal of the frog NMJ (Figure 8F) into an MCell 
simulation of 10000 VGCCs (Figure 13A; see section 2.2.4). This simulation predicted that the 
probability of VGCCs opening during a single AP were .203, .307, and .436 for APs from near the 
end, the middle, and near the last node, respectively, and also predicted a 48% increase in total 
calcium flux between the end and middle AP waveform, and a 119% increase in calcium flux 
between the nerve terminal end and AP waveform near the last node (Figure 13B). Next, we used 
these APs in our previously validated MCell model of a frog AZ (see section 2.2.4; (Dittrich et al., 
2013; Homan et al., 2018; Laghaei et al., 2018; Ma et al., 2014)). The frog AZ model predicted 
large differences in the magnitude of transmitter release caused by the APs recorded from different 
regions of the motor nerve terminal, with the AP waveform from near the last node of Ranvier 
triggering approximately double the transmitter release as comparted to the AP waveform recorded 
near the middle, and approximately four times the transmitter release as compared to the AP 
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waveform recorded near the end of the nerve terminal (Figure 13C). These computational results 
show that small changes in the width of the AP waveform can result in large changes in presynaptic 
calcium entry and transmitter release (Figure 13B, C). Furthermore, these results are consistent 
with the proximal-distal gradient in the magnitude of transmitter release along the frog motor nerve 
terminal reported by D’Alonzo and Grinnell (D'Alonzo & Grinnell, 1985). Therefore, we 
hypothesize that changes in the AP waveform along the length of the adult frog motor nerve 
terminal may be responsible for the proximal-distal decrease in neurotransmitter release found at 
the presynaptic nerve terminal of the frog NMJ (Figure 14). 
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Figure 13 MCell predictions for calcium entry and transmitter release induced by AP waveforms measured 
from three distinct electrical regions of the nerve terminal. 
A, AP waveforms used for computational simulations based on the recorded AP waveforms from near the 
last node of Ranvier (green), the middle region of the nerve terminal (magenta), and near the end of the nerve terminal 
(black). B, Predicted calcium current induced by each AP near the last node of Ranvier (green), the middle region of 
the nerve terminal (magenta), and the end of the nerve terminal (black) based on a MCell box simulation of 10,000 
VGCCs. C, Histogram of the time course of vesicle release events predicted from 4800 runs of the frog active zone 
MCell model in response to calcium-entry triggered vesicle fusion induced by the APs measured from near the last 
node of Ranvier (green), the region of the nerve terminal (magenta), and the end of the nerve terminal (black). 
 65 
 
Figure 14 Changes in the AP waveform along the length of the adult frog motor nerve terminal may be 
responsible for the proximal-distal decrease in neurotransmitter release found at the presynaptic nerve 
terminal of the frog NMJ. 
An outline of a single adult frog NMJ (A) and the associated histograms of the measured probability of 
release along the length of this nerve terminal. In this figure, adapted from (D'Alonzo & Grinnell, 1985), the 
probability of release per unit nerve length (B) is greatest near the last node of Ranvier, relatively constant through 
the middle region of the terminal, and lowest near the ends of the terminal. Red line shows changes in transmitter 
release predicted by our model shown in Figure 13. C, Raw data from B that was not normalized to the nerve terminal 
length. D, Variations in the measured nerve terminal length. Red circle identifies the last node of Ranvier where 
measured nerve terminal length is very short, leading to the relatively large increase in probability of release per unit 
terminal length at this central position shown in B. Except for this large peak in release at the nodal entry point (created 
by the short nerve terminal length calculated at this location), our model predictions based on changes in AP duration 
closely predict the measured changes in transmitter release probability along the length of this sample NMJ. Therefore, 
we hypothesize that these changes in transmitter release could be caused by the changes in the AP waveform we 
measured along the length of similar frog NMJs. 
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2.4.3 Relationship between axon width, the duration of the AP waveform, and AP 
propagation speed 
We measured the propagation speed along the length of the adult frog motor nerve 
terminals and determined the average to about 0.6 m/s. This value is relatively slow when 
compared to the range of propagation speeds previously measured in mammalian peripheral axons, 
(even when accounting for temperature differences, for which a Q10 of 1.5 has been reported for 
AP conduction velocities at the squid giant synapse; Rosenthal & Bezanilla, 2000) which can range 
from about 120 m/s for the fastest large diameter (~20 μm) myelinated axons, to about 0.3 m/s for 
small diameter (~0.1 μm) unmyelinated axons (Swadlow & Waxman, 2012). Theoretically, the 
diameter of a nerve terminal should impact the AP waveform shape and propagation speed along 
a long linear nerve terminal. However, by comparing the width of the nerve terminal with both the 
FWHM of the AP waveform and the AP propagation speed we found no significant correlation. 
We hypothesize that this is because the distribution of ion channels plays a much larger role in 
determining the shape of the AP waveform such that modest changes in nerve terminal geometry 
have a negligible impact. Neurons are known to use a large variety of voltage-gated sodium and 
potassium channels that can lead to different AP shapes (Bean, 2007). In particular, fast-spiking 
neurons that employ very brief APs express higher densities of specific types of voltage-gated 
potassium channels (Rudy & McBain, 2001). In fact, even within the same neuron, APs can differ 
significantly when comparing the soma with the nerve terminal due to a non-uniform distribution 
of voltage-gated sodium and potassium channels (Geiger & Jonas, 2000). It is thought that the 
presynaptic terminal of the frog NMJ contains voltage-gated sodium channels (although the 
subtype is unknown, they are expected to be similar to the TTX-sensitive channels reported in 
mammalian axons (Caldwell et al., 2000), and BK channels have been localized selectively to AZs 
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within frog NMJs (Robitaille, Adler, & Charlton, 1993a; Robitaille et al., 1993b). The types of 
voltage-gated potassium channels are unknown, but we hypothesize that the presynaptic terminal 
of the frog NMJ might contain Kv3 subtypes based on reports in mammalian motor nerve terminals 
(Brooke et al., 2004; Zemel et al., 2018). Despite decades of study, with the exception of AZ-
localized BK channels (Robitaille et al., 1993a; Robitaille et al., 1993b), little is known of the 
expression of sodium and potassium channels within the adult frog motor nerve terminal. Further 
studies aimed at elucidating the density and distribution of these channels within the frog NMJ 
will be required to determine the mechanisms responsible for changes in the AP waveform. 
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3.0 A high affinity, partial antagonist effect of 3,4-diaminopyridine mediates action 
potential broadening and enhancement of transmitter release at NMJs 
3,4-diaminopyridine (3,4-DAP) increases transmitter release from neuromuscular 
junctions (NMJs), and low doses of 3,4-DAP (estimated to reach ~1 M in serum) are the FDA-
approved treatment for neuromuscular weakness caused by Lambert-Eaton Myasthenic Syndrome 
(LEMS). Canonically, 3,4-DAP is thought to block voltage-gated potassium (Kv) channels, 
resulting in prolongation of the presynaptic action potential (AP). However, recent reports have 
shown that high concentrations of 3,4-DAP have an off-target agonist effect on the Cav1 subtype 
(“L-type”) of voltage-gated calcium (Cav) channels, and have speculated that this agonist effect 
might contribute to 3,4-DAP effects on transmitter release at the NMJ. To address 3,4-DAP’s 
mechanism(s) of action, we first use patch-clamp electrophysiology to characterize the 
concentration-dependent block of 3,4-DAP on the predominant presynaptic Kv channel subtypes 
found at the mammalian NMJ (Kv3.3 and Kv3.4). We identify a previously unreported high-
affinity (1-10 M) partial antagonist effect of 3,4-DAP in addition to the well-known low affinity 
(0.1-1mM) antagonist activity. Next, we use voltage imaging to show that 3,4-DAP broadens the 
AP waveform in a dose dependent manner, independent of Cav1 calcium channels. Finally, we 
demonstrate the 3,4-DAP augments transmitter release in a dose-dependent manner and this effect 
is also independent of Cav1 channels. From these results, we conclude that low concentrations of 




Lambert-Eaton Myasthenic syndrome (LEMS) is a neuromuscular disease caused by an 
autoantibody-mediated attack on the presynaptic Cav2.1 type (also called “P/Q-type”) voltage-
gated calcium channels as well as other presynaptic proteins at neuromuscular junctions (NMJs) 
(Lambert, Eaton, & Rooke, 1956; Lang et al., 1983; Meriney et al., 1996; Nagel et al., 1988; Tarr 
et al., 2013b; Vincent et al., 1989). The resulting antibody-mediated loss of proteins associated 
with transmitter release sites results in a reduction of acetylcholine release from the NMJ and leads 
to a failure of some postsynaptic muscle fibers to initiate an action potential (AP), leading to a 
weaker muscle contraction. Clinical and animal model studies suggest that neuromuscular 
transmission, and subsequently muscle strength, can be improved by the use of 3,4-
diaminopyridine (3,4-DAP), which is a small molecule that acts as an antagonist at voltage-gated 
potassium (Kv) channels. 3,4-DAP was recently approved by the FDA to treat LEMS (FDA, 2018, 
2019; Voelker, 2019; Yoon et al., 2020), and has been shown to be effective at increasing 
neuromuscular strength in LEMS patients (Oh, 2016; Sanders et al., 2018; Shieh et al., 2019; 
Strupp et al., 2017). However, 3,4-DAP has dose-dependent side effects that restrict the amount 
that patients take to relatively small doses, which prevents full symptomatic relief in many LEMS 
patients (Lindquist & Stangel, 2011; Wirtz et al., 2010). Patients are typically prescribed 10-20 
mg oral doses of 3,4-DAP to be taken several times during the day and report peak clinical effects 
for 3-8 hours after each dose (Sanders, 1998). 3,4-DAP has been reported to have a serum half-
life of 1-3 hours, and pharmacokinetic studies cite peak serum concentrations of ~40-110 ng/ml 
after a 20 mg oral dose (Haroldsen et al., 2015a; Haroldsen et al., 2015b; Ishida et al., 2015; 
Thakkar et al., 2017; Wirtz et al., 2009). Similar doses of 3,4-DAP have also been used off-label 
for a variety of other neuromuscular weakness conditions, including congenital myasthenic 
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syndrome (Banwell et al., 2004; Natera-de Benito et al., 2016a; Natera-de Benito et al., 2016b; 
Rodríguez Cruz et al., 2016; Rodríguez Cruz et al., 2019; Witting et al., 2015), muscle-specific 
receptor tyrosine kinase myasthenia gravis (Bonanno et al., 2018), downbeat nystagmus (Thurtell 
& Leigh, 2012), and multiple sclerosis (Flet et al., 2010; Mainero et al., 2004; Polman et al., 1994; 
Sheean et al., 1998). 
The mechanism of action of 3,4-DAP at neuromuscular synapses is canonically thought to 
be a block of Kv3 (also called “A-type”) voltage-gated potassium channels. Kv3.3 and Kv3.4 
channels are the subtypes selectively localized at mammalian neuromuscular motor nerve 
terminals (Brooke et al., 2004; Zemel et al., 2018) and are thought to be predominantly responsible 
for speeding the repolarization of the presynaptic AP. By blocking Kv3 channels, 3,4-DAP is 
hypothesized to broaden the presynaptic AP duration, thus indirectly increasing calcium ion flux 
by increasing the number of presynaptic voltage-gated calcium (Cav2) channels that open during 
an AP. Because calcium-triggered acetylcholine release is non-linearly dependent on calcium 
concentration in nerve terminals, a relatively small increase in calcium ion entry can generate a 
much larger increase in neurotransmitter release (Dodge & Rahamimoff, 1967). 
Recent investigations have challenged the conventional mechanism of action of 
aminopyridines. First, prior concentration-response studies of aminopyridine action on Kv 
channels have often been restricted to the use of 4-aminopyridine, and yielded an IC50 between 30 
M – 2.5 mM depending on the types of potassium channels expressed (Castle et al., 1994; 
Grissmer et al., 1994; Luneau et al., 1991; Muqeem et al., 2018; Rettig et al., 1992; Schaarschmidt 
et al., 2009; Stephens et al., 1994; Vega-Saenz de Miera et al., 1992; Wu et al., 2009; Yokoyama 
et al., 1989), with a high sensitivity to 4-aminopyridine reported for Kv3 channels (80 M IC50; 
(Kirsch & Drewe, 1993)). Because 4-AP crosses the blood-brain barrier better than 3,4-DAP, the 
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latter has been preferred for the treatment of peripheral neuromuscular diseases (Lemeignan et al., 
1984; Lindquist & Stangel, 2014). Therapeutic concentrations of 3,4-DAP are predicted to be in 
the low micromolar range, and 3,4-DAP has been reported to have significant effects on squid 
giant axon potassium channels at these concentrations (Kirsch & Narahashi, 1978). Second, a 
direct agonistic action of 3,4-DAP on Cav1 type (also called “L-type”) voltage-gated calcium 
channels was reported (Li et al., 2014; Wu et al., 2009). However, the clinical relevance of the 
reported effects of 3,4-DAP on Cav channels was debated because the 3,4-DAP concentrations 
evaluated in these studies were significantly above blood serum levels found in LEMS treatment 
conditions (Meriney & Lacomis, 2018; Wu, Chen, & Pan, 2018b). Furthermore, because Cav1 
channels usually lack the synaptic protein interaction sites present in Cav2 channels (Catterall, 
1999; Mochida et al., 2003; Sheng et al., 1998), Cav1 channels are thought to reside outside of 
synaptic vesicle release sites in the neuromuscular junction and therefore are not thought to directly 
control acetylcholine release (as Cav2 channels do) at healthy synapses. However, it is possible 
that Cav1 channels may have a minor role at neuromuscular synapses that is revealed under 
pharmacological conditions (Atchison, 1989; Atchison & O'Leary, 1987; Flink & Atchison, 2002; 
Pancrazio, Viglione, & Kim, 1989; Urbano, Rosato-Siri, & Uchitel, 2002), and Cav1 channels may 
have a compensatory contribution to the control of transmitter release in diseased conditions such 
as LEMS (Flink & Atchison, 2002; Xu et al., 1998).  
Therefore, to investigate the physiological mechanism accounting for the clinical response 
to 3,4-DAP, we tested the effects of a therapeutic concentration of 3,4-DAP (1.5 μM) on (a) peak 
currents of Kv3 channels expressed in HEK293T cells, (b) the presynaptic AP waveform at frog 
and mouse motor nerve terminals, and (c) transmitter release from weakened frog and mouse 
NMJs. To explore the role of Cav1 channels in 3,4-DAP-mediated effects at NMJs, we conducted 
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our transmitter release and AP experiments in the presence or absence of a Cav1 antagonist 
(nitrendipine) and compared the results. In addition, we examined the effects of a supra-therapeutic 
concentration of 3,4-DAP (100 µM) to allow direct comparisons with prior studies that employed 
this higher concentration (Li et al., 2014; Wu et al., 2018b; Wu et al., 2009). For the purpose of 
this report, we define a supra-therapeutic concentration as one that is about 100 fold higher (100 
M) than the measured concentration in the serum of LEMS patients after taking the typical 
prescribed dose of 3,4-DAP (Haroldsen et al., 2015a; Haroldsen et al., 2015b; Ishida et al., 2015; 
Thakkar et al., 2017; Wirtz et al., 2009). 
Our results demonstrate that the therapeutic concentration of 1.5 M 3,4-DAP has a small 
but significant effect on both Kv3.3 and Kv3.4 channels, and we show that this concentration 
broadens the presynaptic AP waveform to increase the magnitude of neuromuscular transmission 
independent of a Cav1 contribution. The effect of the supra-therapeutic concentration of 100 M 
3,4-DAP was more pronounced, but broadening of the AP and the increase in the magnitude of 
transmitter released remained independent of effects on Cav1 channels. These results support the 
hypothesis that the clinical effects of 3,4-DAP in the treatment of LEMS are caused by a partial 




3.2.1 3,4-DAP effects on Kv3 potassium channels 
When considering which subtypes of Kv channels might be blocked by 3,4-DAP within 
mammalian motor nerve terminals, we were guided by prior work at the mouse NMJ which 
demonstrated that Kv3.3 and Kv3.4 were the subtypes detected by immunohistochemistry (Brooke 
et al., 2004). To determine the concentration-dependent effects of 3,4-DAP on these channel types, 
we expressed Kv3.3 and Kv3.4 channels in HEK293T cells and used whole-cell patch clamp 
electrophysiology to measure the change in current after 3,4-DAP application. Using a 100 or 500 
ms step depolarization protocol (-100 mV to +40 mV), we activated Kv3.3 or Kv3.4 current and 
then measured the peak current before and after application of 3,4-DAP (at concentrations ranging 
between 0.15 - 5000 M). We found a concentration-dependent block of both Kv3.3 and Kv3.4 
currents that was similar for each channel subtype. Importantly, the therapeutic concentration of 
3,4-DAP (1.5 M) significantly reduced Kv3.3 and Kv3.4 currents by about 10% (Figure 15). We 
observed that the concentration-response relationship appeared to be best fit by a biphasic Hill 
equation (Figure 15; Prism, GraphPad, San Diego, CA). For Kv3.3 and Kv3.4, the high affinity fit 
yielded IC50 values of 2.5 and 10.3 M and Hill coefficients of 0.7 and 0.6 respectively. Because 
the maximum inhibition for this high affinity activity was approximately 20-25%, 3,4-DAP 
binding to high affinity sites on Kv3.3 and Kv3.4 exhibited partial antagonist activity. The low 
affinity fits of the Kv3.3 and Kv3.4 data yielded IC50 values of 151 and 231 M and Hill 
coefficients of 3.0 and 1.4 respectively. The maximum inhibition for this low affinity activity was 
near 100%. 
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Because we were interested in a therapeutic concentration of 3,4-DAP with respect to its 
effect on calcium-triggered transmitter release at the NMJ, we confirmed that 1.5 µM 3,4-DAP 
had no effect on Cav2.1 or Cav1.2 current. When comparing the peak and integral of calcium 
current before and after application of 1.5 µM 3,4-DAP, we found no significant effects on either 
Cav2.1 (drug/control = 1.04 ± 0.08 peak; 1.01 ± 0.09 integral; n = 3; mean ± SD) or Cav1.2 
(drug/control = 0.95 ± 0.21 peak; 0.94 ± 0.08 integral; n = 3; mean ± SD) currents. 
 
 
Figure 15 Concentration-dependent effects of 3,4-DAP on Kv3.3 and Kv3.4 potassium currents expressed in 
HEK293T cells. 
A, plot of the inhibition of current through Kv3.3 (open squares, solid fit line) and Kv3.4 (open circles, dashed 
fit line) channels after exposure to varying concentrations of 3,4-DAP; n = 3-6. The red arrow indicates the data at 1.5 
μM 3,4-DAP concentration for which sample currents are shown in B and C; S.D. bars are smaller than the symbol 
sizes. B, sample Kv3.3 currents activated by a voltage step from -100 mV to +40 mV and shown before (black trace) 
and after (red trace) exposure to 1.5 μM 3,4-DAP. C, sample Kv3.4 currents activated by a voltage step from -100 mV 
to +40 mV and shown before (black trace) and after (red trace) exposure to 1.5 μM 3,4-DAP.     
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3.2.2 3,4-DAP effects on the presynaptic AP waveform at the NMJ 
The mechanism of action underlying the effects of 3,4-DAP at the NMJ is canonically 
thought to be due to a partial block of presynaptic Kv channels leading to a broadening of the 
presynaptic AP. To date, no studies have directly measured 3,4-DAP-mediated effects on the 
presynaptic AP waveform at the neuromuscular junction. Thus, we utilized a voltage-sensitive 
fluorescent dye (BeRST 1;(Huang et al., 2015)) to directly measure the impact of 3,4-DAP on the 
duration of the presynaptic AP waveform at frog and mouse NMJs. The BeRST 1 dye is fast 
enough to resolve the AP and has been shown to not affect the electrical properties or AP 
waveforms of neurons (Huang et al., 2015). We performed a paired experiment where the control 
AP waveform was recorded from a single nerve terminal, which was then was exposed to 3,4-DAP 
for 30 minutes before the AP waveform was recorded again at the same nerve terminal. To 
determine the duration of the presynaptic AP waveform, we measured the full width at half 
maximum (FWHM) of the recorded AP waveforms. This technique was performed in separate 
neuromuscular preparations in either vehicle or nitrendipine conditions to determine if blocking 
Cav1 channels affected the 3,4-DAP-mediated effects on the AP waveform.  
To ensure that AP duration was not altered by prolonged experimental time in the imaging 
setup, we performed the imaging procedure on control experiments without 3,4-DAP over the 
same time course as a typical 3,4-DAP experiment. We found no significant changes in AP 
duration during these control experiments, demonstrating that our imaging procedure itself was 
not impacting the AP waveform (data not shown). 
We first measured the impact of a therapeutic concentration of 1.5 µM 3,4-DAP on the 
duration of the presynaptic AP waveform at mouse motor nerve terminals (Figure 16). We found 
that 1.5 μM 3,4-DAP broadened the presynaptic AP in vehicle-treated mouse NMJs, increasing 
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the FWHM of the AP waveform from 262.2 ± 40.7 µs to 332.2 ± 49.6 µs. The presence of 
nitrendipine did not significantly alter the impact of 1.5 µM 3,4-DAP, with the FWHM of the AP 
waveform in the nitrendipine-treated mouse NMJs increasing from 266.1 ± 50.0 µs to 306.7 ± 30.5 
µs after the application of 1.5 µM 3,4-DAP (Figure 16E). 
We next investigated the impact of 1.5 μM DAP on the AP waveform at frog motor nerve 
terminals to determine if the effects of 3,4-DAP on the AP waveform are conserved across species 
(Figure 17). We found that 1.5 μM 3,4-DAP broadened the presynaptic AP in vehicle-treated frog 
NMJs, increasing the FWHM of the AP waveform from 272.5 ± 16.9 µs to 519.5 ± 120.5 µs. 
Again, we found no significant impact of the presence of nitrendipine on the effect of 1.5 µM 3,4-
DAP, with the FWHM of the AP waveform in the nitrendipine-treated frog NMJs increasing from 
277.9 ± 22.9 µs to 481.3 ± 58.3 µs after the application of 1.5 µM 3,4-DAP (Figure 17E).   
Finally, we tested the impact of a supra-therapeutic concentration (100 µM) of 3,4-DAP 
on the duration of the presynaptic AP waveform at the frog NMJ (Figure 18). In vehicle-treated 
frog NMJs, 100 μM 3,4-DAP broadened the duration of the AP waveforms from a FWHM of 
280.4 ± 32.6 µs to 1729.7 ± 197.0 µs. Even at this higher concentration of 3,4-DAP, we did not 
see any significant impact of nitrendipine on the 3,4-DAP-mediated broadening of the presynaptic 
AP waveform. The FWHM of the AP waveform in the nitrendipine-treated frog NMJs increased 
from 270.9 ± 51.1 µs to 1925.4 ± 210.3 µs after the application of 100 µM 3,4-DAP (Figure 18C). 
These data demonstrate that 3,4-DAP increases the duration of the presynaptic AP 
waveform at mammalian and frog NMJs in a dose-dependent manner, and that Cav1 calcium 
channels have no interaction with this effect. Since small changes in the duration of the AP 
waveform can greatly increase calcium flux and transmitter release at the NMJ (Dodge & 
Rahamimoff, 1967; Ginebaugh et al., 2020), these data further support the hypothesis that 
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broadening of the presynaptic AP via the blocking of Kv3 channels is the primary mechanism by 













Figure 16 Therapeutic concentrations of 3,4-DAP broaden the presynaptic AP waveform independent of 
Cav1 channels at the mammalian NMJ. 
A, a BeRST 1 dye-stained image of a mammalian presynaptic motor nerve terminal. B, an Alexa Fluor 488 
α-BTX stained image of the same terminal as in A. C, normalized splines of presynaptic AP waveforms recorded from 
a single nerve terminal before (black) and after (red) the addition of 1.5 μM 3,4-DAP. D, the normalized average of 
all pre-drug (black) and post 1.5 μM 3,4-DAP (red) presynaptic AP waveform splines recorded from mammalian 
motor nerve terminals (n = 11). E, FWHMs of recorded AP waveforms before (circles) or after (triangles) 1.5 μM 3,4-
DAP application to vehicle (peach) or nitrendipine (red) treated mouse NMJs. 1.5 μM 3,4-DAP significantly broadens 
the AP waveform independent of nitrendipine (two-way mixed ANOVA: there was a significant main effect of 1.5 
μM 3,4-DAP (F (1,9) = 22.40, **p = 0.0011), but no main effect of nitrendipine (F (1,9) = 0.2139, p = 0.6547), or 
interaction between 1.5 μM 3,4-DAP and nitrendipine (F (1,9) = 1.583, p = 0.2399); vehicle, n = 5; nitrendipine, n = 
6). F-G, plots of individual paired recorded values (grey dotted lines) of AP duration (FWHM) before and after 





Figure 17 Therapeutic concentrations of 3,4-DAP broaden the presynaptic AP waveform independent of Cav 
1 channels at the frog NMJ. 
A, a BeRST 1 dye-stained image of a frog presynaptic motor nerve terminal. B, an Alexa Fluor 488 α-BTX 
stained image of the same terminal as in A. C, normalized presynaptic AP waveform splines recorded from a single 
nerve terminal before (black) and after (red) the addition of 1.5 μM 3,4-DAP. D, the normalized average of all pre-
drug (black) and post-1.5 μM 3,4-DAP (red) presynaptic AP waveform splines recorded from all frog motor nerve 
terminals (n = 12). E, FWHMs of recorded AP waveforms before (circles) or after (triangles) 1.5 μM 3,4-DAP 
application to vehicle (pink) or nitrendipine (blue) treated frog NMJs. 1.5 μM 3,4-DAP broadens the AP waveform 
independent of nitrendipine (two-way mixed ANOVA: there was a significant main effect of 1.5 μM 3,4-DAP (F 
(1,10) = 77.68, ***p < 0.0001), but no main effect of nitrendipine (F (1,10) = 0.2967, p = 0.5979), and no significant 
interaction between 1.5 μM 3,4-DAP and nitrendipine (F (1,10) = 0.7278, p = 0.4136); vehicle, n = 6; nitrendipine, n 
= 6). F-G, plots of individual paired recorded values (grey dotted lines) of AP duration (FWHM) before and after 
application of 1.5 μM 3,4-DAP with a superimposed average (vehicle, solid pink line; nitrendipine, solid blue line). 
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Figure 18 A supra-therapeutic concentration of 100 μM 3,4-DAP significantly broadens the frog presynaptic 
AP waveform independent of Cav1 channels. 
A, normalized presynaptic AP waveform splines recorded from a nerve terminal before (black) and after (red) 
the addition of 100 μM 3,4-DAP. B, the normalized average of all pre-drug (black) and post 100 μM 3,4-DAP (red) 
presynaptic AP waveform splines recorded from all frog motor nerve terminals (n = 10). C, FWHMs of recorded AP 
waveforms before (circles) or after (triangles) 100 μM 3,4-DAP application to vehicle (pink) or nitrendipine (blue) 
treated frog NMJs. 100 μM 3,4-DAP broadens the AP waveform independent of nitrendipine (Two-way mixed 
ANOVA: significant main effect of 100 μM 3,4-DAP (F (1,8) = 524.7, ***p < 0.0001), but no main effect of 
nitrendipine (F (1,8) = 2.035, p = 0.1916), and no interaction between 3,4-DAP and nitrendipine (F (1,8) = 2.292, p = 
0.1685); vehicle, n = 6; nitrendipine, n = 4). D-E, plots of individual paired recorded values (grey dotted lines) of AP 
duration (FWHM) before and after application of 1.5 μM 3,4-DAP with a superimposed average (vehicle, solid pink 
line; nitrendipine, solid blue line). 
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3.2.3 3,4-DAP increases neuromuscular transmission in a dose-dependent manner 
independent of Cav1 calcium channels 
To characterize the dose-dependent effects of 3,4-DAP on weakened transmitter release at 
the NMJ, we used paired intracellular microelectrode recordings in ex vivo neuromuscular 
preparations to measure endplate potentials (EPPs) in response to nerve-evoked APs, both before 
and after exposure to either therapeutic (1.5 M) or supra-therapeutic (100 M) concentrations of 
3,4-DAP. Additionally, we measured spontaneous miniature EPPs (mEPPs) from the same 
population of muscle fibers to determine quantal content. We performed both EPP and mEPP 
recordings in the presence or absence of the Cav1 blocker nitrendipine to test the hypothesis that 
Cav1 calcium channels are important for 3,4-DAP effects.  
We reduced the magnitude of transmitter release by performing all recordings in the 
presence of low concentrations of the calcium channel antagonist -agatoxin IVA (for Cav 2.1 
channels at mouse NMJs) or -conotoxin GVIA (for Cav 2.2 channels at frog NMJs). Reducing 
transmitter release magnitude following exposure to sub-maximal concentrations of these toxins 
mimics the effect of neuromuscular diseases that weaken NMJs, and importantly minimizes 
complications during data analysis due to non-linear summation, ensuring that correction for non-
linear summation is accurate (McLachlan & Martin, 1981). In the absence of these selective Cav2 
calcium channel blockers, control EPPs average 10-40 mV in amplitude above resting membrane 
potential (e.g. from -70 mV resting membrane potential to a peak of -60 to -30 mV) at mouse and 
frog NMJs (Sosa & Zengel, 1993; Tarr et al., 2013b). After exposure to 3,4-DAP (especially the 
100 M concentration), EPP size can approach the acetylcholine receptor channel reversal 
potential (-10 mV), making 3,4-DAP-induced changes in transmitter release difficult to interpret 
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and analyze. For these reasons, all experiments were performed using sub-maximal concentrations 
of a calcium channel blocker to reduce quantal content, allowing a more accurate assessment of 
3,4-DAP effects on weakened neuromuscular transmission. 
We first evaluated the effects of 1.5 M 3,4-DAP at the mouse NMJ (Figure 19), since 
mouse NMJs are phylogenetically similar in structure and calcium channel subtype expression to 
human NMJs. We measured quantal content (QC; the number of vesicles released in response to 
an AP and calculated as the corrected and normalized mean EPP amplitude divided by corrected 
and normalized mean mEPP amplitude) in vehicle or nitrendipine conditions because it has been 
previously hypothesized that 3,4-DAP might increase neurotransmission via a direct effect on 
Cav1 channels to increase calcium flux (Li et al., 2014; Wu et al., 2009). 
We first evaluated the effects of 1.5 M 3,4-DAP in vehicle-treated mouse NMJs (Figure 
19). After exposure to -agatoxin IVA, the baseline quantal content averaged approximately 14 
(14.2 ± 7.0; Figure 19C-D), while the mean mEPP amplitude was 0.4 ± 0.2 mV, and nerve 
stimulation produced a mean baseline EPP of 5.2 ± 1.8 mV (Figure 19G-H). Bath application of a 
therapeutic concentration of 3,4-DAP (1.5 μM) to vehicle-treated NMJs increased EPP amplitudes 
by approximately 3.2-fold (16.3 ± 5.2 mV; Figure 19H), without altering mEPP amplitudes (0.4 ± 
0.2 mV; Figure 19G), and increased quantal content to approximately 44 quanta per trial (44.1 ± 
15.3; a 3.1-fold increase; Figure 19C-D). These results are similar to 3,4-DAP effects reported 
previously in LEMS model mice (Tarr et al., 2014; Tarr et al., 2013b) and in pharmacological 
conditions with low probability of release (Fiona et al., 2017; Molgó, Lundh, & Thesleff, 1980).  
After -agatoxin IVA block in the presence of nitrendipine, the mean baseline EPP 
amplitude averaged 4.8 ± 2.0 mV, the mean mEPP amplitude averaged 0.4 ± 0.1 mV (Figure 19G, 
I) and the resulting quantal content was 11.7 ± 5.0; Figure 19C, E). After application of 1.5 μM 
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3,4-DAP, the mean EPP amplitude increased about 3.7-fold (18.5 ± 10.8 mV), without altering 
mEPP amplitude (0.4 ± 0.2 mV; Figure 19G, I), and quantal content increased 3.6-fold (QC = 41.6 
± 18.9; Figure 19C, E). The presence of nitrendipine did not significantly alter the effects of 1.5 
M 3,4-DAP on quantal content (Figure 19C), indicating that antagonism of Cav1 channels did 
not alter the effects of a therapeutic concentration (1.5 M) of 3,4-DAP at mouse NMJs. However, 
we did observe a significant increase in mEPP frequency in the vehicle condition, but not the 
nitrendipine condition (vehicle: baseline = 129.3 ± 44.9, post-3,4-DAP = 153.3 ± 49.3; 
nitrendipine: baseline = 153.3 ± 38.1; post-3,4-DAP = 143 ± 70.9; values are number of events per 
30 seconds; Figure 19F).  
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Figure 19 1.5 μM 3,4-DAP dose-dependently increases neuromuscular transmission independent of Cav1 
channels in mouse neuromuscular junctions. 
A-B, sample traces of electrophysiological recordings of EPPs (A) and mEPPs (B) before and after 1.5 μM 
3,4-DAP application. C, quantified quantal content before (circles) or after (triangles) 1.5 μM 3,4-DAP application to 
vehicle (peach) or nitrendipine (red) -treated mouse NMJs. Two-way mixed ANOVA was used (there was a significant 
main effect of 1.5 μM 3,4-DAP (F (1, 81) = 347.5, *** p < 0.0001); no significant main effect of nitrendipine (F (1,81) 
= 1.136, p = 0.2897) or interaction between 3,4-DAP x nitrendipine (F (1,81) = 0.0002, p = 0.9887); vehicle, n = 35; 
nitrendipine n = 48). D-E, plots of individual paired values (grey dotted lines) with a superimposed average (solid 
peach line, vehicle; solid red line, nitrendipine). F, There was a significant interaction between the effects of 1.5 μM 
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3,4-DAP and nitrendipine on mEPP frequency (two-way mixed ANOVA; no main effect of nitrendipine; F (1,81) = 
0.4209, p = 0.5183) or 3,4-DAP; F (1,81) = 1.634, p = 0.2048), but a significant interaction between 3,4-DAP x 
nitrendipine (F (1,81) = 10.02, p = 0.0022)). Post-hoc simple main effect analysis showed a significantly increased 
mEPP frequency in the vehicle (peach, **p = 0.0090) but not the nitrendipine (red, p = 0.3004) condition. G, The 1.5 
μM dose of 3,4-DAP did not significantly alter mEPP amplitude in vehicle (peach) or nitrendipine (red) conditions; 
two-way mixed ANOVA (no significant main effect of nitrendipine; F (1,81) = 0.08568, p = 0.7705, or 3,4-DAP; F 
(1,81) = 0.2994, p = 0.5857, nor significant interaction between 3,4-DAP x nitrendipine; F (1,81) = 2.45, p = 0.1214). 
H-I, The 1.5 μM dose of 3,4-DAP increased EPP amplitude, shown as individual pairs (grey dotted lines) with a 
superimposed average (solid peach line, vehicle, H; solid red line, nitrendipine, I); Wilcoxon signed-rank test, *** p 
< 0.0001. 
 
Next, we evaluated the effects of a supra-therapeutic concentration of 3,4-DAP (100 μM) 
in vehicle or nitrendipine-treated, 3,4-DAP-naïve mouse NMJ preparations (Figure 20). In NMJs 
treated with the vehicle, the mean mEPP amplitude was 0.4 ± 0.1 mV, and motor nerve stimulation 
produced a mean baseline EPP amplitude of 5.8 ± 1.9 mV after exposure to -agatoxin IVA 
(Figure 20G-H). Quantal release under these conditions was approximately 16 (15.5 ± 6.9; Figure 
20C-D). After exposure to 100 μM 3,4-DAP, the mean EPP amplitude was significantly increased 
by approximately 8.8-fold (50.8 ± 12.3 mV), without a significant change in mean mEPP 
amplitude (0.4 ± 0.2 mV; Figure 20G-H). This resulted in an increase in quantal content from 15.5 
quanta per trial to approximately 126 quanta per trial (126.3 ± 35.2), which is an 8.1-fold increase 







Figure 20 100 μM 3,4-DAP dose-dependently increases neuromuscular transmission independent of Cav1 
channels in mouse neuromuscular junctions. 
A-B, sample traces of electrophysiological recordings of EPPs (A) and mEPPs (B) before and after 100 μM 
3,4-DAP application. C, quantified quantal content before (circles) or after (triangles) 100 μM 3,4-DAP application 
to vehicle (peach) or nitrendipine (red) -treated mouse NMJs. Two-way mixed ANOVA was used (there was a 
significant main effect of 100 μM 3,4-DAP (F (1, 58) = 548, *** p < 0.0001); no significant main effect of nitrendipine 
(F (1,58) = 0.01559, p = 0.9011) or interaction between 3,4-DAP x nitrendipine (F (1,58) = 0.2182, p = 0.6421); 
vehicle, n = 33; nitrendipine, n = 27). D-E, plots of individual paired values (grey dotted lines) with a superimposed 
average (solid peach line, vehicle; solid red line, nitrendipine). F, The 100 μM dose of 3,4-DAP did not alter mEPP 
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frequency in the vehicle (peach) or nitrendipine (red) condition; two-way mixed ANOVA (no main effect of 
nitrendipine; F (1,58) = 0.1773, p = 0.4209, or 3,4-DAP; F (1,58) = 2.523, p = 0.1176, or significant interaction 
between 3,4-DAP x nitrendipine; F (1,58) = 2.051, p = 0.1575). G, There was a significant interaction between the 
effects of 100 μM 3,4-DAP and nitrendipine on mEPP amplitude (two-way mixed ANOVA: significant main effect 
of nitrendipine; F (1,58) = 10.91, p = 0.0016) and 3,4-DAP; F (1,58) = 19.03, p < 0.0001), and significant interaction 
between 3,4-DAP x nitrendipine; F (1,58) = 7.380, p = 0.0087)). Post-hoc simple main effect analysis showed a 
significantly altered mEPP amplitude in the nitrendipine (red, ***p < 0.0001) but not vehicle condition (peach, p = 
0.4497). The 100 μM dose of 3,4-DAP increased EPP amplitude, shown as individual pairs (grey dotted lines) with a 
superimposed average (solid peach line, vehicle, H; solid red line, nitrendipine, I); Wilcoxon signed-rank test, *** p 
< 0.0001. 
 
We next assessed whether nitrendipine could alter the effects of a supra-therapeutic 
concentration of 3,4-DAP (100 M). After -agatoxin IVA treatment in the presence of 
nitrendipine, EPP amplitude averaged 5.7 ± 2.0 mV, mEPP amplitude averaged 0.5 ± 0.2 mV 
(Figure 20G, I) and this resulted in a quantal content of 12.5 ± 6.8 (Figure 20C, E). Bath application 
of 100 μM 3,4-DAP increased EPP amplitude by about 12.3-fold (70.5 ± 17.8 mV), and mEPP 
amplitude averaged 0.6 ± 0.2 mV (Figure 20G, I). Quantal content significantly increased to 127.8 
± 48.6 after application of 100 μM 3,4-DAP, or a 10.2-fold increase (Figure 20C, E). We did not 
observe a significant effect of nitrendipine on quantal content (Figure 20C) or mEPP frequency 
(vehicle: baseline = 193.2 ± 54.8, post-3,4-DAP = 195.6 ± 112.4; nitrendipine: baseline = 179.9 ± 
69.4; post-3,4-DAP = 226.7 ± 148.1; values are number of events per 30 seconds; Figure 20F). 
However, we did observe a significant effect of 3,4-DAP on mEPP amplitude in the nitrendipine 
condition (Figure 20G).  
We also tested the effect of 3,4-DAP at frog NMJs (a traditional model of neuromuscular 
function) in order to evaluate whether 3,4-DAP mechanisms of action are phylogenetically 
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conserved, and determine if nitrendipine alters 3,4-DAP effects. We first assessed the effects of 
1.5 M 3,4-DAP on vehicle-treated frog NMJs (Figure 21). After exposure to -conotoxin GVIA, 
motor nerve stimulation evoked a mean baseline EPP amplitude of 3.7 ± 2.7 mV, and spontaneous 
release resulted in a mean mEPP amplitude of 0.8 ± 0.3 mV in vehicle-treated NMJs (Figure 21G-
H), producing a quantal content of about 5 (QC = 4.8 ± 3.1; Figure 21C-D). After application of 
1.5 μM 3,4-DAP, the mean EPP amplitude increased approximately 2-fold (to 7.6 ± 5.9 mV), 
without significantly altering mEPP amplitude (0.9 ± 0.4 mV; Figure 21G-H). Therefore, after 
exposure to 1.5 μM 3,4-DAP, quantal content increased to 8.8 ± 6.1 (a 1.8-fold increase; Figure 
21C-D).  
We next assessed 1.5 M 3,4-DAP on frog NMJs in the presence of nitrendipine. After 
exposure to -conotoxin GVIA, the average baseline EPP amplitude was 1.3 ± 0.7 mV, the average 
mean mEPP amplitude was 0.5 ± 0.3 mV (Figure 21G, I), and quantal content was about 3 (QC = 
3.2 ± 2.2; Figure 21C, E). After bath application of 1.5 μM 3,4-DAP, the mean EPP amplitude 
increased by about 2.3-fold to 3.0 ± 2.1 mV, with an average mEPP amplitude of 0.7 ± 0.3 mV 
(Figure 21G, I), which resulted in a quantal content of 6.0 ± 0.8 (a 1.9-fold increase; Figure 21C, 
E). We did not observe a significant effect of nitrendipine on quantal content (Figure 21C), though 
we did observe a significant difference in mEPP amplitudes in vehicle-treated versus nitrendipine-
treated NMJs (Figure 21F-G). Neither 3,4-DAP nor nitrendipine altered mEPP frequency (vehicle: 
baseline = 61 ± 24.2, post-3,4-DAP = 57.4 ± 31.9; nitrendipine: baseline = 115.6 ± 125.3; post-






Figure 21 1.5 μM 3,4-DAP dose-dependently increases neuromuscular transmission independent of Cav1 
channels in frog neuromuscular junctions.  
A-B, sample traces of electrophysiological recordings of EPPs (A) and mEPPs (B) before and after 1.5 μM 
3,4-DAP application. C, quantified quantal content before (circles) or after (triangles) 1.5 μM 3,4-DAP application to 
vehicle (pink) or nitrendipine (blue) -treated frog NMJs. Two-way mixed ANOVA was used (there was a significant 
main effect of 1.5 μM 3,4-DAP (F (1, 35) = 28.62, *** p < 0.0001); no significant main effect of nitrendipine (F (1,35) 
= 3.517, p = 0.0691) nor a significant interaction between 3,4-DAP x nitrendipine (F (1,35) = 0.785, p = 0.3817); 
vehicle, n = 18; nitrendipine n = 19). D-E, plots of individual paired values (grey dotted lines) with a superimposed 
average (solid pink line, vehicle; solid blue line, nitrendipine). F, The 1.5 μM dose of 3,4-DAP did not alter mEPP 
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frequency in the vehicle (pink) or nitrendipine (blue) condition; two-way mixed ANOVA (no main effect of 
nitrendipine; F (1,35) = 2.856, p = 0.0999) or 3,4-DAP; F (1,35) = 3.418, p = 0.0729, nor a significant interaction 
between 3,4-DAP x nitrendipine; F (1,35) = 2.352, p = 0.1341). G, mEPP amplitude was significantly different 
between the vehicle (pink) and nitrendipine (blue) conditions, but was not affected by 3,4-DAP; two-way mixed 
ANOVA (significant main effect of nitrendipine (F (1,35) = 7.019, p = 0.0121), and there was no significant main 
effect of 3,4-DAP (F (1,35) = 2.604, p = 0.1156) nor significant interaction between 3,4-DAP x nitrendipine (F (1,35) 
= 0.6628, p = 0.4211)). H-I, The 1.5 μM dose of 3,4-DAP increased EPP amplitude, shown as individual pairs (grey 
dotted lines) with a superimposed average (solid pink line, vehicle, H; paired t test, ** p = 0.0012; solid blue line, 
nitrendipine, I; Wilcoxon signed-rank test, *** p < 0.0001).  
 
Next, we assessed the effects of 100 μM 3,4-DAP on frog NMJs in the presence of vehicle 
(Figure 22). Before 3,4-DAP exposure, motor nerve stimulation produced an average EPP 
amplitude of 2.4 ± 1.2 mV, and spontaneous release resulted in an average mean mEPP amplitude 
of 0.7 ± 0.3 mV (Figure 22G), resulting in a quantal content of about 4 (QC = 3.8 ± 2.3; Figure 
22C-D). After 100 μM 3,4-DAP treatment, the EPP amplitude increased to an average of 100.2 ± 
36.5 mV (Figure 22H), and the mEPP amplitude was 0.9 ± 0.3 mV (Figure 22G). This resulted in 
a significant increase in quantal content to 142.6 ± 97.9 (a 37.5-fold increase; Figure 22C-D). 
We subsequently assessed whether nitrendipine could modulate 100 μM 3,4-DAP effects 
on neurotransmission at frog NMJs. For these experiments, the average baseline EPP amplitude in 
the presence of nitrendipine was 2.3 ± 1.5 mV, with an average mEPP amplitude of 0.8 ± 0.2 mV 
(Figure 22G, I), resulting in a quantal content of about 3 (QC = 2.9 ± 1.8; Figure 22C, E). After 
bath application of 100 μM 3,4-DAP in the presence of nitrendipine, EPP amplitude increased to 
59.6 ± 32.1 mV, the average mEPP amplitude was 0.9 ± 0.2 mV (Figure 22G), resulting in a 
quantal content of about 68 (QC = 67.8 ± 38.3, a 23.4-fold increase; Figure 22C, E). We did not 
observe an effect of nitrendipine on 3,4-DAP-induced changes in quantal content. Therefore, there 
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was no significant difference between the effect of 100 M 3,4-DAP in the absence or presence of 
nitrendipine (Figure 22C). However, we did find that 100 M 3,4-DAP increased mEPP frequency 
regardless of vehicle or nitrendipine condition (vehicle: baseline = 46 ± 37.0, post-3,4-DAP = 73.9 
± 65.0; nitrendipine: baseline = 46.8 ± 23.8; post-3,4-DAP = 79.3 ± 45.4; values are number of 
events per 30 seconds; Figure 22F-G). Therefore, we found that 100 M 3,4-DAP increased mEPP 
frequency and amplitude regardless of vehicle or nitrendipine condition. 
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Figure 22 100 μM 3,4-DAP dose-dependently increases neuromuscular transmission independent of Cav1 
channels in frog neuromuscular junctions.  
A-B, sample traces of electrophysiological recordings of EPPs (A) and mEPPs (B) before and after 100 μM 
3,4-DAP application. C, quantified quantal content before (circles) or after (triangles) 100 μM 3,4-DAP application 
to vehicle (pink) or nitrendipine (blue) -treated frog NMJs. Two-way mixed ANOVA was used (there was a significant 
main effect of 100 μM 3,4-DAP (F (1, 19) = 31.66, *** p < 0.0001; no significant main effect of nitrendipine (F (1,19) 
= 4.226, p = 0.0538) nor a significant interaction between 3,4-DAP x nitrendipine (F (1,19) = 4.162, p = 0.0555): 
vehicle, n = 13; nitrendipine n = 8). D-E, plots of individual paired values (grey dotted lines) with a superimposed 
average (solid pink line, vehicle; solid blue line, nitrendipine). F, The 100 μM dose of 3,4-DAP increased mEPP 
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frequency in both the vehicle (pink) and nitrendipine (blue) conditions; two-way mixed ANOVA (significant main 
effect of 3,4-DAP; F (1,19) = 9.541, p = 0.006; no main effect of nitrendipine; F (1,19) = 0.0264, p = 0.8727) nor a 
significant interaction between 3,4-DAP x nitrendipine; F (1,19) = 0.0568, p = 0.8143). G, The 100 μM dose of 3,4-
DAP significantly altered mEPP amplitude in both the vehicle (pink) and nitrendipine (blue) conditions; two-way 
mixed ANOVA (significant main effect of 3,4-DAP; F (1,19) = 11.88, p = 0.0027, but not nitrendipine; F (1,19) = 
0.3468, p = 0.5628, and no significant interaction between 3,4-DAP x nitrendipine; F (1,19) = 1.436, p = 0.2454). H-
I, The 100 μM dose of 3,4-DAP increased EPP amplitude, shown as individual pairs (grey dotted lines) with a 
superimposed average (solid pink line, vehicle, H; solid blue line, nitrendipine, I); paired t test, ** p = 0.0012, *** p 
< 0.0001. 
 
These data, taken together with the effect of low micromolar concentrations of 3,4-DAP 
on Kv3 channels (Figure 15) and action potential waveforms (Figure 16), lead us to conclude that 
low micromolar concentrations of 3,4-DAP enhance the magnitude of AP-evoked transmitter 
release at mammalian NMJs by partial antagonist activity on Kv3 channels in the motor nerve 
terminal, which broaden the presynaptic action potential without directly affecting Cav1 channels. 
Furthermore, Cav1 channels do not significantly contribute to the effects on AP waveforms or 
quantal content at the NMJ of a higher concentration (100 M) of 3,4-DAP. 
3.3 Discussion 
3,4-DAP is the FDA-approved first-line treatment for patients with Lambert-Eaton 
Myasthenic Syndrome (LEMS; (FDA, 2018, 2019; Voelker, 2019; Yoon et al., 2020)). Although 
3,4-DAP is canonically thought to mediate its effects by partially blocking presynaptic voltage-
gated potassium channels, a previous report that millimolar concentrations of 3,4-DAP could have 
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off-target effects on Cav1 channels led to the question of whether 3,4-DAP mechanisms of action 
at therapeutic concentrations (estimated to be in the low micromolar range) involve Cav1 channels. 
For this reason, we sought to characterize the effects of 3,4-DAP on Kv3 potassium current, the 
presynaptic AP waveform, and transmitter release to determine if effects on AP waveforms and 
transmitter release were altered after using nitrendipine to block Cav1 (L-type) calcium channels. 
We found that the effects of 3,4-DAP on AP-evoked transmitter release at low micromolar 
concentrations could be explained by a partial block of Kv3 channels that results in the broadening 
of the presynaptic AP independent of any contribution from Cav1 calcium channels.    
We did observe some small but significant effects of 3,4-DAP on mEPP frequency and 
amplitude, which may be due to as yet undetermined presynaptic and/or postsynaptic effects. It is 
possible that high doses of 3,4-DAP are not selective for presynaptic Kv3 channels, and affect 
postsynaptic Kv channels to indirectly modulate acetylcholine receptor sensitivity. In addition, the 
large amount of calcium influx into motor nerve terminals induced by 100 M 3,4-DAP may alter 
normal homeostatic mechanisms of calcium buffering and handling, resulting in increased 
spontaneous vesicle release. While it is also unclear how nitrendipine might alter the effects of 
3,4-DAP on mEPPs in mouse and frog NMJs, it is evident that the change in the magnitude of 
neurotransmission (quantal content) induced by 3,4-DAP is unaffected by Cav1 channels. 
Previously, 4-aminopyridine has been reported to have IC50 values for blocking Kv3 
channels of 30 M – 2.5 mM (depending in the Kv subtype; (Castle et al., 1994; Grissmer et al., 
1994; Luneau et al., 1991; Muqeem et al., 2018; Rettig et al., 1992; Schaarschmidt et al., 2009; 
Stephens et al., 1994; Vega-Saenz de Miera et al., 1992; Wu et al., 2009; Yokoyama et al., 1989)), 
and while 3,4-DAP effects on the squid giant axon potassium channel (SqKv1A; (Rosenthal, 
Vickery, & Gilly, 1996)) have been reported in the low micromolar range (Kirsch & Narahashi, 
 95 
1978), we are not aware of any prior study characterizing the concentration-dependent effects of 
3,4-DAP on the Kv3 subtype of potassium channels. While we found that 3,4-DAP could strongly 
inhibit Kv3 channels in the high micromolar to millimolar range with IC50 values of 150-250 M 
(which we defined as low affinity binding), we remarkably discovered distinct high affinity effects 
of 3,4-DAP on Kv3 channels. We have shown that 3,4-DAP has similar effects on Kv3.3 and 
Kv3.4 and acts as a partial antagonist, binding in the low micromolar range (IC50 = 2.5-10 M). 
In particular, Kv3.3 and Kv3.4 are both blocked by about 10% following exposure to the 
therapeutically relevant concentration of 1.5 M 3,4-DAP. Thus, we predict that even a 10% 
decrease in Kv3.3 or Kv3.4 current would have a significant effect on the AP duration in motor 
nerve terminals.  
Kv3 currents have been shown to mediate the dominant outward current during brief AP 
depolarizations within many nerve terminals (Alle, Kubota, & Geiger, 2011; Rowan et al., 2016; 
Rowan et al., 2014; Rowan & Christie, 2017), and have also been shown to have rapid activation 
and inactivation characteristics that enable nerve terminals to fire APs with short duration and at 
high frequency (Kaczmarek & Zhang, 2017; Rudy & McBain, 2001; Zemel et al., 2018). These 
data are consistent with the AP waveforms that were recently optically recorded from frog 
presynaptic nerve terminals (Ginebaugh et al., 2020). Here, we report concentration-dependent 
broadening of the presynaptic AP at the frog and mouse NMJ after exposure to 3,4-DAP. Even 
relatively small changes in presynaptic AP duration (15-20%) have been predicted to have 
significant effects on calcium ion entry and transmitter release (Ginebaugh et al., 2020). Thus, the 
roughly 20% broadening reported here at the mouse NMJ would be predicted to underlie the 
approximate 3-fold increase in transmitter release we observed (Ginebaugh et al., 2020). 
Interestingly, we found that 1.5 M 3,4-DAP broadened the presynaptic AP waveform in the frog 
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NMJ to a greater extent that at the mouse NMJ. A potential species difference in presynaptic ion 
channel subtype expression and/or density may underlie these results and requires further 
investigation.  
At neuromuscular synapses, the very brief presynaptic AP waveform only activates a small 
percentage of the Cav2 voltage-gated calcium channels positioned within transmitter release sites 
(Luo et al., 2015; Luo et al., 2011). This is thought to ensure that each of the hundreds of transmitter 
release sites within a single NMJ releases transmitter with low probability, conserving resources 
for repeated activation during normal activity (Tarr, Dittrich, & Meriney, 2013a). A brief AP 
activating only a small subset of available presynaptic Cav2 channels leads to neuromuscular 
weakness after many of these calcium channels are attacked and removed by autoantibodies in the 
disease LEMS. Mechanistically, 3,4-DAP is an effective symptomatic treatment for LEMS 
because the partial block of presynaptic Kv3 channels broadens the presynaptic AP, which 
increases the percentage of presynaptic voltage-gated calcium channels that open, and thus 
increases calcium entry and calcium-triggered transmitter release, leading to an improvement in 
neuromuscular strength in LEMS patients.   
3.4 Experimental procedures 
3.4.1 Ethics statement 
The experimental procedures in this study were conducted in compliance with the US 
National Institutes of Health laboratory animal care guidelines and approved by the Institutional 
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Animal Care and Use Committee of the University of Pittsburgh. All efforts were made to 
minimize the suffering of animals. 
3.4.2 Whole-cell perforated patch clamp electrophysiology 
Recordings were performed as previously described (Wu et al., 2018a) using HEK293T 
cells transfected with either Kv3.3 (Kv 3.3  subunit (Dr. Leonard Kaczmarek) and GFP at a DNA 
ratio of 1:1), Kv3.4 (Kv 3.4  subunit (Dr. Manuel Covarrubias) and GFP at a DNA ratio of 1:1), 
Cav2.1 (Cav 2.1 1 subunits, Addgene #26573; Cav β3, Addgene #26574; Cav α2δ1, Addgene 
#26575, and GFP at a DNA ratio of 1:1:1:1), or Cav1.2 (Cav 1.2 1 subunits, Addgene #26572; 
Cav β3, Addgene #26574; Cav α2δ1, Addgene #26575, and GFP at a DNA ratio of 1:1:1:1). All 
recordings were performed at room temperature (20-22 °C).  
For recording potassium currents, the pipette solution contained 70 mM CH3KO3S, 60 mM 
KCl, 10 mM HEPES, and 1 mM MgCl2 at pH 7.4, and the bath saline contained 130 mM NaCl, 
10 mM HEPES, 10 mM glucose, 3 mM CaCl2, and 1 mM MgCl2 at pH 7.4. For recording calcium 
currents, the pipette solution contained 70 mM CH3O3SCs, 60 mM CsCl, 10 mM HEPES, and 1 
mM MgCl2 at pH 7.4, and the bath saline contained 130 mM choline chloride, 10 mM HEPES, 10 
mM TEA-Cl, 5 mM BaCl2, and 1 mM MgCl2 at pH 7.4. Patch pipettes were fabricated from 
borosilicate glass and pulled to a resistance of ~1-4 MΩ. Prior to each experiment, 3 mg 
amphotericin-B was dissolved in 50 μM DMSO. Each hour, 10 l of this amphotericin-B stock 
was mixed with 500 l of pipette solution and vortexed. Pipettes were filled in a two-step process. 
The tip of the pipette was dipped into a droplet of filtered pipette solution for 1 second, and then 
the remainder of the pipette was back-filled with the amphotericin-B/pipette solution mixture using 
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a syringe and a 34 G quartz needle (MicroFil MF34G, World Precision Instruments, Sarasota, FL). 
This filled pipette was then used to make a GΩ seal with a fluorescent cell and 5-10 minutes was 
provided for amphotericin-B-mediated perforated patch access. Access resistances ranged from 5-
15 MΩ and were compensated by 85%. Voltage clamp of cells under study was controlled by an 
Axopatch 200B amplifier driven by Clampex 10 software (Molecular Devices, Sunnyvale, CA). 
Data were filtered at 5 kHz, digitized at 10 or 50 kHz, and analyzed using Clampfit 10 software 
(Molecular Devices). Capacitive transients and passive membrane responses to the voltage steps 
were subtracted, and the liquid junction potential was corrected before each recording. Current 
through calcium or potassium channels was activated by depolarizing steps from a holding 
potential of -100 mV to +20 or +40 mV. In all cases currents were activated both before and after 
exposure to 3,4-DAP (dissolved in extracellular saline) in each cell, and current amplitudes were 
compared. For analysis before plotting, each current amplitude was normalized to its peak current 
amplitude before 3,4-DAP application to derive the normalized block at each concentration. The 
ratio described above was subtracted from 1 and the resulting value then was multiplied by 100 to 
obtain the percent inhibition. 
3.4.3 Tissue preparation 
Adult male and female frogs (Rana pipiens) were anaesthetized via immersion in 0.6% 
tricaine methane sulphonate, decapitated, and double pithed. The cutaneous pectoris 
neuromuscular preparation was dissected and bathed in normal frog Ringer saline (NFR, in mΜ: 
116 NaCl, 10 mM BES buffer, 2 mM KCl, 5 mM glucose, 1 mM MgCl2, 1.8 mM CaCl2, pH 7.3). 
Adult male and female Swiss Webster mice (3-6 months of age; Charles River Laboratories, 
Wilmington, MA) were sacrificed using CO2 inhalation, followed by thoracotomy. The 
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epitrochleoanconeous neuromuscular preparation was bilaterally dissected and bathed in normal 
mouse Ringer saline (NMR, in mΜ: 150 NaCl, 10 mM BES buffer, 5 mM KCl, 11 mM glucose, 
1 mM MgCl2, 2 mM CaCl2, pH 7.4).  
3.4.4 Intracellular microelectrode electrophysiology 
The muscle nerve was stimulated using a suction electrode and muscle contraction was 
blocked following a 1 hr incubation in a bath containing 50 µM of the irreversible muscle myosin 
inhibitor BHC (Heredia et al., 2016). After BHC washout using normal saline, microelectrode 
recordings were made in the presence of 1 µM nitrendipine (Sigma, St. Louis, MO) or the vehicle 
(0.01% DMSO) plus a selective muscle voltage-gated sodium channel blocker (1 µM µ-conotoxin 
PIIIA for the frog NMJ or 5 M µ-conotoxin GIIIB for the mouse NMJ; Alomone Labs Ltd, 
Jerusalem, Israel). Additionally, in order to reduce the magnitude of transmitter released, 250-900 
nM ω-conotoxin GVIA (to block N-type channels at the frog NMJ) or 50 – 100 nM ω-agatoxin 
IVA (to block P/Q-type channels at the mouse) was included in the recording bath. The range of 
concentrations listed was used iteratively with each preparation to reduce control endplate 
potentials (EPPs) to below 10 mV. Intracellular recordings of muscle cell membrane potentials 
were obtained using borosilicate glass microelectrodes pulled to a resistance of ~40-60 MΩ and 
filled with 3 M potassium chloride. For each muscle fiber recording made adjacent to visualized 
NMJs, spontaneous miniature synaptic events (mEPPs) were collected for 1-2 min, followed by 
10-30 EPPs elicited by low frequency (0.2 Hz) stimulation. Subsequently, neuromuscular 
preparations were incubated in freshly made 1.5 µM or 100 µM 3,4-DAP for 30-60 minutes. After 
3,4-DAP incubation, paired recordings were made from the same neuromuscular junctions that 
had been studied in control saline (resulting in paired data sets). Data were collected using an 
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Axoclamp 900A and digitized at 10 kHz for analysis using pClamp 10 software (Molecular 
Devices). Spontaneous and evoked endplate potentials were normalized to -70 mV and corrected 
for non-linear summation (McLachlan & Martin, 1981). We measured the magnitude of 
transmitter release by determining the quantal content (QC) using the direct method of dividing 
the peak of the averaged and normalized EPP trace by the peak of the averaged and normalized 
mEPP trace. 
3.4.5 Voltage imaging 
Voltage imaging was performed as described previously (Ginebaugh et al., 2020). To load 
nerve terminals with dye for the voltage-imaging procedure, a mixture of 5 mL of NFR (for frog 
preparations) or NMR (for mouse preparations) with a BeRST 1 voltage-sensitive dye (Huang et 
al., 2015) concentration of 0.5 μM and 10 g/mL of Alexa Fluor 488-conjugated α-bungarotoxin 
(BTX; to counterstain postsynaptic receptors at the NMJ and block muscle contractions) was 
freshly made before each experiment. Then, the neuromuscular preparation was bathed in this dye 
mixture for 90 minutes, rinsed, and mounted on the stage of an Olympus BX61 microscope with 
a 60x water immersion objective. The nerve was then drawn into a suction electrode for supra-
threshold stimulation. If the BTX conjugated to Alexa Fluor 488 did not completely block muscle 
contractions, 10 μM curare was added to the imaging saline to completely block any remaining 
nerve-evoked muscle contractions. 
 The postsynaptic BTX stain was used to identify nerve terminals and bring them into focus 
for voltage imaging. After locating a well-stained nerve terminal, an imaging region of interest 
(ROI) that contained a large portion of the nerve terminal branch (usually an ROI of approximately 
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80x30 μm for frog or 60x40 μm for mouse) was selected. All voltage imaging recordings were 
performed at room temperature (20-22 °C). 
After a nerve terminal was selected for imaging, the presynaptic axon was stimulated at 
0.2 Hz. During each stimulation, there was a brief 100 μs image collection window where the 
preparation was illuminated by a 640 nm laser (89 North laser diode illuminator) and the BeRST 
1 dye fluorescence of the nerve terminal was recorded by an EMCCD camera (Pro-EM 512, 
Princeton Instruments). A custom routine on a Teensy 3.5 USB development board (PJRC) created 
a delay between the stimulation of the nerve and the triggering of the camera and laser. This delay 
in the 100 μs collection window was increased by 20 μs after each stimulation. After 100 sequential 
delays of 20 μs, a full time-course of 2 ms in which the entire AP waveform could be sampled was 
obtained (for 100 μM 3,4-DAP recordings, 300 moving bins for a total time course of 6 ms were 
used). For each frog nerve terminal recording, this process was repeated 5-15 times. For mouse 
nerve terminal recordings, this process was repeated 10-50 times (the BeRST 1 dye signal at the 
mouse terminals was weaker than at the frog terminals, and thus required more recordings to obtain 
a high-quality averaged AP waveform). 
Custom written scripts in ImageJ and MATLAB (Mathworks) were used to analyze 
images. An “align slices in stack” ImageJ plugin 
(https://sites.google.com/site/qingzongtseng/template-matching-ij-plugin; see (Tseng et al., 2012; 
Tseng et al., 2011)) was used to correct the image stack for x-y drift. Then, an unbiased ROI 
selection (a subsection of the full imaging ROI) containing the nerve terminal was created by 
applying an Otsu local imaging threshold (Otsu, 1979) to the average fluorescence z-projection of 
the BeRST 1 image stack. The average fluorescence inside this ROI was used as the nerve signal 
(for frog recordings, 20 μm near the end of the nerve terminal and last node of Ranvier were 
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excluded to restrict recordings to the middle electrical region of the terminal; see (Ginebaugh et 
al., 2020)). The average fluorescence from the region outside of the Otsu-selected ROI was used 
as the background signal. Both the nerve and background signals were then low-pass filtered 
offline (fpass= 4 kHz). The following analysis was then performed separately for both the filtered 
and unfiltered signals: the background signal was divided from the nerve signal to generate a 
corrected fluorescence signal. We then fit a cubic B-spline through the unstimulated points in the 
fluorescence time course (the first and last 15 points of the 100 total points in each time series), 
and divided this cubic spline from each point in the fluorescence signal. This resulted in a ∆F/F 
fluorescence signal that did not fluctuate as a result of drift of the nerve muscle preparation or dye 
bleaching. 
Two AP waveforms were then created by separately averaging the APs from the filtered 
and unfiltered ∆F/F fluorescence signal. The R2 value between the filtered and unfiltered AP 
waveforms was then calculated. Since these are not linear models, the R2 is not an exact measure 
of fit between the filtered and unfiltered AP waveforms, but rather is a metric of fit that is heavily 
weighted by the strength (in terms of the amplitude of the ∆F/F fluorescence signal) of the recorded 
signal. This weight is important because normalizing slight bumps on an almost flat signal could 
appear as an AP. Thus, the R2 value provides a heuristic metric to estimate the quality of our 
recorded AP waveforms, and is not used for any statistical purposes.  
Image artifacts in the background (e.g. a BeRST 1 dye-stained free-floating piece of 
connective tissue) occasionally resulted in the background not properly dividing the nerve signal, 
resulting in a noisier signal (and worse R2 value). If the R2 was less than 0.95 for frog recordings 
(or 0.90 for the 300 bin recordings for the 100 μM 3,4-DAP recordings), or 0.85 for the mouse 
recordings, the fluorescence of an approximately 15x30 μm section of the background near the 
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nerve terminal was used as the background fluorescence rather than the complete background 
region. If this smaller background subsection also resulted in a R2 value lower than the values 
listed above, the recording was not included in the data analysis. If the recording was of high 
enough quality to produce a sufficient R2 value, the average filtered AP was normalized to the first 
15 points (the baseline of the trace) and fit with cubic spline interpolation at an oversampled time 
resolution of 2 μs. Finally, the full width at half maximum (FWHM) of the normalized spline of 
the AP waveform was calculated.   
3.4.6 Statistical analysis 
Data was statistically analyzed using Prism v.7 or v.8 (Graphpad). Electrophysiology data 
were determined to be outliers if the data exceeded 1.5 times the interquartile range. The 
distribution of the data was assessed for normality using Shapiro-Wilk test. Statistical comparisons 
were performed using a two-way repeated measures mixed ANOVA with a between-subjects 
factor of bath (nitrendipine or control vehicle bath) and a within-subjects factor of 3,4-DAP 
(baseline or post 3,4-DAP bath application), or with a paired t test or Wilcoxon matched-pairs 
signed-rank test. If there was a significant interaction found, post-hoc simple effect tests were 
performed. Results were considered statistically significant when the p-value was < 0.05. The 
results represent the mean ± standard deviation (S.D.) of at least three independent experiments. 
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4.0 Development of a computational model of neuromuscular active zones in seropositive 
and seronegative Lambert-Eaton myasthenic syndrome predicts that a reduction in 
synaptotagmin can match known physiology in seronegative LEMS 
Lambert-Eaton Myasthenic Syndrome (LEMS) is an autoimmune-mediated 
neuromuscular disease thought to be caused by autoantibodies against voltage-gated calcium 
channels (VGCCs) reducing the number of VGCCs in the presynaptic terminal of the 
neuromuscular junction (NMJ) and disrupting the organization of active zones (AZs; sites of 
transmitter release sites). However, up to 15% of LEMS patients are seronegative for antibodies 
against VGCCs. Furthermore, the specificity of these antibodies has been brought into question by 
multiple reports of antibodies against VGCCs in patients with other diseases but not LEMS, as 
well as healthy controls. Here, we construct a computational model of healthy mammalian NMJ 
AZs and then utilize this model to study LEMS-mediated effects on AZ organization and 
transmitter release. We show that healthy AZs can be modified to predict the transmitter release 
and short-term facilitation characteristics of LEMS by altering the AZs according to microscopy 
and electrophysiology data, and that disruption of AZ structure contributes more than the decrease 
in number of VGCCs to the LEMS-mediated reduction in transmitter release. We also show that 
seronegative LEMS can be caused by reducing the number of fast synaptotagmin proteins in 
healthy AZs, and that LEMS treatment with 3,4-diaminopyridine is less effective in this model. 
These results suggest that antibodies against AZ proteins may play an important role in 
seropositive LEMS in combination with anti-VGCC antibodies, antibody-mediated removal of 
synaptotagmin could cause seronegative LEMS, and an in-depth characterization of autoantibodies 
in LEMS patient serum will be crucial to understanding seropositive and seronegative LEMS.  
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4.1 Introduction 
Lambert-Eaton Myasthenic Syndrome (LEMS) is an autoimmune-mediated 
neuromuscular disease that causes a reduction in synchronous neurotransmitter release from the 
presynaptic terminal of the neuromuscular junction (NMJ), which results in severe muscle 
weakness.  The reduction of neurotransmitter release is typically ascribed to antibodies targeting 
the P/Q-type voltage gated calcium channels (VGCCs) that are primarily responsible for the 
calcium flux that triggers transmitter release in the active zones (AZs; the site of neurotransmitter 
release) of healthy mammalian NMJs. However, antibodies to VGCCs are not detected in 10-15% 
of LEMS patients (Kesner et al., 2018; Lennon et al., 1995; Motomura et al., 1997; Nakao et al., 
2002; Takamori et al., 1995). These seronegative LEMS patients have similar clinical 
presentations to the seropositive LEMS patients that express the P/Q-type VGCC antibodies 
(Nakao et al., 2002; Oh et al., 2007). Although the seronegative LEMS patients do not produce 
antibodies to the P/Q-type VGCCs, the repeated injection of mice with seronegative LEMS patient 
serum is able to passively transfer LEMS symptoms to the mice, suggesting that seronegative 
LEMS is still antibody mediated (Nakao et al., 2002). These findings suggest that seronegative 
LEMS may be caused by antibodies targeting other proteins important to the release of 
neurotransmitter in the AZ. 
Synaptotagmin-1 and synaptotagmin-2 are both found in the AZs of mouse NMJs (Pang et 
al., 2006a), and are known to be the calcium-sensing proteins responsible for fast synchronous 
release of neurotransmitter (Pang et al., 2006b).  Antibodies to synaptotagmin-1 have been found 
in the serum of LEMS patients (Takamori, Komai, & Iwasa, 2000a; Takamori et al., 1995). Thus, 
it has been hypothesized that synaptotagmin antibodies could be responsible for seronegative 
LEMS. This hypothesis is supported by the finding that rats injected with synaptotagmin 
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antibodies developed electrophysiological characteristics of LEMS (Takamori et al., 1994), 
experiments demonstrating that synaptotagmin-2 knock-out mice display similar 
electrophysiological characteristics to LEMS (Pang et al., 2006a), and a recent report of a rare 
genetic alteration of synaptotagmin-2 in human patients that causes symptoms similar to LEMS 
(Herrmann et al., 2014). 
We have previously developed computational models of an AZ in the healthy frog NMJ 
(Dittrich et al., 2013; Ma et al., 2014), and have recently developed a preliminary model of AZs 
in the mouse NMJ (Laghaei et al., 2018). Here, we further develop our computational model of 
AZs in the healthy mouse NMJ, and then utilize it to investigate LEMS induced changes to the 
AZs. We find that rearranging the number and placement of VGCCs within our model of healthy 
mouse AZs is able to predict the electrophysiological behavior of LEMS, consistent with the 
hypothesized mechanism of seropositive LEMS. We then show that removal of a majority of the 
synaptotagmin-1-like fast calcium sensors produces similar results, providing computational 
evidence in support of the synaptotagmin-antibody hypothesis of seronegative LEMS. Finally, we 
test the impact of experimentally-recorded AP waveforms from mouse NMJs in the presence of 
3,4-diaminopyridine (3,4-DAP) on our seronegative- and seropositive-LEMS computational AZ 
models, and hypothesize that the heterogeneity of antibodies in LEMS patients could be primarily 
responsible for the wide range of effectiveness of 3,4-DAP in the treatment of muscle weakness 
in LEMS patients. 
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4.2 Methods 
4.2.1 Monte Carlo simulations 
MCell version 3.4 (www.mcell.org) was used to study synchronous vesicle release at the 
mouse NMJ. MCell is a stochastic particle-based diffusion-reaction simulator that can model 
biological systems with arbitrarily complex 3D geometries (Bartol et al., 1991; Kerr et al., 2008; 
Stiles et al., 1996). For each simulation, 6000-10000 sperate MCell seeds were run. During each 
run, an AP (or a train of APs) caused VGCCs to open according to a Markov-chain ion channel 
gating scheme. Calcium was then released from open VGCCs and diffused into the terminal. As 
they diffused, the calcium ions either bound to calcium sensors located on synaptic vesicles or to 
calcium buffer molecules evenly distributed throughout the terminal. Our models are based on 
previously developed MCell models of the frog AZ (Dittrich et al., 2013; Ma et al., 2014) and a 
recently developed preliminary model of mouse AZs (Laghaei et al., 2018). We then further 
constrained these models with new biophysical parameters from literature. 
4.2.2 Action potentials and VGCCs 
To constrain our model to biological data, we used AP waveform inputs based on recently 
published AP waveforms recorded from the mouse NMJ via voltage-imaging (chapter 3.0). We 
used the average AP waveforms from both control and 3,4-DAP recordings, and prepared them 
for use in our simulations similarly to previously described (Ginebaugh et al., 2020). In brief, the 
average AP waveforms were normalized to a peak voltage of 30 mV and a resting potential of -60 
mV. We then removed fluctuations caused by noise in the experimental data in the onset of the 
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rising edge of each of the AP waveforms by replacing the first 10% of the rising edge with a line 
that had the same slope as the next 10% of the rising edge. We then removed fluctuations in the 
falling edge of each AP waveform by fitting a second-degree polynomial through the last 30% of 
the falling edge and then replacing that 30% with the polynomial (Figure 23 A and B). 
The kinetics of the VGCCs were based on the Markov-chain model used in our excess-
calcium-binding-site model of the frog NMJ (Dittrich et al., 2013), which consisted of three closed 
states and one open state. However, because the previously published model was based on the frog 
which uses primarily N-type VGCCs, whereas the mouse uses primarily P/Q-type VGCCs and 
because prior research has shown that VGCC gating is best fit by a model with two open states 
(DeStefino et al., 2010), we altered the previous VGCC gating scheme to contain two open states 
and reparametrized it to fit the average calcium currents from previously-published recordings 
from HEK293 cells expressing P/Q type VGCCs (Tarr et al., 2014) (Figure 23 C and D). The rate 
constants α, β, and k were the same as used in previous models (Dittrich et al., 2013; Ma et al., 
2014) except the reversal potential for calcium used in the calculation of k was +60 mV rather than 




Figure 23 AP waveforms and VGCC kinetics in the MCell models. 
A: The normalized average of AP waveforms recorded from mouse NMJs (black) and the computational AP 
waveform used in MCell simulations (magenta). B: The normalized average of AP waveforms recorded from mouse 
NMJs in the presence of 1.5 μM 3,4-DAP (black) and the computational AP waveform used to simulate 3,4-DAP in 
MCell (green). C: A comparison of the computational AP waveforms used in control (magenta) and 3,4-DAP (green) 
simulations. D: The Markov-chain ion channel gating scheme used to determine the behavior of VGCCs in our 
simulation. E: Model output of calcium current (red) overlaid onto experimental data (black) from the average trace 
of 6 recordings from P/Q-type VGCCs expressed in HEK293 cells. The voltage steps used to activate the currents are 
shown above each set of traces. Average AP waveforms in A and B are from (Ginebaugh et al., 2020). Patch clamp 
recordings of P/Q-type VGCCs expressed in HEK293 cells are from (Tarr et al., 2014). 
4.2.3 Mouse MCell model and vesicle fusion 
To construct an MCell model of mouse NMJ AZs, the NMJ ultrastructure and placement 
of the AZs was the same as previously described in our preliminary mouse model (Laghaei et al., 
2018). The healthy mouse model consisted of six AZs placed 500 nm apart, and each AZ contained 
two docked synaptic vesicles (Figure 24A).  
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The vesicle fusion mechanism was similar to our previously described mechanism (Ma et 
al., 2014). In brief, the bottom of each vesicle contained two different types of calcium sensors. 
The first type was a fast sensor which represents synaptotagmin-1 (syt1) or synaptotagmin-2 
(syt2). The second was a slow second-sensor binding site. Since the publication the NMJ AZ model 
that contained a second-sensor binding site (Ma et al., 2014), it was revealed that this second sensor 
is likely to be synaptotagmin-7 (syt7) (Jackman et al., 2016). Thus, to be more consistent with the 
literature, we altered the calcium binding on- and off-rates of both the syt1-like and syt7-like 
sensors based on a previous simulation of phospholipid binding of both sty1 and syt7 (Jackman & 
Regehr, 2017). The calcium binding rates for the syt1-like sensor were set to kon = 2.2 * 10
7 M-1s-
1 and koff = 910 s
-1, and the calcium binding rates for the syt7-like sensor were set to kon = 1 * 
107 M-1s-1 and koff = 15 s
-1. 
When bound by a sufficient number of calcium ions, the calcium sensors were considered 
activated and contributed to increasing the probability of vesicular fusion. Vesicles fuse in a 
probabilistic manner, with fusion for each vesicle determined with the Metropolis-Hastings 




) , 1). Here, Eb = 40 kBT is the free energy barrier preventing 
vesicle release (Li et al., 2007; Martens et al., 2007), nS1 and nS7 are the number of syt1-like sensors 
and syt7-like sensors that have been activated by calcium, and ∆ES1 and ∆ES7 are the amount each 




Figure 24 Diagrams of the healthy mouse AZ MCell model and VGCC placement parameter sweep. 
A: Visualization of the geometry of the health mouse AZ MCell model. Six AZs are modeled and each AZ 
consists of VGCCs (small black dots) and two docked synaptic vesicles (black spheres). B: A diagram of the calcium 
sensors on the underside of each synaptic vesicle. Each vesicle has up to 8 syt1-like sensors, consisting of 5 binding 
sites each. A syt1-like sensor is activated when at least two of its 5 sites are bound to calcium. Each vesicle also has 
16 syt7-sensors, positioned in a single annulus around the outside of the syt1-like sensors. Each syt-7 like sensors only 
contain one calcium-binding site, and are activated when the site is bound by a calcium ion. Adapted from (Laghaei 
et al., 2018). C: A schematic of the AZ from above, showing the possible placement positions for VGCCs based on 
freeze-fracture data. The schematic shows two docked synaptic vesicles (grey translucent circles) with a row of 5 
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VGCCs placed on each side (numbered circles). The VGCC placement must be symmetrical over both the x and y 
axes (dotted lines), resulting in only 3 different positions which may be selected for VGCCs placement (i.e., a selection 
of position 3 requires all four of the VGCCs labeled 3 to be selected). D: An example of a 6 VGCC AZ model created 
by selecting positions 1 and 3 to contain VGCCs. E: The 4 VGCC AZ model, created by selecting position 2 to contain 
VGCCs, which best predicted experimental results. 
4.3 Results 
4.3.1 Constraining the healthy mouse AZ model 
Our MCell model of the healthy mouse AZ was initially based on previous MCell models 
of the frog AZ (Dittrich et al., 2013; Ma et al., 2014), a preliminary model of the mouse AZ 
(Laghaei et al., 2018), and experimental and biophysical data (see section 4.2). The only free 
parameters in our model were the number and location of VGCCs as well as the number and energy 
contribution of the syt1-like and syt7-like calcium binding sites toward overcoming the 40 kBT 
free energy barrier for synaptic vesicle fusion. We constrained the number of syt1-like sensors to 
between 5 and 8 based on based our previous model (Ma et al., 2014) and the geometrical 
arrangement of 5 to 8 syntaxin that helps form the fusion pore (Han et al., 2004). Based on 
biophysics literature, we constrained the energy contribution of calcium-activated syt1-like 
sensors toward overcoming the 40 kBT free energy barrier for vesicle fusion to be either 18 kBT 
(Gruget et al., 2020; Gruget et al., 2018) or 20 kBT (Martens et al., 2007). Although much has been 
learned about synaptotagmin-7 since its discovery as an important calcium sensor in 
neurotransmitter release (Jackman et al., 2016), much is still unknown. Thus, we decided to keep 
the number of syt7-like binding sites at 16 as was used in our previous model (Ma et al., 2014) due 
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to the ability of this model to fit experimental data, since this aspect of syt7 stoichiometry remains 
unknown (Figure 24B). Based on computational predictions that the energy contribution of syt7 is 
lower than syt1 (Jackman & Regehr, 2017), as well as our previous model (Ma et al., 2014), we 
allowed the syt7-like contribution to vesicle fusion energy to be any positive integer less than or 
equal to 11.  
To constrain the number of possible placements for the VGCCs, we assumed that VGCCs 
must be represented by the double rows of intramembranous particles on each side of the vesicles 
seen in freeze-fracture electron microscopy, and constrained the placement of the VGCCs to the 
average measured placement of these particles in freeze-fracture electron microscopy replicas 
(Fukuoka et al., 1987). Based on the rapid release of neurotransmitter during an AP, and the known 
close association of P/Q-type VGCCs with various AZ proteins (Catterall, 1999; Kaeser et al., 
2011; Mochida et al., 2003; Sheng et al., 1998), we constrained the placement of VGCCs to the 
first row of the double rows on each side of the AZ. Although this narrowed the placement of 
VGCCs to 10 possible locations, this still created 210-1 = 1023 different possible placement 
combinations for VGCCs. To further narrow down the possible VGCC configurations, we 
constrained the placement of VGCCs in the AZ to be symmetrical across both the vertical and 
horizontal midline of the AZ. This results in only three different locations for VGCC placement, 
resulting in only 7 different possible VGCC-placement configurations (Figure 24C).  
With these constraints, we performed a parameter sweep of VGCC placement 
combinations and synaptotagmin-like sensor number and energy contributions to find model 
conditions which best fit experimental data (Table 1). We found that two possible 6-channel 
models (Figure 24D) with 5 syt1-like sensors, 18 kBT energy contribution of activated syt1-like 
sensors, and no syt7-like energy contribution (i.e. the synaptotagmin parameters that would cause 
 114 
the fewest number of vesicles to be released) resulted in a probability of release per active zone 
(PrAZ) higher than the experimentally calculated value of 0.22 PrAZ (Laghaei et al., 2018) (Table 
1). Similarly, we found that the 2-channel model with 8 syt1-like sensors, 20 kBT syt1-like energy 
contribution, and 11 syt7-like energy contribution (i.e., the synaptotagmin parameters that would 
cause the greatest number of vesicles to fuse) resulted in a PrAZ lower than the experimental value. 
Thus, only the two possible four-VGCC placements remained as plausible organizations for our 
AZ model. 
To determine which of these VGCC placements and synaptotagmin parameters best fit 
experimental results, we first ran a parameter sweep to find all combinations of synaptotagmin 
parameters that would predict the experimental PrAZ value of 0.22. We then investigated the ability 
of these parameters to fit the experimental paired pulse facilitation (PPF) results (Table 1). We 
found that the 4-VGCC model with VGCCs in position 2 (Figure 24E) best predicted the 
experimental PrAZ and PPF (Table 1). This model also accurately predicted a slight depression 
over short trains of stimuli (Figure 25A), a paired pulse facilitation that is relatively unchanged by 
changes in inter-spike interval (Figure 25B), and a vesicle release latency following an AP (Figure 
25C) that is in agreement with previously published experimental data (Wang, Pinter, & Rich, 
2010). In addition, our model predicted a log-log ratio between extracellular calcium and 
transmitter release (also known as the calcium-release ratio, or CRR; Figure 25D) of ~2.7, which 
is consistent with experimental data (Urbano et al., 2003). Thus, this model that resulted from our 
evaluation of VGCC placement closely recapitulates experimental results for a variety of 
experiments. Our model places VGCCs only ~15 nm away from the nearest synaptic vesicle (and 
the calcium sensors attached to it), which is similar to the estimated distance between VGCCs and 
calcium sensors in fast-spiking hippocampal GABAergic interneurons (Arai & Jonas, 2014; 
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Bucurenciu et al., 2008) and the mature calyx of Held (Chen et al., 2015; Nakamura et al., 2015). 
Thus, our VGCC placement agrees with the hypothesis that VGCCs are tightly coupled to docked 
synaptic vesicles in the NMJ to mediate fast synchronous transmitter release (Stanley, 2016).  
 
Table 1 Parameter sweep of VGCC configuration and calcium-sensor settings. 
#VGCCs VGCC 
position(s) 
nS1 ∆ES1 ∆ES7 PrAZ PPF 
P2/P1 
PPF P3/P1 
6 1,3 5  18 0 0.251 0.828 0.742 
6 1,2 5  18 0 0.271 0.813 0.691 
2 1 8 20 11 0.161 0.982 0.941 
4 2 5 18 7 0.200 1.014 0.981 
4 2 5 18 8 0.228 1.009 0.952 
4 2 5 18 9 0.241 1.015 0.949 
4 2 5 20 6 0.203 0.993 0.949 
4 2 5 20 7 0.228 0.992 0.940 
4 2 5 20 8 0.242 1.002 0.933 
4 2 6 18 4 0.205 0.918 0.862 
4 2 6 18 5 0.214 0.945 0.897 
4 2 6 18 6 0.224 0.962 0.905 
4 3 5 18 8 0.207 0.993 0.955 
4 3 5 18 10 0.222 0.988 0.922 
#VGCCs, number of VGCCs in the model; VGCC position(s), position of VGCCs based on Figure 
24; nS1, number of syt1-like sensors; ∆ES1, energy contribution toward fusion of activated 
syt1-like sensors; ∆ES7, energy contribution toward fusion of syt7-like sensors; PrAZ, 
probability of release per AZ; PPF, paired pulse facilitation for the second or third pulse 
(P2,P3) compared to the first pulse (P1). Values in bold show the model which best matches 




Figure 25 Validation of the healthy mouse AZ MCell model. 
A: Plot of tetanic potentiation at 50 Hz. Our MCell model of the healthy mouse AZs (black circles) closely 
matched experimental results (open circles). The tetanic potentiation seen in LEMS-model mice (open squares) is 
added for comparison. Experimental results for both LEMS and control tetanic potentiation from (Tarr et al., 2013b). 
B: The paired pulse ratio measured as the interstimulus interval is changed from 10 to 90 msec. The outputs from the 
MCell model (grey circles) and the experimental data (black squares) both predict little change over a changing 
interstimulus interval. Experimental data from (Laghaei et al., 2018) C: Plot of changes in transmitter release 
magnitude in our MCell model as the extracellular calcium concentration was varied. The log-log best fit line for the 
data is shown with a slope of 2.69 and an R2 value of 0.998. D: The predicted latency of vesicle release following a 
single presynaptic AP is plotted based on our MCell model. 
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4.3.2 Constructing a MCell model of LEMS-modified AZs 
We sought to create a MCell model which would fit the experimental electrophysiological 
characteristics seen in LEMS-model mice by altering our model of healthy mouse AZs. We altered 
our model of healthy mouse AZs based on the experimental evidence that LEMS (1) reduces the 
number of P/Q-type VGCCs in the AZs (Smith et al., 1995; Xu et al., 1998), (2) causes a 
compensatory upregulation of other VGCC subtypes (primarily L-type) outside of the AZs (Flink 
& Atchison, 2002; Xu et al., 1998), (3) reduces the number of AZs, (Fukunaga et al., 1982; 
Fukunaga et al., 1983) and (4) disrupts the organization of particles in many of the remaining AZs 
(Fukuoka et al., 1987). The experimental results we sought to predict with our model were: a 60-
75% reduction in quantal content compared to healthy control mice, an increase in facilitation over 
short trains of stimuli,  (Lang et al., 1984; Lang et al., 1983; Tarr et al., 2014; Tarr et al., 2013b), 
and a large portion of transmitter release being attributed to VGCCs located outside of the AZs 
(Flink, 2003; Flink & Atchison, 2002; Giovannini et al., 2002).  
Since LEMS both decreases the number of P/Q-type VGCCs and increases the number of 
L-type VGCCs, we decided to begin creating our MCell model of LEMS-modified AZs by first 
constructing a model of P/Q-type-VGCC-only LEMS-modified AZs without any compensatory 
upregulation of L-type VGCCs. Experiments measuring quantal release in LEMS-model mice 
before and after exposure to the L-type VGCC blocker nimodipine revealed that blocking L-type 
VGCCs in LEMS-model mice reduces transmitter release ~40% compared to LEMS-model mice 
without the channel blocker (Flink & Atchison, 2002). Since LEMS-model mice have a 60-75% 
reduction of transmitter release compared to controls, and blocking L-type VGCCs further 
decreases the transmitter release of LEMS-model mice by ~40%, LEMS-model mice with blocked 
L-type calcium currents are expected to release 76-85% less transmitter release than healthy 
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controls. Thus, to fit experimental data, a model of LEMS AZs with only P/Q-type VGCCs should 
have 76-85% less quantal release than the healthy control AZ model.  
Perineural recordings of calcium currents at the NMJs of ex vivo nerve-muscle 
perpetrations from healthy and LEMS-model mice indicate that calcium current from P/Q-type 
VGCCs is only reduced by about 30-40% in LEMS-model mice (Smith et al., 1995; Xu et al., 
1998). We found that randomly removing ~40% (9 out of 24) of the VGCCs only reduced 
transmitter release by 42%. This is a less than the 60-75% reduction of transmitter release seen in 
LEMS-model mice, and is much less than the 76-85% reduction in transmitter release seen in 
LEMS-model mice with blocked L-type calcium current (Flink & Atchison, 2002). We found that 
in order to reduce transmitter release to 22% compared to control by randomly removing VGCCs, 
it was necessary to remove 75% (18 out of 24) of the VGCCs. This results in a much greater 
reduction in calcium current than the experimentally measured value of a 30-40% reduction (Smith 
et al., 1995; Xu et al., 1998). These results suggest that simply removing VGCCs is not sufficient 
to explain the effect of LEMS on transmitter release. 
Not only does LEMS reduce the current through P/Q-type VGCCs, but freeze-fracture 
electron microscopy reveals that LEMS also disrupts the normally well-organized structure of the 
AZs and reduces the number of well-organized AZs by 70-85% (Fukunaga et al., 1982; Fukunaga 
et al., 1983; Fukuoka et al., 1987). These studies also found that LEMS causes a large number of 
clusters of intramembranous particles (which are likely highly unorganized AZs (Fukuoka et al., 
1987)) to appear, and to outnumber the remaining well-organized AZs. Thus, we investigated the 
impact of structural disorganization of the AZs in our model by moving the VGCCs way from the 
AZs. We found that by simply moving the VGCCs 20 nm away from the synaptic vesicles in the 
AZ (Figure 26A) we were able to reduce transmitter release by 61%. This suggests that the 
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disorganization of the AZs structure plays an essential role in determining the reduced magnitude 
of transmitter release seen in LEMS.  
Thus, to create our LEMS MCell model, we first altered our 6 AZ healthy mouse model 
by removing 2 AZs and denoting the remaining 4 AZs as 1 “normal” AZ with unaltered P/Q-type 
VGCC locations (Figure 24E) and 3 “clusters” with the P/Q-type VGCCs moved an additional 20 
nm away from the AZ (Figure 26A). We then randomly removed 6 of the 16 remaining VGCCs 
to simulate the 30-40% reduction in P/Q-type calcium current (assuming that all VGCCs are 
equally likely to be removed by anti-VGCC antibodies, and that the VGCCs from the two 
otherwise destroyed AZs remain in the presynaptic terminal). We found that this P/Q-type-only 
LEMS model resulted in an 80% reduction in transmitter release compared to control, which is a 
good fit for the experimentally measured values of transmitter release recorded from LEMS-model 
mice in the presence of drugs to block L-type VGCCs (Flink & Atchison, 2002). 
Having successfully constructed an MCell model of P/Q-type-only LEMS-modified AZs, 
we next sought to add in L-type VGCCs to construct a more complete model of LEMS with both 
P/Q- and L-type VGCCs. Although it is known that L-type VGCCs are upregulated in LEMS and 
contribute to transmitter release, little is known about their number and location relative to the 
AZs. However, it is thought that they do not localize with the AZs because they lack the necessary 
synaptic protein interaction site (Catterall, 1999; Mochida et al., 2003; Sheng et al., 1998). 
Furthermore, buffer experiments have shown that the contribution of L-type VGCCs to transmitter 
release in LEMS is blocked by low concentrations of fast calcium buffer, placing them outside of 
the AZ (Flink, 2003). To model this increase in L-type current and its effect on transmitter release, 
we simply placed another row of 2 VGCCs on each side of the AZ an additional 55 nm beyond 
the first rows of VGCCs in our P/Q-type-only LEMS model (Figure 26A). In our MCell models, 
 120 
we use the same channel gating scheme (Figure 23D) for all VGCCs, but for simplicity we will 
herein refer to VGCCs in our model placed inside the AZs as P/Q-type and VGCCs placed further 
outside the AZs as L-type. We also did not randomly remove a proportion of the L-type VGCCs 
as we did with P/Q-type VGCCs. We found that the addition of L-type VGCCs to our P/Q-type-
only LEMS model increased transmitter release from an 80% reduction to a 65% reduction when 
compared with controls. This 65% reduction is within the range of experimentally measured 
reductions in quantal content in LEMS. The addition of L-type VGCCs also increased the 
facilitation over short trains of stimuli to levels seen in experimental data from LEMS-model mice 
(Figure 26B). These results show that we were able to alter our MCell model of the healthy mouse 
AZs to predict the electrophysiology observed in LEMS by reducing the number of AZs and 
altering the number and location of VGCCs within the remaining AZs. 
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Figure 26 The seropositive LEMS MCell model. 
A: A diagram of the AZ in the MCell model, showing the location of vesicles (grey circles) P/Q-type VGCCs 
in “normal” MCell model AZs (dashed circles), the location of P/Q-VGCCs in “cluster” MCell model AZs (black 
circles), and the location of L-type VGCCs in both the “normal” and “cluster” LEMS MCell model AZs (circles with 
lines through them). Diagram is to scale except for the size of the VGCCs. B: Plot of tetanic potentiation at 50 Hz. 
Our model predicts that moving P/Q-type VGCCs and randomly removing some P/Q-type VGCCs (black triangles) 
increases tetanic potentiation, but not to the experimentally measured value of LEMS-model mice (open squares). The 
addition of L-type VGCCs to our MCell model (black squares) increases the predicted tetanic potentiation to levels 
consistent with experimental results. Experimental results from (Tarr et al., 2013b). 
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4.3.3 Loss of fast-synaptotagmin-like sensors produces similar results to LEMS-model AZs 
We next wanted to investigate the nature of seronegative LEMS by attempting to alter our 
healthy mouse AZ MCell model to predict the electrophysiological behavior of LEMS, but without 
altering the number or location of VGCCs. Based on reports of seronegative LEMS patients 
producing antibodies to syt1, we hypothesized that reducing the number of fast syt1-like calcium 
sensors on our healthy mouse model would also be able to predict the electrophysiological 
properties of LEMS-model mice NMJs. We expected that reducing the number of syt1-like sensors 
would reduce the magnitude of transmitter release. In addition, reducing the number of syt1-like 
sensors would increase the reliance on the syt7-like sensors for release, which we hypothesized 
would produce the increased facilitation over short trains of stimuli seen in LEMS. Indeed, we 
found that transmitter release decreased and short-term facilitation increased relative to the number 
of syt1-like sensors removed (Figure 27). These results suggest that antibodies against 
synaptotagmin-1 and synaptotagmin-2 may be sufficient to cause LEMS-like effects on transmitter 




Figure 27 Reducing the number of syt1-like sensors in the MCell model produces levels of transmitter release 
and tetanic potentiation similar to those seen in experiments on LEMS-model mice. 
A: The level of transmitter release of our healthy mouse AZ MCell model with reduced numbers of syt1-like 
sensors compared to the control model with 5 syt1-like sensors. Bar showing general range of experimental values for 
quantal content in LEMS-model mice compared to controls (25-40%) is added for comparison. B: tetanic potentiation 
over short trains of stimuli at 50 Hz, showing that a decrease in syt1-like sensors is associated with an increase in 
facilitation. Experimental results from (Tarr et al., 2013b). 
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4.3.4 Mechanisms of LEMS-induced reduction in transmitter release are predicted to 
differentially impact treatment effectiveness 
3,4-DAP is a potassium channel antagonist that indirectly increases calcium flux into the 
nerve terminal by broadening the AP, which increases the probability that VGCCs in the terminal 
open during an AP (see chapter 3.0). It has been shown to be effective in increasing transmitter 
release in LEMS-model mice (Tarr et al., 2014) and partially alleviating symptoms of muscle-
weakness in LEMS patients (Sanders, 1998; Sanders et al., 2018; Shieh et al., 2019; Strupp et al., 
2017), and is currently the only FDA approved treatment for LEMS (Oh, 2020; Voelker, 2019; 
Yoon et al., 2020). However, 3,4-DAP has dose-limiting side effects, and the effectiveness of 3,4-
DAP can vary greatly between patients such that up to 70% of LEMS patients require other 
treatments, such as immunotherapy, in combination with 3,4-DAP (Maddison et al., 2001; Titulaer 
et al., 2011a).  
To our knowledge, no studies to date have studied potential mechanistic differences in the 
effectiveness of 3,4-DAP on seropositive and seronegative LEMS. However, one study on patients 
with a congenital syt2 mutation found that treatment with 3,4-DAP provided only slight 
improvements in symptoms and had provided no measurable change in initial compound muscle 
action potential although slight improvements were detected with single-fiber EMG (Whittaker et 
al., 2015). In comparison, 3,4-DAP was shown to increase compound muscle action potential in 
seropositive LEMS patients (Wirtz et al., 2009). Thus, we used our seronegative and seropositive 
LEMS models to investigate if the antibodies in LEMS could play a role in determining the 
effectiveness of 3,4-DAP treatment. We tested the effects of a clinically-relevant concentration 
(1.5µm) of 3,4-DAP on our MCell models by replacing the AP waveform in the simulations 
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(Figure 23A) with the average AP waveform from voltage-imaging recordings of the presynaptic 
terminal of the mouse NMJ in the presence of 1.5 µm 3,4-DAP (chapter 3.0) (Figure 23 B&C).  
Experiments on LEMS-model mice generated using patient serum from seropositive 
patients found that 1.5 µm 3,4-DAP increased the quantal content of the LEMS-weakened NMJ 
terminals by 1.84 fold (Tarr et al., 2014). This result was accurately recapitulated by our 
seropositive LEMS MCell model, which predicted a 1.78 fold increase in transmitter release from 
the 1.5 µm 3,4-DAP-modified AP waveform compared to the control AP waveform. In contrast, 
the seronegative MCell models (MCell models with the same VGCC placement as the control 
MCell model, but fewer syt1-like sensors) did not see substantial increases in transmitter release 
from the 1.5 µm 3,4-DAP-modified AP waveform compared to the control AP waveform (Figure 
28). These results suggest that the mechanism by which the AZ function is disrupted in LEMS 
may impact the effectiveness of LEMS treatments. 
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Figure 28 MCell models of seronegative LEMS have less improvement in transmitter release from 1.5 µM 
3,4-DAP than the seropositive model. 
The fold change in transmitter release resulting from the 3,4-DAP AP waveform compared to the control AP 
waveform for MCell models (black bars) of the seropositive LEMS model and the seronegative LEMS model with 1 
or 2 syt-1 like sensors are compared to the experimentally recorded value (empty bar) from (Tarr et al., 2014). 
4.4 Discussion 
Here, we have constructed a computational model of a healthy mouse NMJ AZ. We then 
explored the impact of modifying this model based on physiological data collected in the mouse 
model for the neurological disease LEMS, which attacks the AZ. We demonstrated that by 
rearranging our healthy mouse model based on findings from freeze-fracture electron microscopy 
and measured calcium currents in LEMS-model mice, we were able to construct models of LEMS-
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modified AZs that were able to predict the electrophysiological behavior of LEMS. We then 
utilized our models to investigate the hypothesis that antibodies against fast calcium-sensing 
proteins (synaptotagmin-1 and -2) can result in the electrophysiological behavior seen in LEMS. 
Finally, we tested the impact of 3,4-DAP broadened AP waveforms, and found that our model 
predicted that the molecular mechanisms behind the loss of transmitter release in LEMS could 
impact response to this FDA-approved treatment. 
4.4.1 Disruption of the AZ structure is essential for the presentation of seropositive LEMS 
It is generally thought that, other than in rare seronegative cases, LEMS is caused by 
antibodies to P/Q-type VGCCs. The electrophysiological behavior of LEMS is often ascribed 
entirely to a loss of P/Q-type VGCCs and a compensatory upregulation of other VGCC types. 
However, this is a simplified notion of LEMS that ignores evidence from freeze-fracture electron 
microscopy showing a significant reduction in the number of AZs and a high level of dysregulation 
in the organization of many of the remaining AZs. Early freeze-fracture electron microscopy 
studies in human LEMS patients (Fukunaga et al., 1982) and LEMS-model mice which had been 
injected with low doses of human LEMS serum daily for several weeks (Fukunaga et al., 1983) 
found that LEMS NMJs had 70-85% fewer AZs per µm2 than controls as well as a large increase 
in the number of disorganized clusters of intramembranous particles. A later study, which instead 
created LEMS-model mice by injecting a high dose of IgG three times daily for two days, again 
found a 70% reduction of normal AZs per µm2 in LEMS-model mice compared to controls. They 
found an increase in the number of clusters, but also identified the presence of partially disrupted 
“abnormal” AZs. The authors of this study suggested these abnormal AZs were an intermediate 
stage between the normal well-organized AZ and the highly disorganized cluster, and this implied 
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that the clusters were actually highly disorganized AZs (Fukuoka et al., 1987). Furthermore, these 
results showed that a removal of AZs and disruption of the remaining AZs was not a delayed 
response, but a rapid effect of the LEMS IgG. 
Our model suggested that removing 40% of the P/Q-type VGCCs (as suggested by 
recordings of calcium currents in LEMS-model mice (Smith et al., 1995; Xu et al., 1998)) only 
reduced transmitter release by 42%. This is a lesser reduction of transmitter release than the 60-
75% reduction seen in LEMS, and is much less than the 76-85% reduction in transmitter release 
seen in LEMS without compensatory upregulation of other VGCC types (Flink & Atchison, 2002). 
We also found that moving the location of VGCCs within the AZ an additional 20 nm away from 
the docked synaptic vesicles in AZ created a greater reduction in transmitter release than removing 
40% of the VGCCs. Based on these computational results and the level of disorganization seen in 
freeze-fracture electron microscopy of LEMS NMJs, we hypothesize that the disorganization of 
normally well-ordered structure of AZs, beyond the simple removal of VGCCs, is an essential part 
of the pathology of seropositive LEMS. 
4.4.2 VGCC antibodies and LEMS 
Our results, along with the findings of other studies on seronegative LEMS, suggest that 
anti-VGCC antibodies are not necessary for LEMS. In addition, other evidence suggests that anti-
VGCC antibodies alone may also not be sufficient for LEMS. In patients with small cell lung 
cancer and no symptoms of LEMS or other neurological dysfunction, it was found that 1-4% 
produced P/Q-type VGCC antibodies (Titulaer et al., 2009; Zalewski et al., 2016). Antibodies to 
P/Q-type VGCCs have been found in patients that present with a variety of other neurological 
conditions but not with symptoms of LEMS (Di Lorenzo et al., 2018; Zalewski et al., 2016), and 
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also in healthy controls (Di Lorenzo et al., 2018; Lennon et al., 1995; Zalewski et al., 2016).  
Recent studies have found that tests for the presence of P/Q- and N-type VGCC antibodies have 
low sensitivity to detecting LEMS and produce a large number of false positives (Abboud et al., 
2017; Albadareen et al., 2017; Di Lorenzo et al., 2018). Furthermore, rats injected with peptides 
or recombinant proteins to various VGCC domains were reported to have a reduction in quantal 
content, but only by about 30% (Komai, Iwasa, & Takamori, 1999; Takamori, Iwasa, & Komai, 
1998), and this result has been difficult to reproduce (personal communication). This is less of a 
reduction than the 60-75% reduction in quantal content seen in LEMS-model mice. These findings 
suggest a possibility that although antibodies to P/Q-type VGCCs play an important role in a 
majority of LEMS cases, they may require cooperation with antibodies targeting other AZ proteins 
to cause the clinical symptoms of LEMS, especially when not present at high titer.  
This multi-antibody hypothesis may be supported by the marked reduction in the number 
of AZs as well as a disruption of the normally well-organized structure of the remaining 
intramembranous particles comprising AZs seen in human LEMS patients (Fukunaga et al., 1982) 
and LEMS passive-transfer mice (Fukunaga et al., 1983; Fukuoka et al., 1987). The AZ contains 
numerous interconnected structural and functional proteins (Sudhof, 2012, 2013), and it is possible 
that auto-antibody mediated removal of P/Q-type VGCCs could result in damage to the AZ 
structure which would result in some level of disorganization. Furthermore, both P/Q-type VGCC 
knockout mice and N-type VGCC knockout mice have shown a reduction in the number of AZs 
(Chen, Billings, & Nishimune, 2011). However, the LEMS-mediated reduction in the total number 
of AZs and the high level of disruption in the organization of remaining AZs is perhaps a much 
greater level of damage to the AZ structure than one would expect from the removal of the number 
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of P/Q-type VGCCs necessary to cause the 30-40% reduction in P/Q-type calcium current seen in 
LEMS (Smith et al., 1995; Xu et al., 1998).      
4.4.3 Is the organization of the AZ altered in seronegative LEMS? 
If an autoantibody attack on P/Q-type VGCCs can impact other AZ proteins attached to 
the VGCCs and subsequent disruption of the AZ organization, then there is also the possibility that 
antibody-mediated removal of other AZ proteins could indirectly result in the removal and 
disorganization of VGCCs. For example, the protein laminin β2 has been found to be essential for 
the expression of P/Q-type VGCCs in the AZs (Chand et al., 2015), and the interaction of laminin 
β2 and VGCCs is essential for the organization of the AZs (Chen et al., 2011; Nishimune, Sanes, 
& Carlson, 2004). Antibodies against the laminin β2-binding domain on P/Q-type VGCCs (Rogers 
& Nishimune, 2017; Takamori, Maruta, & Komai, 2000b) have been identified in LEMS patients. 
Although antibodies specifically against laminin β2 have not been identified in LEMS, it has been 
hypothesized that the presence of anti-laminin β2 antibodies (or antibodies against a variety of 
other AZ proteins) could cause LEMS. We propose that an in-depth characterization of antibodies 
present in LEMS patients could provide insight into seronegative LEMS and the mechanism of 





5.0 General discussion 
5.1 The contribution of brief AP waveforms to the reliability of NMJs 
Voltage imaging experiments in chapter 2.0 revealed that the AP waveform is very brief in 
the motor nerve terminal of the adult frog NMJ, with an average FWHM of only 274 μs. This is 
much briefer than the AP waveforms recorded from spinal motoneuron cell bodies of adult frogs 
(Dambach & Erulkar, 1973; Erulkar & Soller, 1980; Ovsepian & Vesselkin, 2006), and these AP 
waveforms from adult frog motoneurons are narrower than AP waveforms recorded from frog 
embryonic motoneuron synaptic varicosities (Pattillo et al., 2001; Yazejian et al., 1997). In chapter 
3.0, we found that the AP waveform in the nerve terminals of adult mouse NMJs is also very brief, 
with an average FWHM of 264 μs. Furthermore, a recent study has found that the AP waveform 
in the soma of mouse spinal motoneurons is broader than our recorded waveform from the nerve 
terminal, and that the AP waveform in the soma narrows during maturation (Smith & Brownstone, 
2020). Although the AP waveforms in the soma of frog and mouse spinal motoneurons are broader 
than the AP waveforms at the motoneuron nerve terminals, they are still quite narrow (<1 ms 
FWHM) compared to many other neuron types. For example, the AP in a mammalian midbrain 
dopamine neuron has an FWHM of approximately 4 ms (Bean, 2007). This suggests that mouse 
and frog spinal motoneurons share conserved mechanisms for a relatively narrow AP waveform 
in the soma, narrowing the AP waveform during maturation, and a further narrowing of the AP 
waveform as it propagates from the soma to the nerve terminal.  
In section 2.4.1, we discussed how the narrowing of the AP during maturation in frog 
motoneurons is analogous to changes seen during maturation in the calyx of Held, and how those 
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changes contribute to the strength and reliability of the adult calyx of Held. We also discussed how 
this narrow AP waveform could contribute to the strength and reliability of the NMJ by ensuring 
that only a small number of VGCCs open during an AP, which helps prevent depletion of the 
docked synaptic vesicles during trains of stimuli. 
Narrow APs are often associated with a behavior referred to as “fast spiking”. Fast-spiking 
refers to the ability of some neurons to fire at high frequency for prolonged periods (Bean, 2007). 
This fast-spiking phenotype has been observed in several types of neurons including interneurons 
(Berke, 2011; Martina et al., 1998), Purkinje neurons (Martina, Metz, & Bean, 2007; Martina, Yao, 
& Bean, 2003; McKay & Turner, 2004; Southan & Robertson, 2000), neurons in the subthalamic 
nucleus (Bevan & Wilson, 1999; Wigmore & Lacey, 2000), and the calyx of Held (Brew & 
Forsythe, 1995; Ishikawa et al., 2003; Wang et al., 1998). The common mechanism creating the 
narrow APs that allow fast spiking in all of these neurons is thought to be the presence of the Kv3 
family of voltage-gated potassium channels (Kaczmarek & Zhang, 2017; Rudy & McBain, 2001). 
This is the same type of Kv channel found in the mouse NMJ (Brooke et al., 2004), and likely the 
frog NMJ (although this has not yet been directly investigated experimentally). Thus, the narrow 
AP of the motoneurons and the presence of Kv3 channels suggests that frog and mouse 
motoneurons, like fast spiking neurons, are built for their reliability during repeated stimulation. 
Another phenomenon seen in both mouse and frog motoneurons is the narrowing of the 
AP waveform as it propagates from the soma to the axon. This too is seen in other types of neurons, 
including granule cells in the dentate gyrus (Geiger & Jonas, 2000), layer 5 pyramidal neurons 
(Popovic et al., 2011), and cerebellar stellate cells (Rowan et al., 2016). The exact mechanisms by 
which this occurs are not completely understood, but appear to be a combination of changes in ion 
channel type and distribution as well as changes in membrane geometry (Ginebaugh et al., 2020; 
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Rowan et al., 2016; Rowan et al., 2014). We hypothesize that this narrowing of the AP between 
the soma and the axon further contributes to the reliability of the NMJ by helping to prevent 
depletion of docked synaptic vesicles. 
Interestingly, these mechanisms are not conserved across all NMJs. The AP waveform at 
presynaptic terminal of the Drosophila NMJ is approximately six times broader than the AP 
waveforms at frog and mouse motoneuron terminals and does not narrow between soma and axon 
(Ford & Davis, 2014). The broader AP at the Drosophila motoneuron is likely due partially to the 
presence of Kv1 channels (Jan, Jan, & Dennis, 1977). Furthermore, the large difference in behavior 
and structure between the Drosophila NMJ and the mouse and frog NMJs is likely driven by the 
differences in function and organization of the muscle system of arthropods compared to 
vertebrates (Slater, 2015). 
5.2 LEMS-modified organization of the AZ and its effects on synaptic transmission 
It has long been thought that the reduction in calcium current through P/Q-type VGCCs is 
the primary mechanism by which transmitter release is reduced in LEMS. However, this is likely 
an over-simplistic view of LEMS. Measurements of calcium current in LEMS-model mice only 
saw a 30-40% reduction in P/Q-type calcium current (Smith et al., 1995; Xu et al., 1998),  and 
freeze-fracture electron microscopy has shown a reduction in the number of AZs found in the 
NMJs of LEMS-model mice and human patients as well as a disorganization in the structure of 
remaining AZs.  In chapter 4.0, our MCell models predicted that reducing 40% of P/Q-type 
VGCCs to match the experimentally measured LEMS-mediated reduction in P/Q-type calcium 
current would only cause a 42% reduction in quantal release; not nearly enough to match the 
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experimentally measured reduction in transmitter release found in LEMS. In comparison, moving 
VGCCs 20 nm away from the docked synaptic vesicles in the AZs of the healthy mouse MCell 
model was predicted to reduce transmitter release by 61%. These results suggest that subtle 
changes to the normally well-organized structure of the mammalian AZ can have large effect, such 
that moving all of the VGCCs 20 nm away from the synaptic vesicles in the AZ had almost 1.5-
fold greater of an effect on transmitter release than removing 40% of the VGCCs. The importance 
of AZ structure in determining its function (especially the distances between VGCCs and the 
calcium sensing proteins) is consistent with other modeling results (Bennett, Farnell, & Gibson, 
2000a, 2000b; Matveev, Bertram, & Sherman, 2011) 
 In our P/Q-type-only LEMS model, removing 2 of the 6 AZs and moving the VGCCs 20 
nm away from the docked synaptic vesicles in 3 of the 4 remaining AZs resulted in a 64% reduction 
in transmitter release compared to the control model. Randomly removing ~40% of the remaining 
channels only reduced transmitter release another 16% (for a total reduction of 80%). These 
findings suggest that the disruption of the AZ structure (the removal of AZs and the displacement 
of intramembranous particles in remaining AZs) has a much greater role in LEMS pathology than 
what is suggested in much of the LEMS literature. In fact, these results suggest that the removal 
and disorganization of AZs contributes much more to LEMS pathology than a reduction in the 
number of P/Q-type VGCCs.  
Other than the reduction in transmitter release, another electrophysiological feature of 
LEMS is a large increase in tetanic potentiation over short trains of stimuli from a slight depression 
in healthy mouse NMJs to a facilitation in LEMS-model mouse NMJs. We found that removing 
~40% of VGCCs in our healthy mouse MCell model only slightly increased tetanic potentiation. 
In contrast, moving all of the VGCCs 20 nm further away from the AZ greatly increased the 
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facilitation. Surprisingly, a model in which the VGCCs were moved as well as having ~40% of 
them removed had a lesser facilitation than only moving the channels (Figure 29). The fact that 
two changes that each increase tetanic potentiation do not cause an even greater tetanic potentiation 
when combined suggests that the relationships between tetanic potentiation and VGCC number 
and placement are complex and nonlinear. 
In our P/Q-type only LEMS model, the tetanic potentiation was much higher than in the 
control model, but was less than the model with both ~40% of VGCCs removed and all channels 
moved 20 nm away from the AZ. This is because the one “normal” AZ in our LEMS P/Q-only 
model was responsible for as much transmitter release as 2 to 3 of the “cluster” AZs, so the 
facilitation was skewed toward the levels seen in the “normal” AZ. 
Our P/Q-type only LEMS model had less facilitation and transmitter release than the LEMS 
experimental results. Based on experimental data that L-type VGCCs are upregulated in LEMS 
and contribute to transmitter release, we examined the effect of placing more VGCCs even further 
outside the AZs. We found that adding more VGCCs further outside of the AZ was able to increase 
transmitter release and facilitation to LEMS experimental levels. This is consistent with the 
experimental data showing that L-type VGCCs contribute to transmitter release in LEMS (Flink 
& Atchison, 2002), and is also consistent with experimental results showing that L-type VGCCs 
contribute to facilitation in LEMS (Flink, 2003). 
The experimental results from LEMS-model mice are highly variable. This is likely due to 
the high variability in antibody titer and type from the LEMS patients. In LEMS-model mice, the 
reduction in transmitter release often ranges from 60-75%. Similarly, there are differences seen in 
the levels of facilitation. During a short train of stimuli, the quantal content of the 4th stimulus 
commonly ranges from 1.2-1.4 times the quantal content of the 1st stimuli. The high impact of 
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VGCC placement in our model on both transmitter release and facilitation suggest that differences 
in the extent of AZ disorganization caused by variation in the antibody makeup of serum from 
LEMS patients could be a determining factor for electrophysiological variation in LEMS-model 
mice.   
 
 
Figure 29 Changes in tetanic potentiation from altering the number and location of VGCCs in the healthy 
MCell model. 
Removing 9/24 VGCCs (37.5%) in the MCell model causes a slight increase in facilitation compared to the 
control model. Moving all VGCCs in the MCell model 20 nm further away from the synaptic vesicles in the AZs 
causes a much greater facilitation. Both removing 9/24 VGCCs and moving the remaining VGCCs 20 nm further 
away from the synaptic vesicles in the AZs causes less facilitation than only moving the VGCCs. 
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5.3 The interaction between LEMS and the AP waveform at the NMJ 
In Chapter 2.0 (Ginebaugh et al., 2020), it was shown that slight changes in the width of 
the AP waveform could create large changes in the calcium flux and transmitter release. Even a 
35% increase in AP width was predicted to cause the probability of VGCCs opening and the total 
calcium flux during the AP to more than double. In an MCell model of an AZ in the frog NMJ, 
this AP-broadening-mediated increase in calcium flux was predicted to quadruple transmitter 
release (Figure 13). In our modeling of LEMS in chapter 4.0, we utilized the average AP waveform 
of our recordings from healthy mouse NMJs. However, it is possible that LEMS itself could alter 
the AP waveform and its propagation through the presynaptic terminal of the NMJ. 
Calcium-activated potassium (BK) channels are known be present in NMJ AZs (see section 
1.2.2). These BK channels help speed the repolarization phase of the AP, and blocking them has 
been shown to increase transmitter release — presumably through a broadening of the AP 
waveform. The BK channels are thought to be colocalized with VGCCs in the AZ to allow for a 
rapid transduction of the calcium signal from the VGCCs to the BK channels. It is unclear how the 
AZ disruption in LEMS would impact the BK channels: when VGCCs are targeted by antibodies 
and removed, are BK channels removed as well or do they remain in the AZ? When VGCCs are 
moved during the disorganization of the AZ, are the BK channels moved with them, or do the BK 
channels remain in their original position, or are the BK channels and VGCCs moved 
independently? It is almost certain that a reduction in the number of VGCCs alone would disrupt 
at least some of the BK channel activity, but the extent of this disruption would depend largely on 
how much the LEMS-induced disorganization of the AZ decouples the positioning of the VGCCs 
and BK channels. This disruption would be expected to broaden the AP waveform and reduce the 
impact of the BK channel blocker iberiotoxin (IBTX) on the behavior of the NMJ.  
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As mentioned previously, a slight broadening of the AP waveform can cause a large 
increase in calcium flux and transmitter release. For the construction of the LEMS MCell model, 
we removed 37.5% of the P/Q-type VGCCs to simulate the 30-40% reduction in P/Q-type calcium 
current seen in experiments on LEMS-model mice (Smith et al., 1995; Xu et al., 1998). Removing 
~40% of the P/Q-type VGCCs to simulate a ~40% reduction in P/Q-type calcium current relies on 
the assumption that the AP waveform driving the behavior of VGCCs and calcium influx is 
unchanged. If there is a significant disruption of BK channel activity in LEMS and a subsequent 
broadening of the AP waveform, then the probability of VGCCs opening would increase, and a 
40% reduction in P/Q-type calcium current would require a removal of greater than 40% of the 
P/Q-type VGCCs. 
We performed some preliminary voltage-imaging experiments investigating the effects of 
the BK channel blocker iberiotoxin (IBTX) on the AP waveform in LEMS-model mice. These 
experiments were a pre- and post-drug paired-recording design similar to the experiments in 
section 3.2.2, where the AP waveform was recorded from a nerve terminal in a control bath and 
then the AP waveform was recorded again from the same nerve terminal after 30 minutes of bath 
exposure to the drug. In this experiment, the mice used were C57BL/6 mice that had been passively 
transferred LEMS via repeated injection of serum from human LEMS patients, and the drug used 
was 200 nM IBTX. In total, we successfully recorded pre-post drug effects from 6 different mice. 
We also recorded AP waveforms from an additional 5 terminals of LEMS model mice that did not 
have paired post-drug data. In the paired experiments, we found that there was a slight but not 
statistically significant broadening of the AP waveform after the addition of IBTX (Figure 30 
Error! Reference source not found.A&B). Furthermore, there was no significance difference in 
FWHM between of the LEMS AP waveforms in control bath and the AP waveforms from healthy 
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mice in the pre-drug vehicle bath from section 3.2.2 (Figure 30 C&D). However, the strain of the 
mice used in section 3.2.2 was swiss-webster rather than C57BL/6, and it is possible that 
differences in mouse strain could make a statistical comparison between the two experimental 
results incompatible. For proper conclusions regarding the impact of LEMS on the AP waveform 
and BK channel activity, the paired pre-post IBTX experiments should be performed on nerve 
terminals from healthy C57BL/6 mouse NMJs. I hypothesize that the pre-drug AP waveforms from 
healthy mice would be slightly narrower than the pre-drug AP waveform from the LEMS-model 
mice, and that IBTX would broaden the AP waveform in healthy mouse NMJs to the width of the 
LEMS-model mice AP waveforms. I also hypothesize that there is in fact a very slight broadening 
of the AP waveform in the LEMS-model mice. However, due to the high variability in voltage 
imaging and the small expected effect of IBTX on the AP waveform in LEMS-model mice, a 









Figure 30 Effect of LEMS and IBTX on the presynaptic AP waveform in LEMS-model mouse NMJs. 
A: The normalized average of all pre-drug (black) and post 200 nM IBTX (red) presynaptic AP waveform 
splines recorded from LEMS-model mouse motor nerve terminals (n = 6). B: Plots of individual paired recorded values 
(grey dotted lines) of AP duration (FWHM) before and after application of 200 nM IBTX with a superimposed average 
(solid black line). There is a slight but not statistically significant increase in FWHM (n = 6, p = 0.138, paired t-test). 
C: The normalized average of all control recordings from LEMS passive-transfer C57BL/6 mice (green trace, n = 11) 
and all pre-drug recordings from swiss-webster mice in section 3.2.2 (magenta trace, trace from Figure 16D, n = 11). 
D: There is no significant difference (p = 0.9883) in FWHM between AP waveforms recorded from ex vivo 
preparations from LEMS-model C57BL/6 mice (n = 11) and healthy Swiss Webster mice (n = 11, data from section 
3.2.2). 
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5.4 BK channels as a future direction for research  
The effect of IBTX on transmitter release in both mouse and frog NMJs suggests the 
presence of an important feedback mechanism by which VGCCs can alter the AP waveform and 
thus the behavior of the nerve terminal. In the presynaptic terminals of the frog and mouse NMJs, 
blocking BK channels causes an increase in transmitter release (Anderson et al., 1988; Flink & 
Atchison, 2003; Robitaille et al., 1993a; Robitaille & Charlton, 1992; Vatanpour & Harvey, 1995), 
and it is thought that the main function of BK channels in these NMJs is to create a more rapid 
repolarization of the AP. BK channels can have a wide variety of effects, and BK channels in other 
types of neurons and the NMJs of other species can have different effects than the BK channels in 
frog and mouse NMJs. For example, blocking BK channels in Drosophila NMJs (Lee, Ueda, & 
Wu, 2008) or mammalian CA1 pyramidal cells of the hippocampus (Hu et al., 2001) does not 
increase transmitter release. However, BK channels have been found to compensate for Kv channel 
inactivation during repeated stimulation in the presynaptic terminal of the Drosophila NMJ (Ford 
& Davis, 2014). This suggests that the BK channels are part of a complex feedback mechanism 
involving VGCCs, BK channels, and the AP waveform. To understand this feedback mechanism, 
a detailed analysis of the relationships between VGCCs, BK channels, and the AP waveform is 
necessary.  
The impact of BK channels on the function of the nerve terminal and the unknowns 
regarding their functions suggest that research into BK channels is an important future direction. 
Future research into BK channels will help elucidate the behavior of the presynaptic terminal of 
the NMJ as well as the mechanisms regulating synaptic transmission in general. Furthermore, the 
behavior of BK channels in neurological diseases including LEMS is greatly understudied. 
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Currently, many of the computational tools available for the study of the behavior of 
neurons are not able to thoroughly investigate the mechanisms of BK channels. Because the 
function of BK channels is so heavily linked to their organization and relationship with VGCCs, 
programs such as NEURON that are not able to model neurons at the level of AZ organization 
have difficulty modeling the structure-function relationship between BK channels and VGCCs. 
Particle-based programs such as MCell can handle the structure-function relationship between BK 
channels and VGCCs, but are unable to rapidly analyze the output from the BK channels and use 
the information to accurately alter the AP waveform to simulate the effects of the BK channel 
feedback loop in subsequent time steps. To address this, development of a program called 
pyNEUCell is underway. This program is a combination of NEURON and MCell (with a python 
interface). At each time step, this program will compute the movement and behavior of particles 
using MCell and then send the results of the time step to NEURON, which will then use these 
results to recalculate input parameters for the next time step. For our MCell models of AZs in the 
frog and mouse NMJs, this would allow us to track the calcium ion binding and voltage activation 
of BK channels, and then use the information from the BK channels to alter the AP waveform for 
subsequent time steps. This will allow for the complete feedback mechanism of the BK channels 
to be simulated. 
5.5  Heterogeneity or homogeneity among AZs? 
Although our MCell model of healthy mouse AZs assumes that all AZs are the same, there 
is evidence that AZs are not homogenous. As mentioned in section 2.4.2, transmitter release in the 
frog motor nerve terminal has been found to be highest near the last node of Ranvier and decrease 
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along the length of the terminal (D'Alonzo & Grinnell, 1985). We showed that changes in AP 
waveform may be responsible for some of these difference in transmitter release, but there is also 
the possibility that other unknown factors could be influencing differences in transmitter release 
along the length of the terminal. There is also evidence of AZ heterogeneity at the mouse NMJ. 
Much of this evidence comes from experiments utilizing synaptopHluorin (spH), a pH-sensitive 
exocytosis reporter (Miesenbock, De Angelis, & Rothman, 1998). The first spH studies at the 
mouse NMJ found that there were “hot spots” of release, suggesting that only some of the AZs 
contributed to release while the others were silent (Tabares et al., 2007; Wyatt & Balice-Gordon, 
2008). However, these studies used repeated trains of stimuli to increase the fluorescence signal. 
A later study found that these hot spots were not present during single stimuli or short trains, but 
only appeared after a high frequency train of 5-25 stimuli (Gaffield, Tabares, & Betz, 2009).  
The frog and mouse NMJs are not the only synapses with AZ heterogeneity. The 
Drosophila NMJ also shows significant variability in probability of release amongst AZs (Melom 
et al., 2013; Peled & Isacoff, 2011), as does the calyx of Held (Sheng et al., 2012). Multiple 
mechanisms for this variation in AZ function have been proposed. These include differences in 
actin (Sakaba & Neher, 2003), cAMP (Sakaba & Neher, 2001; Zhong & Zucker, 2005), and 
SNARE repriming (Deak et al., 2006; Rizo & Rosenmund, 2008). However, recent evidence at 
the Drosophila NMJ has suggested that variability in the number of VGCCs per AZ could be 
responsible for much of the variability for AZs (Akbergenova et al., 2018), and evidence from the 
calyx of Held has suggested that the distance between VGCCs and synaptic vesicles could 
contribute to AZ heterogeneity (Fekete et al., 2019). 
Freeze-fracture electron microscopy of human LEMS patients and LEMS-model mice 
suggests that LEMS causes some AZs to be completely removed, other AZs to be turned into 
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disorganized clusters of intramembranous particles, and a small portion of the AZs to remain 
relatively unchanged. The possibility of heterogeneity amongst AZs raises an important question 
about this phenomenon: is the outcome of a given AZ in LEMS a random chance based on which 
particles happen to be attacked by antibodies, or is the outcome influenced by the individual 
physiology of the AZ? If the heterogeneity among mouse AZs is caused by differences in the 
number or location of VGCCs within the AZs (similar to proposed mechanisms for AZ 
heterogeneity at the Drosophila NMJ or the calyx of Held), then it is possible that anti-VGCC 
antibodies would cause greater disruption to AZs that contain a greater number of VGCCs or have 
a tighter coupling of VGCCs with the AZ. 
5.6 What causes seronegative LEMS? 
Early investigations into LEMS revealed that repeatedly injecting mice with serum from 
human LEMS patients was able to passively transfer the disease, suggesting it was antibody 
mediated (Fukunaga et al., 1983; Lang et al., 1983). It was later discovered that LEMS patients 
expressed anti-VGCC antibodies (el Far et al., 1995; Lennon et al., 1995; Takamori et al., 1995). 
However, a minority of LEMS patients are seronegative for anti-VGCC antibodies.  
The absence of anti-VGCC antibodies in some LEMS patients was noted in the first studies 
that identified P/Q-type VGCCs as the primary antibody for seropositive LEMS patients (Lennon 
et al., 1995; Takamori et al., 1995). In a later study, Nakao et al. discovered that seronegative 
LEMS can also be passively transferred to mice, and thus seronegative LEMS is also antibody 
mediated. The authors of that study suggested several different explanations for this phenomenon, 
including the possibility that antibodies toward certain P/Q-type VGCCs epitopes may not be 
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detectable in their test, the titer of anti-VGCC antibodies were too low for detection by the test, or 
that seronegative LEMS was cause by antibodies to molecules other than P/Q type VGCCs (Nakao 
et al., 2002). There is growing evidence in support of their hypothesis that molecules other than 
P/Q-type VGCCs are responsible for seronegative LEMS. This includes reports that antibodies 
against P/Q-type VGCCs are not specific to LEMS and can occur in patients with other 
neurological diseases or even healthy controls (Abboud et al., 2017; Albadareen et al., 2017; Di 
Lorenzo et al., 2018; Lennon et al., 1995; Zalewski et al., 2016), multiple reports of antibodies 
against synaptotagmin-1 in both seropositive and seronegative LEMS patients (Takamori et al., 
2000a; Takamori et al., 1995), experiments in mice showing that disrupting the function of 
synaptotagmin causes LEMS-like features (Pang et al., 2006a; Takamori et al., 1994), and reports 
of various congenital myasthenic syndromes  in human patients (notably, one of which is caused 
by a mutation of synaptotagmin-2 (Herrmann et al., 2014)) that cause LEMS-like symptoms (Engel 
et al., 2015; Lorenzoni et al., 2018; Rodriguez Cruz, Palace, & Beeson, 2018). However, the 
specific antibodies responsible for seronegative LEMS have not yet been identified. 
Myasthenia gravis (MG) is similar to LEMS in that both MG and LEMS are autoimmune-
mediated neuromuscular diseases characterized by muscle weakness (Conti-Fine, Milani, & 
Kaminski, 2006). However, MG results from the immune system attacking the postsynaptic side 
of the NMJ, rather than the presynaptic side as in LEMS. In MG, the most common target for 
antibodies is the nicotinic acetylcholine receptor. The antibody mediated disruption of the 
acetylcholine receptors prevents muscles from receiving signals from the presynaptic terminal of 
the NMJ. Antibodies toward muscle-specific tyrosine kinase, which helps cluster the acetylcholine 
receptors in the postsynaptic membrane of the NMJ, can also be the main autoantibody in some 
MG patients (Hoch et al., 2001). Like LEMS, some MG patients are seronegative for these 
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common MG-associated antibodies. The double-seronegative MG patients have been found to 
produce a variety of autoantibodies specific to other NMJ proteins, including antibodies toward 
LRP4, Kv1.4 channels, collagen Q, agrin, and contractin (Yi et al., 2018). Furthermore, a recent 
study using a high-sensitivity radioimmunoprecipitation assay identified titin autoantibodies in 
several seronegative MG patients (Stergiou et al., 2016). Thus, seronegative MG can likely be 
caused by a variety of autoantibodies, and it is likely that an in-depth investigation into 
autoantibodies produced by seronegative LEMS patients will also find a variety of pathogenic 
autoantibodies. 
The most likely target for antibodies responsible for seronegative LEMS is synaptotagmin. 
As mentioned above, antibodies to synaptotagmin-1 have been identified in some, but not all, 
seronegative LEMS patients. However, synaptotagmin-2 is also important to transmitter release at 
mammalian NMJs (Pang et al., 2006a; Pang et al., 2006b), and it is not clear if the tests use to 
identify antibodies against synaptotagmin-1 would be able to identify antibodies against 
synaptotagmin-2. Thus, there is a possibility that the seronegative LEMS patients who tested 
negative for synaptotagmin-1 antibodies were simply producing synaptotagmin-2 antibodies 
instead. The hypothesis that anti-synaptotagmin antibodies could be responsible for seronegative 
LEMS is further supported by our computational modeling of AZs in the mouse NMJ in chapter 
4.0, which showed that reducing the number of fast calcium sensors (that simulate the behavior of 
synaptotagmin-1 or -2) can predict the reduced transmitter release and increased facilitation seen 
in electrophysiology on LEMS-model mice. 
There are several potential targets for autoantibodies in seronegative LEMS other than 
synaptotagmin. One potential target is M1 muscarinic acetylcholine receptors, as antibodies 
against these receptors have been found in LEMS patients (Takamori, 2008). In experiments on 
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adult rat NMJs, chemically blocking M1 muscarinic acetylcholine receptors was found to reduce 
EPP amplitude by approximately 50% (Santafe et al., 2006; Santafe et al., 2003). Another potential 
target is laminin β2. Although antibodies against laminin β2 have not been identified in LEMS 
patients, mutations in laminin β2 have been found to cause a congenital myasthenic syndrome and 
a severe reduction in transmitter release at the NMJ (Maselli et al., 2009). Because laminin β2 has 
been shown to be important for the organization of AZs at the NMJ (Nishimune et al., 2004; Rogers 
& Nishimune, 2017), an antibody-mediated destruction of laminin β2 could cause disorganization 
in the AZs leading to LEMS. Many of the other mutations that cause congenital myasthenic 
syndromes affect proteins that are located inside the presynaptic terminal and do not contain 
transmembrane domains, so they are not likely targets for antibody-mediated removal. It is clear 
that a complete understanding of seronegative LEMS will require an extensive characterization of 
antibodies in LEMS patient serum. 
5.7 Future research in LEMS treatment 
Although much is understood about LEMS, the current FDA approved LEMS treatment 
(3,4-DAP) only provides a moderate improvement in symptoms. It is clear that there is still much 
to be done both in understanding the basic biology of LEMS and its effects on the NMJ as well as 
in development of more effective treatment for LEMS. 
Our lab recently developed a novel calcium channel agonist, called GV-58, which directly 
increases transmitter release through P/Q- and N-type VGCCs by increasing their mean open time 
after they are opened by an increase in membrane voltage. GV-58 was found to have a similar 
effect on transmitter release as 3,4-DAP, but in combination with 3,4-DAP was shown to have a 
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super-additive effect that completely restored neurotransmission in LEMS-model mice ex vivo 
preparations to healthy levels (Tarr et al., 2014). However, these ex vivo experiments were 
performed using the maximum tolerated concentration (1.5 µM) of 3,4-DAP and the maximally 
effective (50 µM) concentration of GV-58. Prior to potential clinical trials of this drug 
combination, a parameter sweep is necessary to determine the optimal combination of the two 
drugs to maximize effectiveness while minimizing dose-dependent side effects. Due to the 
difficulty in obtaining the human LEMS serum required to create LEMS-model mice, a large-scale 
parameter sweep of dose combinations is difficult. It may be possible to reduce the number of mice 
needed for such a parameter sweep by utilizing our MCell model of the LEMS-modified AZs to 
estimate the optimal combination of the two drugs. Using calcium current data from P/Q-type 
VGCCs expressed in HEK293 cells in the presence of GV-58 (Tarr et al., 2014) and new 
information on the mechanism of GV-58 (unpublished), we were able to simulate the effects of 
GV-58 and the supra-additive effects of GV-58 + 3,4-DAP on transmitter release in our MCell 
model of LEMS AZs from section 4.3.2 (Figure 31). This shows that utilizing our MCell models 
to perform an in silico parameter sweep of drug concentration combinations may be able to 
accurately estimate the optimal combination of GV-58 + 3,4-DAP for preclinical trails.  
Another potential treatment for LEMS could come from improvements on the molecular 
structure of 3,4-DAP. 3,4-DAP was originally created by modifying the structure of another 
potassium channel agonist, 4-aminopyridine (4-AP). 4-AP, like 3,4-DAP, broadens the 
presynaptic AP at the NMJ. However, it crosses the blood-brain barrier at a higher rate than 3,4-
DAP, and thus causes more severe central nervous system side effects that prevent it from being 
used at a high enough concentration to significantly improve symptoms in LEMS 
patients(Lemeignan et al., 1984; Lindquist & Stangel, 2014). Although 3,4-DAP does not cross 
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the blood-brain barrier as easily as 4-AP, it still does so at high enough concentrations to limit its 
dosage in LEMS patients; at high concentrations, 3,4-DAP can cause seizures (Lindquist & 
Stangel, 2011; Wirtz et al., 2010; Wirtz et al., 2009). Our understanding of chemistry and ability 
to develop new drugs have significantly improved since the original synthesis of 3,4-DAP in the 
1970s. A novel potassium channel agonist with an even lower ability to cross the blood-brain 
barrier could possibly be used at higher concentrations in LEMS patients to further broaden the 
AP waveform and increase transmitter release at the NMJ without causing severe central nervous 
system side effects like seizures. 
Finally, our understanding of the immune system and our ability to modulate its function 
have recently greatly improved, largely due to advances in sequencing technology and systems 
biology. Single-cell RNA-seq is particularly useful for investigating the transcriptomic changes in 
immune cells that contribute to diseased states. Recent preliminary investigations have been made 
in myasthenia gravis transcriptomics (Guo et al., 2019; Lee et al., 2020; Park et al., 2016), however 
these used bulk transcriptomic techniques rather than single-cell, which would not allow 
investigations into the changes in gene expression of specific immune cell types (Chen, Ye, & 
Guo, 2019). Using single-cell RNA-seq, future investigations into the transcriptomic alterations of 
immune cells in LEMS patients may provide novel insights into the causes and potential treatments 




Figure 31 MCell model of LEMS AZs predicts a super-additive effect of DAP + GV-58. 
Quantity of transmitter release of various MCell models of LEMS AZs relative to the MCell model of healthy 
mouse AZs. Values for the LEMS AZ with the 3,4-DAP-modified AP waveform, a GV-58-modified VGCC gating 
scheme, or both the modified AP waveform and the modified VGCC gating scheme are shown. The combination of 
the two drugs has a super-additive effect in that it caused a greater improvement in transmitter release than the sum of 
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